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CHAPTER 1 
The biology of the Hepatitis C virus 
a review of the literature 
A condensed version of this chapter has been accepted for publication in the Journal of Medical 
Virology as a review article. 
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Introductiou 
The term hepatitis literally means 'inflammation of the liver', Hepatitis can be caused by toxic 
substances. metabolic disorders or viral infections. Most clinical hepatitis cases have a viral 
etiology. Viral hepatitis appears to be an ancient disease (Deinhardt, 1991) and has been 
recognized as infectious since centuries. Evaluation of hepatitis outbreaks led to the hypothesis that 
more than one type of viral hepatitis existed. Initially, two different forms of viral infectious 
agents were identified (Krugman et aI., 1962, 1967). Hepatitis A virus (HA V) is orally transntitted 
and bas a short incubation period. The hepatitis B virus (HBV) is transntitred parenterally and has 
a long incubation period. HA V contains a single stranded RNA genome and belongs to the 
Picornaviridae, whereas the Hepatitis B virus (HBV) contains a partially double stranded DNA 
genome and is classified as a Hepadnavirus (Tiollais et aI., 1985). In the early 1980s, an RNA 
virus designated as hepatitis Delta (Rizetto, 1983) was recognized. This defective hepatotropic 
virus requires helper functions provided by HBV or another Hepadnavirus (Wang et aI., 1986). 
After the discovery of hepatitis A and B viruses as etiological agents for viral hepatitis, 
sensitive serologic assays were developed to diagnose the presence of these viruses. However, 
after excluding hepatitis B surface antigen positive donor blood. posttransfusion hepatitis remained 
a significant problem. Post-transfusion hepatitis is rarely caused by hepatitis A virus (Wick et aI., 
1985). Therefore, another form of hepatitis was postulated in the early 1970s, which could not be 
explained by hepatitis A or B virus infections, and was provisionally named 'Non~A, Non-B 
hepatitis' (NANBH, Prince et aI., 1974, Alter et aI., 1975, Feinstone et aI., 1975). The average 
incidence rate among transfused recipients was 7% in the United States (Hollinger, 1990). Due to 
lack of an identification method for NANBH, diagnosis was based on exclusion of HAV and HBV 
as well as all other possible viral causes, like hepatitis Delta virus, Epstein-Bart virus and 
Cytomegalovirus. The observed incubation period of NANBH was intermediate between HA V and 
HBV. Although most of the patients with NANBH remain anicteric and asymptomatic, a 
significant number of cases progresses towards chronicity (Koretz et 31., 1976) and liver cirrhosis 
(Realdi et aI., 1982). 
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Non-A, non-B hepatitis could be subdivided into parenterally transmitted (PT-NANBH, 
predominantly caused by blood transfusion) and enterically transmitted (ET -NANBH) forms. The 
majority of cases of ET -NANBH are associated with the hepatitis E virus provisionally classified 
as a Calicivirus (Reyes et al., 1990). 
Initial characterization of PT-NANB 
Many attempts were made to identify the causative agent of PT-NANBH. Multiple reports of 
'specific' antibody systems appeared and several virus-like particles were visualized by electron 
microscopy (Spichtin, 1985), but these findings were not confirmed. Other unproven reports 
claimed that PT-NANBH may be caused by a serologically silent HBV variant (Wands, 1982), or 
a retrovirus (Seto et al., 1984, Itoh et al., 1986). 
After the recognition of PT-NANBH, an anim.al model was developed. It was possible to 
infect chimpanzees experimentally by infectious human sera (Hollinger et al., 1978, Alter et al, 
1978, Tabor et al., 1978), or contaminated factor IX concentrates (Wyke et al., 1979) and 
antihemophilic (factor VIII) materials (Bradley et al., 1979). Extensive in vivo studies in 
chimpanzees were performed by Bradley and co-workers at the Centers for Disease Control 
(CDC), mainly with a contaminated Factor VIII preparation (Bradley et al., 1979). As in humans, 
alanine aminotransferase (AL T) elevations were observed after an incubation period of 
approxlmately 7 weeks and the infectious agent could be transmitted to other chimpanzees by 
serum. Some animals showed persistent and fluctuating AL T levels indicative of continuing liver 
dysfunction, and suggesting the development of chronic PT-NANB infections (Bradley et al., 
1981). 
Different types of ultrastructural alterations have been consistently observed in hepatocytes 
infected by the chloroform-sensitive PT-NANBH. The most prominent alteration is the formation 
of tubular structures in the cytoplasm. Although these observations were used as a 
pseudodiagnostic tool, the ultrastructural alterations are not specific for PT-NANB and have been 
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also observed in several kinds of cells infected with RNA viruses (Bradley, 1991a, de Yos et al" 
1983, McCaul et al" 1985), 
There are several indications for the existence of more than ODe agent causing PT-
NANBH: multiple attacks of hepatitis in one patient (Mosley et al" 1977), the occurrence of a 
long and a short incubation period, different ALT patterns (pastore et al" 1985), the results of 
cross-challenge studies in experimentally infected chhnpanzees (Bradley et al" 1980, Yoshizawa et 
al" 1981, Tabor et al" 1984), and different ultrastructural observations (Shimizu et al" 1979), 
However, interpretation of these findings was often controversial (Brotman et al" 1985), The 
existence of two distinct agents could be most clearly demonstrated by their different sensitivity to 
chloroform, The infectivity of the most predominant PT-NANBH causing agent could be destroyed 
by chloroform extraction. whereas the other agent was resistant. Chloroform sensitivity suggested 
the presence of an envelope contaIning lipid (Bradley et al., 1983). It was also possible to purify 
infectious particles by ultracentrifugation through sucrose gradients (Bradley et al., 1985). 
Filtration studies of infectious plasma indicated that the diameter of the agent was between 30 and 
60 DID (He et al., 1987). These experimental data led to the hypothesis that the causative agent 
was a small enveloped virus, and might be a togavirus (Bradley et al .• 1985). Togaviruses are 
small enveloped viruses, sensitive to chloroform, containing a single stranded, positive sense RNA 
genome. 
Molecular biological characterization of Hepatitis C virus 
After the initial physiC<H:hemical characterization of the putative viral agent, molecular biological 
tools were applied to identify its genome. The prerequisite for this was the availability of a well 
defined sample, with an infectious titer of at least 10' viral particles per ml. Dilution of infectious 
materials revealed that the infectious titer is often less than 10" Chhnpanzee Infectious Dose 
(CID)/ml (Bradley, 1984). Sufficiently high-titered chimpanzee plasma was obtained by pooling 
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several samples obtained at the periodic ALT peaks (Bradley, 199Ib). This material was used for 
further cloning experiments by Houghton and co-workers. 
The working hypothesis, based on all physico-chemical data obtained previously, was that 
the etiologic agent was a small, enveloped virus, with a sedimentation coefficient that permitted 
concentration by ultracentrifugation, and presumably contained an RNA genome. From the high-
titer plasma pool the viral particles were pelleted by centrifugation and RNA was purified. RNA 
was converted into c(omplementary) DNA by random priming (anticipating that the viral RNA has 
no poly (A) tail) and cloned into a bacteriophage lambda expression library. 
By screening the expression library. using serum of chronically infected patients as a 
source of virus-specific antibodies, one clone. designated as 5-1-1. was isolated. Analysis of this 
clone showed that it was not host-derived. expressed a virus-specific antigen and hybridized 
specifically to RNA extracted from infectious plasma and liver (Choo et al., 1989). Clone 5-1-1 
was used as a probe to isolate overlapping clones and a larger clone, CI00-3, was constructed and 
expressed in yeast for the development of antibody detection assays (Kuo et al., 1989). This first 
generation antibody assay allowed identification of most PT -NANB cases. The newly identified 
agent was designated hepatitis C virus (HCV). The entire nucleotide sequence of the virus was 
rapidly deterntined (Houghton et al., 1990) via isolation of overlapping clones and revealed the 
presence of an RNA genome of approximately 9400 nucleotides. 
Genomic organization of Hepatitis C virus 
The RNA genome of hepatitis C virus, shown in figure I, contains a large translational open 
reading frame (ORF) which spans almost the entire genome and encodes a polyprotein of at least 
3010 antino acids (Choo et al., 199Ia). At the 5' terntinus an untranslated region of 341 nt is 
present. A 3' untranslated region of variable length with either a poly(U) (Chen et al., 1992, 
Tanaka et al., 1992, Kato et al., 199Oa, Takamizawa et al., 1990, Okamoto et al., 1991, 1992a) 
or a poly(A) tail (Han et al., 1991) tail has been reported. 
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Figure 1. Outline of the HCV genome 
At present several chimpanzee and human derived isolates have been completely sequenced 
(Choo et al .• 1991a, Kato et al., 1990, Takamizawa et al., 1991, Okamoto et al., 1991, 1992a, 
Chen et al., 1992, Tanaka et al., 1992). There is remarkable similarity between the HCV genome 
and that of Flavi- and Pestiviruses. First, the sizes of the polyproteins encoded by the positive-
stranded RNA genomes of HCV and the Flavi- and Pestiviruses are similar (± 3000, ± 3400 and 
± 4000 amino acids (aa) respectively). Second, there are a number of small dispersed amino acid 
sequence homologies with the non-structura1 proteins 3 and 5 of the Flaviviruses (Miller and 
Purcell, 1990, Choo et al., 199Ia). The first (aa 1230-1500) has residues in common with putative 
nucleoside triphosphate (NTP) binding helicases encoded by Flavi-, Pesti-, and plant Potyviruses, 
with HCV showing the greatest similarity with the Pestiviruses. The second region is upstream of 
the NTP-binding helicase and has similarity to the putative (chymo)trypsin-like serine protease 
from Flavi- and Pestiviruses. The third region (aa 2703-2739) contains the characteristic Gly-Asp-
Asp motif, which is highly conserved among viral-<lncoded RNA-dependent RNA polymerase. 
These homologies are co-linear, i.e., occurring at the same relative position in HeV. Flavi- and 
Pestiviruses (Choo et al., 199Ib). Third, the hydrophobicity profiles of the polyproteins from these 
viruses are remarkably similar (Takarnizawa et al., 1991, Choo et al., 199Ia), except the putative 
envelope coding region. The polyprotein encoded by Flaviviruses is processed into three structural 
proteins: the core or nucleocapsid (C), the prematrix (pre-M), the envelop (E) protein) and 7 non-
structural proteins (NSI, NS2a, NS2b, NS3, NS4a, NS4b, and NS5). The structural proteins form 
the viral panicle. whereas the non-structural proteins are involved in maturation and replication of 
the virus. Based on the similarity between the hydrophobicity profiles, a similar organization of 
the HCV genome has been postulated (Takarnizawa et al., 1991, Choo et al., 199Ia,b). The 
structural proteins are at the N-terminal part of the pOlyprotein. while the non-structural proteins 
originate from the C-terminal region (figure I). 
An interesting difference between the polyproteins from HeV and Flaviviruses is the 
relatively small size of the HCV structural protein region. 1n the Flaviviruses a structural 
membrane protein (pre-M) is located immediately downstream of the core protein, and is followed 
by a viral envelope protein (E). HCV seems to lack the pre-M region and encodes a much smaller 
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E protein. Furthermore. in the Pestiviruses the domain corresponding to non-structural protein 1 of 
Flaviviruses encodes the structural major envelope protein gp53-55. 
HCV, Flavi- and Pestiviruses are all small enveloped viruses and therefore HCV is 
currently classified as a separate genus within the Flaviviridae (Heinz, 1992). 
The different regions of the HeV genome 
From the 5' end to the 3' end the following distinct regions are identified on the HCV genome. 
The location of each region is shown in figure 1 and table I summarizes some important 
characteristics of the individual proteins. 
The 5' untranslated region, translotion and replication 
The 5' UTR seems to comprise approximately 341 nt (Han et al., 1991, Chen et al., 1992), 
although many shorter sequences have been reported (Okamoto et al., 1990a, Choo et al., 1991a, 
Kato et al., 199Oa, Takarnizawa et al., 1991). It is difficult to define the precise tertninus of the 
RNA genome as preliminary data suggested the existence of trtmcated RNA molecules (Han et al., 
1991) in vivo. The 5' terminus of the major trtmcated RNA corresponds to position -196 ( the 
polyprotein starting at position I). The 5'UTR of Flaviviruses is shorter (Brinton and Dispoto, 
1988, Heinz, 1992) and no significant sequence homologies with HCV exist when complete 
genomes are compared. However, there is striking resemblance (fakeuchi et al., 1990) between 
the HCV 5' UTR and the 5' tertninal region of the Pestiviruses, Bovine Viral Diarrhoea virus 
(BVDV) and Hog Cholera virus (HoChV). There are several small co-linear regions of 8-37 nt 
with a homology of more than 70% between HCV, BVDV and HoChV. The overall homology is 
approximately 50% (Houghton et al., 1991). In addition, the 5' UTRs of these viruses are similar 
in length. Like poliovirus, which possesses a 5' UTR of similar size, the HCV 5' UTR contains 
up to five small ORFs, but it is unknown whether these are actually translated and what the 
function of the products might be (Yoo et al., 1992). Alignment of sequences obtained from new 
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genotypes of HCV (see below) indicate that these small ORF's are not conserved. Picornavirus 5' 
UTRs allow cap-independent translation of the polyprotein and contain a cis-acting internal 
ribosomal entry site (IRES; Pelletier and Sonenberg, 1988). The secondary structures of the 5' 
UTRs of HCV, BVDV, and HoChV have been determined by thermodynamic modelling and 
enzymatic cleavage of RNA by specific ribonucleases (Brown E.A. et al., 1992, Tsukiyarna-
Kohara et al., 1992). These studies revealed the presence of a large conserved stern-lOOp structure 
in the proximal part of the 5' UTR, which serves as a purative IRES (figure 2). 
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Figure 2. Predicted secundary structure of nucleotides -170 to -115 in the 5' untranslated region. This 
structure is conserved among all genotypes of HeV. Positions with type-specific covariants are marked with 
corresponding (sub)type indications. 
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The secondary structure of the Flavivirus 5' UTR seems to be different, although a distal stem-
loop structure is present (Brinton and Dispoto. 1988). Studies using mono- and dicistronic RNA 
constructs revealed important fimctional features of the HCY 5'UTR (Wang et al., 1993), although 
other reports are contradictory (Yoo et al., 1992). Based on current knowledge it is most likely 
that the translation mechanism of the HCY genome is similar to that ofPicornaviruses (Jang et al., 
1989). Polyprotein translation is cap-independent and initiated at an IRES within the 5' UTR, 
proxima! to the initiator AUG codon of the polyprotein. The initiation of translation seems 
inhibited by the presence of a 5' terminal 27-nt sequence capable of forming a stable hairpin 
structure (Han et al., 1991). No hairpin structures have been described for the 5' terminus of 
Pestiviruses. but are highly conserved in Picornaviruses. 
The replication mechanism of ReV is poorly understood. Like in Flavi- and Pestiviruses. 
it appears that HCY RNA replicated by a direct RNA-to-RNA mechanism. It has been impossible 
to detect DNA-intermediates in serum or liver of infected individuals. The NS5 region (see below) 
encodes a protein with demonstrated RNA-dependent RNA polymerase activity (Chung and 
Kaplan, 1992). Antigenomic (minus) RNA strands bave been detected in liver (Takehare et al., 
1992) and plasma (pong et al., 1991, Shindo et al., 1992a) of patients. The detection of minns-
strand RNA in plasma is snrprising, because replication is presumably taking place in the liver. 
Minus-strand RNA could also be detected in peripheral blood mononuclear cells (Miil1er et al., 
1993, Zignego et al., 1992, Wang et al., 1992c), which suggests an extrabepatic replication site 
for HCY. Due to technical difficulty, detection of minus-strand RNA should be interpreted with 
care (Willems et aI., 1993). As antigenomic strand synthesis should start at the 3' terminus. some 
small repeated 6-8 bp sequences, present in both the 5' and 3' UTRs may be involved in 
secondary structure formation or cyclization of the RNA genome (Incbauspe et al., 1991). The 
precise mechanism of viral replication remains to be elucidated. 
Since the NS5 encoded protein is the last to be translated from the viral genome, 
translation and replication are linked processes. Efficient translation may lead to high levels of the 
viral replicase. This, in turn may lead to higher production of infectious viral particles, infection 
of more hepatocytes and eventually a higher virus titre in the circulation. 
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Table 1. Hev encoded proteins 
gene function aa pos. N-glyc' name N-cleavage' 
C capsid 1-191 p22 
E1 envelope 192-383 + gp33 signalase 
E2/NS1 envelope 384-809 + gp70 signalase 
NS2 metalloproteinase 810-1009 p23 signalase? 
NS3 ser-protease+ 1010-1619 p72 metalloproteinase 
helicase 
NS4(a+b) ? 1620-2016 p10 NS3 protease 
p27 NS3 protease 
NS5(a+b) replicase/ 2017-3033 p58 NS3 protease 
polymerase p70 NS3 protease 
'N-glyc. indicates presence of putative Asn-linked glycosylation sites. 
'N-cleav. indicates the putative enzyme responsible for proteolytic cleavage at the N-
terminus of the indicated protein. (Hijikata et al, 1993b an,d Grakoui et al.,1993). 
The core region 
The HCV core protein (P22) is highly basic due to the presence of a large amount of Arg and Lys 
residues (±20%). It also contains many Pro (12%) residues (Houghton et al., 1991, Choo et al., 
199Ia). The core protein lacks N-glycosylation sites. The 20 C-terminal amino acids are highly 
hydrophobic and act as a signal sequence (von Heijne, 1986, Takeuchi et al., 1990a,b, Kumar et 
al., 1992, Hijikata et al., 199Ia). P22 may be subject to further processing to generate mature C 
protein to be incorporated in the virion (Hijakata et al., 1991a). P22 has an RNA binding capacity. 
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Specific association between P22 and HCV genomic RNA accounts for the formation of 
nucleocapsid particles (Takahashi et aI., Ima,b). P22 also contains several highly conserved 
immunoreactive epitopes. Both recombinant core proteins and synthetic peptides. representing 
linear core epitopes. can be used for efficient detection of antibodies in most patient sera 
(Katayama et aI., 1992, Nasoff et aI., 1991, Chiba et aI., 1991, Siillberg et aI., 1992a,b, Harada 
et aI., 1991, Hosein et aI., 1991, Ishida et aI., 1993, Okamoto et aI., 1990b, 1992d). 
The envelope regions E1 and E21NS1 
El and E2INSI encode the putative viral envelope proteins. Glycoprotein gp33-36 (table 1) bas a 
protein backbone of 18-21 lcDa (Bradley et aI., 1992) and corresponds to the envelope glycoprotein 
gp33 of BVDV and gp25 of HoChV of the Pestiviruses and the envelope proteins (M/E) of the 
Flaviviruses (Weiner et aI., 1992, Houghton et aI., 1991), although there are no significant 
sequence homologies. The protein contains many potential N-glycosylation sites, and glycosylation 
of gp33 bas been demonstrated in a cell-free translation system (Hijikata et aI., 1991a). 
Transmembrane transport of gp33 is presumably facilitated by an N-terrninal stretch of 
approximately 20 hydrophobic antino acids thar functions as a signal sequence, recognized by 
cellular signalase. thereby also cleaving the core protein C22 from the precursor protein. Between 
residues 350-383 a stretch of hydrophobic antino acids is present thar contains a putative 
membrane anchor for the core protein (Heinz, 1992), and a signal sequence for E2INSI (Hijikata 
et aI., 1991a). 
Glycoprotein gp72, encoded by E2INSI (table 1) bas a protein backbone of 38 lcDa 
(Bradley et aI., 1992, Houghton et aI., 1991, Kato et aI., 1991, Hijikata et aI., 1991a). A 
repetitive antino acid sequence has been observed between residue 471 and 511: Pro-(X),-Pro-(X),-
Pro-(X),-Pro-(X),-Pro-(X),-Pro-(X),-Pro (KatO et aI., 1991). A Cys residue is present in each of 
the last 4 intervening (X) sequences. and their positions seem conserved. These findings suggest 
the importance of the complex secondary and tertiary structures of this glycoprotein. The 
corresponding region in Flaviviruses encodes a non-structural homodimeric protein which is not 
present in extracellular virions (Spaete et aI., 1992, Lee et aI., 1989). In contrast, the analogous 
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Pestivirus region encodes the major envelope protein (gp53-55). The HCV gp72 is more heavily 
N-glycosylated than corresponding Flavivirus NS 1 and Pestivirus gp53-55. Because the prhnary 
sequence homology between HeV is higher with Pestiviruses than with Flaviviruses. it has been 
postulated that gp72 may be a structural envelope protein rather than a non-structura1 protein 
(Houghton et al., 1991, Spaete et al., 1992, Riimenapf et al., 1993). The full-length forru of 
E2/NSI is not secreted from the cell, like the Flavivirus NSI protein, but remains cell-associated, 
presumably by the presence of a single transmembrane anchor, since the C-terruinally truncated 
E2/NSI protein is rapidly secreted (Spaete et al., 1992). While the C-terruinus is membrane-
anchored, the N-terruinus of E2INS 1 is located at the outside, and would be subject to surveillance 
of the inunune system. El and E2/NSI proteins appeared to forru complexes (Ralston et al., 
1993), but whether interruolecular disulfide bondings exist, remains unclear (Grakoui et al., 
1993b). 
Comparison of the available E2INS 1 sequences revealed the presence of 2 hypervariable 
regions (Hijikata et al., 1991b, Kato et al., 1992a,b, Weiner et al., 1991a). The first hypervariable 
region (HVR1) is located directly downstream of the putative cleavage site between El and 
E2INSI (between residue 383 and 384, Hijikata et al., 1991a) and covers the 30 N-terruinal 
residues (384-414) of the E2/NSI protein (Weiner et al., 1991a,b). HVRI seems to lack a 
conserved secondary structure and resembles the V3 loop of human inununodeficiency virus 1 
gpl20 (Weiner et al., 1992). Specific antibody reactions were detected against peptides 
corresponding to linear epitopes in HVRl, indicating that the N-terruinal part of the E2 region 
encodes antigenically distinct variants, SUbjected to inunune selection (Weiner et al., 1992, 
Lesniewski et al., 1993). The observed hypervariability may result >.from sequential mutations 
leading to escape from inununereactivity (Kato et al., 1993a). Although HVRI shows 
hypervariation during most chronic infections. conservation has also been observed (van Doorn et 
al., 1993c). This is presumably caused by absence of an adeqnate inunune response against the 
HVRI epitope due to absence of selection pressure favouring new mutants. HVRI can be used to 
specifically distinguish HCV variants, which provides an important tool to study treatment and 
epidentiology of HCV (Weiner et al., 1993, Okada et al., 1992). 
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The second hypervariable region (HVR2) is much smaller and comprises amino acid 
positions 474 to 480 (Hijikata et al., 1991b, Kato et al., 1992a,b). The variability of gp72 may 
have significant implications for the development of a protective immune response and is important 
with regard to vaccine strategies. 
Based on all these data, it is very likely that gp33 and gp72 are the actual envelope 
proteins. although their presence in the mature ReV virion envelope has never been shown. 
The NS2 and NS3 proteins 
The non-structural proteiu 3, designated p72, shows limited amino acid homology with 
correspondiug Flavi- and Pestivirus proteius (Miller and Purcell, 1990). The N-termiuaI one-third 
of NS3 resembles a trypsiu-like serine protease, similar to that found iu Flaviviruses (Chambers et 
al., 1990) and Pestiviruses. If the Ser-1l65 iu the proposed catalytic site is replaced with another 
amino acid, the proteolytic activity of the p72 is abolished (Tomei et al., 1993, Eckart et al., 
1993). This protease is responsible for some processing steps of the precursor polyprotein into the 
mature proteius. All four cleavages that occur C-termiually of the protease domaiu (NS3-NS4a, 
NS4a-NS4b, NS4b-NS5a, and NS5a-NSSb) where abolished by modification of His-I083 and Ser-
1165. These cleavage sites show several common features, which probably determiue the substrate 
specificity of the NS3 protease (Grakoui et al., 1993a). 
Cellular proteases, such as sigual peptidase, are iuvolved iu sequential cotranslational 
processiug of the cleavage sites on the N-termiuus of EI, E2, aud possibly NS2. The NS2-NS3 
cleavage is mediated in cis by a Zn2+ requiring metalloproteinase. The region between residue 898 
to 1233, which comprises parts of both NS2 aud NS3, was shown to be essential for the detection 
of this second viral protease (Hijakata et al., 1993a). NS3 acts in cis on its own C-termiuus, but 
the remaiuiug 3 C-termiuaI sites cau be ouly processed by NS3 in trans (Tomei et al., 1993). 
There is also homology between NS3 aud nucleoside triphosphate-biudiug helicase enzymes that 
are presumably iuvolved iu the unwiuding of the dsRNA replicative iutermediate necessary for 
genome replication (Houghton et al., 1991). 
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The NS4 protein(s) 
The function of this protein. which is processed into NS4a and NS4b, remains nnknown. The 
proteins contain highly innnnnogenic epitopes and several predicted transmembrane regions. The 
first cloned C 100 antigen, which is used in most antibody detection assays. is an unnatural antigen 
spanning the C-terminns of NS3, NS4a and the N-terminus of NS4b. 
The NS5 protein(s) 
The non-structural protein 5 is processed into NS5a and NSSb. The latter shows significant amino 
acid sequence homology with the putative RNA-dependent RNA replicase from Carnation Mottle 
Virus (CARMY; Miller and Purcell, 1990). This is remarkable as CARMY is a member of the 
Carmovirus group of plant viruses. Furthermore, the NS5 region contains a Gly-Asp-Asp sequence 
(res. 2737-2739), which is a well-known characteristic sequence motif for all RNA-dependent 
RNA polymerases of positive-strand RNA viruses (Koonin, 1991). Therefore, NSSb encodes the 
viral replicase, and the activity of this enzyme has been demonstrated in vitro recently (Chnng et 
al., 1992). The function of NS5a is nnknown, but the protein contains important B-cell epitopes 
(DeLeys, 1993). 
Processing of NS5 into NS5a and b is observed in Pestiviruses but not in -Flaviviruses 
(Selby 1993). The C-terminal pan (P70) contains the consensus polymerase sequences. 
It has been suggested (Okamoto et al., 1992b) that in some isolates a secondary structure 
of the genomic RNA exists at the C-terminal pan of the NS4 region that could possibly form an 
IRES. This IRES would be located just upstream of a common in frame ATG codon, allowing 
earlier production of NS5 encoded replicase. Consequently. this would accellerate the replication 
rate of the genomic RNA. However. no experimental data are yet available to confirm this 
hypothesiS. 
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The 3' uniranslated region 
The stop codon of the large open reading frame is preceeded by a stable DNA stem-loop structure 
at the 3' end of the NS5 region (van Doom, nnpublished observations). This secnndary structure 
might be equally important for proper termination of translation as the structure at the 5' UTR is 
for initiation of translation. The reported 3~ untranslated regions show significant variations. both 
in length and in seqnence. The most important difference is the observation of a poly(rA) tail in 
some isolates (Choo et al., 1991a, Han et al., 1991), whereas in other isolates (Kato et al., 1990a, 
Takamizawa et al., 1991, Chen et al., 1992, Okamoto et al., 1991, 1992a, Tanaka et al., 1992) a 
poly(U) tail is fonnd. It is unknown whether the reported 3' tetminal seqnences are complete. A 
small putative haitpin structure has been described (Inchauspe et al., 1991) but the calculated 
thermodynamic stability is low and significance remains obscure. 
Morphology of the HCV virion 
Little is known about the precise morphology of the HCV viral particle, as the virus has never 
been seen (Overby, 1993). Since 1975, a variety of particles have been observed by electron 
microscopy and were attributed to NANBH (Spichtin, 1985), but these findings could not be 
substantiated. 
Recent filtration studies. using the quantitative reverse transcription polymerase chain 
reaction (RT -PCR) techniqne to detect the viral genome, estimated a particle diameter between 30 
and 38 nm (Yuasa et al., 1991). 
Several authors described the detemtination of the buoyant density of the HCV virions by 
gtadient ultracentrifugation, followed by testing the fractions for infectivity, presence of core 
antigen or HCV RNA. (Bradley et al., 1991c, Carrick et al., 1992, Takahashi et al., 1992, 
Miyamoto et al., 1992, Hijikata et al., 1993b). Usually, two virus containing fractions were 
obtained, with buoyant densities of < 1.03-1.08 glm! and 1.11-1.25 glm!, respectively. 
Differences bet\Veen several reports may be either due to differences in the fractionation protocols 
or may indeed reflect the density variation among HeV isolates. The average density of the 
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presumptive HeV particles (± l.08 g/ml) is similar to that of BVDV (l.09-1.15 g/ml), but 
slightly different from that of the Flaviviruses (±l.20 g/ml, Bradley et al., 1991c). 
The HeV containing fractions with the lower density probably represent the native HeV 
virions (Takabasbi et al., 1992a). Higher density fractions putatively contain nucleocapsid 
particles, consisting of core protein and RNA. Icosabedral-shaped particles with • diameter of 
approximately 33 nm. were observed after specific capture onto anti--core monoclonal antibody 
coated grids. indicating the presence of native core antigen in such particles. Furthermore. these 
nucleocapsid particles could be released from the larger virus-like particles by treatment with mild 
detergents (Takabashi et al., 1992a,b). 
Interaction between HeV virions and anti-Hey innnunogiobulins can affect the buoyant 
density and seems associated with infectivity of the sample (Hijikata et al., 1993b). HeV with low 
infectivity, associated with innnunogiobulins was present in high density ultracentrifugation 
fractions, whereas HeV with high infectivity, without innnunogiobulins, was predominant in low 
density fractions. Furhtermore, examination of serial samples from an HeV-infected chimpanzee 
revealed changes in buoyant density during the course of infection, parallel to the development of 
anti-Hey. These data suggest that Hev is bound to anti-Hey antibodies in antigen-antibody 
complexes. 
In gradient fractions, spherical particles with a diameter of 36-62 nm were observed, 
which morphologically resemble toga- and Flaviviruses, with a unit membrane envelope with 
surface projections. Inside hepatocytes, 37-40 nm particles were found, often in lysosomes (Abe et 
al., 1991.). Toga-like viruses with a diameter of 50-60 nm had been observed previously in nuclei 
of hepatocytes from patients with fuIntinant non-A, non-B hepatitis (Fagan et al., 1989). 
Although these findings are suggestive for the nucleocapsid particles, there is still no direct 
proof that the observed larger virus-like particles indeed represent native HeV virions. 
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Sequence variation and genotyping 
During replication of the viral genome by the NS5 encoded RNA-dependent RNA polymerase, 
errors may occur. resulting in mutations. Some mutations are tolerated whereas others may abolish 
or hamper proper functioning of the resulting virion, By this method of ' error and trial', variant 
RNA genomes evolve. The coexistence of several closely related sequences in a single patient has 
been observed (Oshima et al" 1991, Okada et al" 1992, Murakawa et al" 1992, Tanaka et al" 
1992), 
The distribution of mutations along the genome is not random. First, this depends on the 
impact of each mutation on the efficacy of viral replication, Mutations that disturb the virus life 
cycle will obviously not be detected in the population, The innnune system of the infected host 
offers the second level of selection pressure on mutant viral genomes. 
The 5' UTR is remarkably conserved, whereas E2INS 1 contains a hypervariable region at 
the N-terminus. The overall mutation rate of the ReV RNA genome has been estimated between 
0,9 and 1.92 x I<r' base substitutions per genome site per year (Ogata et al., 1991, Okamoto et 
al., 1992b, Abe et al., 1992). However, it is difficult to assess the real mutation rate. First, the 
sequence analysis is performed on independent clones or directly on amplified DNA. Both methods 
have statistical limitations to detect rare sequences in a population of slightly different viral 
genomes. Secondly. most patients are Dot infected by a single virion. Especially infectious 
materials derived from plasma pools, such as factor vm preparations, may contain a large variety 
of HCV sequences. Consequently, the observation of closely related HCV sequences (designated as 
, quasispecies') in a single patient at different timepoints may be caused by both selection and 
mutation of sequences present in the inoculum. Sequentially emerging HCV sequences, able to 
escape neutralizing innnune activities (Kato et al., 1993), possibly playa crucial role in the 
persistence of virentia during chronic HCV infection. 
The first full-length HCV sequence was derived from a chimpanzee infected with a 
contaminated American Factor vm concentrate (Houghton et al., 1990, Choo et al., 1991a,b). 
This sequence became known as the HCV prototype, HCV-US or HCV-I, to which each new 
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Table 2. Nomenclatures for HeV genotyping 
representative Stuyver BukhI ChanI Cha/ Enomoto! Okamoto 
sequence Purcell Simmonds Urdea Date 
HCV-I, H la la I K-PT I 
HCV-J, HCV-BK Ib Ib II K-I II 
HC-J6 2a 2a 2 ill K-2a ill 
HC-J8 2b 2b 2 ill K-2b IV 
E-bl, Ta 3a 3a 3 IV nc V 
Th, Tr 3b nc nc IV nc VI 
EG-16, GB1l6, 244a 4a 4 nc nc nc 
GB549,21 4b 4b nc nc nc nc 
GB809,26 4c 4c nc nc nc nc 
DKI3 nc 4d nc nc nc nc 
SAl, BE95 5a 5a 5 V nc nc 
HKI nc 6a 6 nc nc nc 
Origin of reported isolates: 
HCV-I: Choo et aI., 1990; H: Ogata et aI.,1991 and Inchauspe et aI., 1991; HCV-J: Kato et 
aI.,1990; HCV-BK: Takatnizawa et aI., 1991; HC-J6: Okamoto et aI., 1991; HC-J8: Okamoto et 
aI., 1992; E-bl : Chan et aI., 1992; Ta: Mori et aI., 1992; Th: Mori et aI.,1992; Tr: Chayama et 
aI., 1993; EG-16: Simmonds et aI., 1993a; GB1l6, 549, 809: Stuyver et al., 1993c; 21, 24, 26, 
DK13: Bukh et aI., 1993b; SA-I, Bukh et aI., 1992a; BE95: Stuyver et aI., 1993c; HKI: 
Simmonds et aI., 1993a. nc= not classified 
sequence is compared. Larer, full-length sequences from Japanese HCV isolates (HCV-J, Kato et 
al., 1990a and HCV-BK, Takatnizawa et aI., 1991) were shown to be significantly different from 
the prototype. The different strains were provisionally designated as 'American' and 'Japanese' 
strains. Since then, several full-length (Okamoto et aI., 1991, 1992a, Chen et aI., 1992, Tanaka et 
aI., 1992) and numerous partial nucleotide sequences (e.g., Kubo et aI., 1989, Kato et al., 1990b, 
Enomoto et aI., 1990, Mori et aI., 1992) from different geographic areas wete reporred. 
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Comparison of various HCV sequences (Kubo et aI., 1989, Simmonds et aI .• 1990, Li et aI .• 
1991) revealed the presence of similar viral variants in different areas of the world, and initiated 
attempts to classify the ReV isolates into distinct groups. Initial classifications were based on 
various genomic regions, and the associated nomenclatures using individual isolate names were 
confusing (table 2). 
Analysis of NS5 sequences among Japanese isolates also revealed the presence of two 
types, designated as KI and K2 (Enomoto et aI., 1990). KI is closely related to the American 
prototype HCV-1. K2 is more homologous to rwo other sequences, HC-J6 and HC-J8 (Okamoto et 
aI., 1991, 1992a) and could be further divided into K2a and K2b with an homology of about 80%. 
Based on these findings, a phylogenetic tree containing four branches was proposed, comprising 
genotypes I-JV (Okamoto et aI., 1992a). This tree was extended with new branches representing 
types V and VI by HCV isolates from Thailand (Mori et aI., 1992) and similar European isolates 
(Chan S.W. et aI., 1992). This provisional classification system was based on chronological order 
of discovery and did not properly reflect the relationship between sequences. 
Recently, a new classification system was proposed (Chan S.W. et aI., 1992, Stuyver et 
aI., 1993a, Simmonds et aI., 1993a) based on sequence aligmnents of a large number of HCV 
sequences derived from several parts of the genome. Construction of phylogenetic trees revealed 
that comparison of 5' UTR, core. NS3 or NS5 resulted in similar classifications of HCV isolates 
into types and subtypes (Chan S.W. et aI., 1992). Isolates belonging to the same subtype show an 
average nucleotide homology of 88%, those belonging to different subtypes 78% and isolates of 
different types about 68% (Weiner et aI., 1991b, Stuyver et aI., 1993a). The proposed 
nomenclature is more functional as it is associated with the degree of homology between 
sequences, and new (sub)types can easily be added to the system. Table 2 shows a summary of the 
different classification systems. 
Geographic distribution of HCV genotypes is subject of current investigations (Takada et 
aI., 1993, Brechot and Kremsdorf, 1993, Cha et aI., 1992, Simmonds et aI., 1993 .. Chan S.W. et 
aI., 1992, Kleter et aI., 1994, Stuyver et aI., 1993a, Chayama et aI .• 1993, Li et aI., 1991). 
Genotype Ib seems to be the most abundant variant worldwide, with a high incidence in Japan and 
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Western Europe. Prototype la is relatively rare in these areas, but more prevalent in America. 
Genotype 2 is found less often in Europe than in Japan and in China. Genotypes 3 to 6 have been 
identified only recently and their distribution is not known at the moment. It is likely that most 
HCV genotypes coexist worldwide, but the incidence may vary considerably between locations. 
There are indications that different (sub)types of HCV may have different clinical relevances. such 
as the success of interferon treaunent (Okamoto et aI .• 1992c. Pozzato et aI., 1991, Yoshioka et 
aI., 1992, Takada et aI., 1992) and may be the risk to develop cirrhosis or hepatocellular 
carcinoma. Also different HCV genotypes may evoke different serological responses (Chan et al., 
1991, van Doorn et aI., 1993b). Sequence diversity may result in the production of type-specific 
antibodies in infected hosts. Genotype-specific antibodies have been foUnd to react with the core 
protein (Machida et aI., 1992), the NS4 protein (Stuyver et aI., 1993b, Sinnnonds et aI., 1993b, 
Tsukiyarna-Kohara et aI., 1993) and the EI envelope protein (Maertens et aI., 1993). However, 
specificity is still limited and prevents routine applications, RNA analysis remains the only 
available technique for HCV genotyping. 
Currently, genotyping can be performed by type-specific PCR primers (Okamoto et aI., 
1992c, Chayarna et aI., 1993), direct sequencing (Kleter et ai, 1994, Cha et aI., 1992), restriction 
fragment length polymorphism (Nakao et aI., 1991), Southern blot hybridization with type specific 
probes (Enomoto et aI., 1990, Takada et aI., 1993) or reverse hybridization to (sub)type specific 
probes (Stuyver et aI., 1993a). 
As each distinct genotype seems to be maintained throughout the HCV genome, the 
possibility to use the 5' UTR for genotyping has been investigated recently and offers several 
advantages. First, many 5' UTR sequences from isolates obtained in various parts of the world 
have been deterntined (Bukh et aI., 1992a, Sinnnonds et aI., 1993a, Kleter et aI., 1994). Sequence 
alignments revealed extreme conservation in this region, except two more variable motifs that 
allow discrimination between (sub)types (Stuyver et aI., 1993a). These motifs, as shown in figure 
2, are partly complementary and can form a stable double-stranded RNA stem-loOp structure 
(Brown E.A. et aI., 1992, Tsukiyarna-Kohara et aI., 1992). Genotypic-specific variations in these 
motifs often occur as covariants, thereby leaving the secundary structure unchanged (Simmonds et 
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aI .• 1993a). This implicates structural and functional conservation of this sequence. Furthermore, 
the 5' UTR is used extensively for determination of viremia by the polymerase chain reaction 
(PCR), and subsequent use of the same PCR product for genotyping is complementary to routine 
HCV diagnostics. 
Clinical aspects and Epidemiology of HCV infection 
Most HCV infections are subclinical, often even asymptomatic, and up to 25% of the patients 
(Alter, 1990) develop jaundice. If symptoms are present during the acute phase they are typical of 
viral hepatitis and indistinguishable from infection with HA V or HEV. Fulminant hepatitis due to 
HCV infection is extremely rare (Theilmarm et aI., 1992, Liang et aI., 1993a, Forayet aI., 1993). 
Elevated levels of liver-specific transaminases. such as ALT. in the serum, provide an important 
tool to assess liver injury due to viral infection. Different patterns of AL T elevations have been 
observed in HCV infections. A serum ALT peak is often detected after about 8 weeks. It is 
assumed that complete clearance of the infection after acute resolving hepatitis is possible. 
although it has been speculated that eventually all HCV infections may become chronic (Prince et 
aI., 1993). It has been established that a relatively high percentage (50.75%) of HCV infected 
individuals proceed towards chronicity. Chronic hepatitis is defined by AL T elevations persisting 
for more than a year after the onset of hepatitis (Alter, 1990). Development of cirrhosis has been 
documented but the factors affecting this course have been incompletely identified. HeV infection 
has been found to be a significant risk factor for the development of hepatocellular carcinoma in a 
number of studies (Saito et aI., 1990, Kew et aI., 1990, Tsukuma et aI., 1993, Bukh et aI., 1993) 
although causality has not been proven. Progression towards liver cancer is slow. and it usually 
follows the development of cirrhosis, although it may evolve more rapidly in elderly patients 
cYano et aI., 1993). 
Most infected patients develop antibodies against HCV epitopes, after a variable period 
after infection. Individual antibody responses may he very different due to the variability of the 
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virus or the host immune system. HeV RNA is detectable (see below) very rapidly after infection, 
usually within one week. During cbronic infection, anti-HeV and HeV RNA may become 
transiently undetectable, indicating that the viral titer may vary considerably. Figure 3 illustrates a 
typical clinical profile of a cbronic HeV infection. 
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Figure 3. Schematic representation of a clinical pattern of a chronic Hev infection. 
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Percutaneous or parenteral transmission of ReV has been documented extensively (Aach 
et aJ., 1991, Mosley et al .• 1991, Esteban et al., 1991, Alter, 1991, Donabue et al .• 1992, van der 
Poe1 et al., 1990). 
The positivity rates of antibodies agaiust HCV in normal blood donors range from 
approximately 0.2% in Northern Europe to 1.5% in Japan. However, positivity rates as high as 
20% in Egypt (Saeed et al., 1991) and 6% in Africa have been described (Alter, 1990). Anti-HCV 
screening programs for blood donations resulted in a significant reduction of posttransfusion cases 
(Alter H.I. et al., 1989, Alter, 1990, Japanese Red Cross NANB Research Group, 1991). 
However. antibody assays have limited sensitivities, and up to 40% of the infectious blood samples 
may remain undetected (Sugitani, 1992). 
Although it has traditionally been considered a transfusion-associated disease, the majority 
of HCV infections occur outside the transfusion setting (Alter M.J., 1991). Intravenous drug users 
and hemophiliacs are at high risk for HCV infection. Prevalence of anti-HCV antibodies among 
these groups can be higher than 50% (Esteban et al., 1989, Stary et al., 1992, Weiland and 
Schvarcz, 1992). Transmission of HCV by sexual contact seems to be inefficient (Brettler et al., 
1992, Kolho et al., 1991, Stary et al., 1992). However, although the sexual transmission is less 
efficient than for HJV, it may not be unimportant for the spread of the disease (Kao et al., 1992, 
Alter M.I. et al., 1989, 1991). Coinfection with HCV and human immunodeficiency virus (HIV) 
increases the risk for sexual ReV transmission considerably, which is important in high risk 
populations (Stary et al., 1992, Eyster et al., 1991, Botti et al., 1992). Mother-to-child (vertical) 
transmission seems a rare event (Fortuny et al., 1991, Nagata et al., 1992, Inoue et al., 1992). 
There may be discrepancies between results of anti-HCV determinations and HCV-RNA assays 
(Roudot-Thoraval et al .• 1993, Lam et al., 1993, Kuroki et al., 1993). Coinfection of HCV and 
HJV in the mother may increase the risk of HCV transmission to the infant (Giovannini, 1990, 
Perez Alvarez et al., 1992, Novati et al., 1992). The positive influence of HIV infection on the 
efficiency of sexual and vertical ReV transmission may be due to increased ReV titers in the 
circulation, probably caused by reduced immune activity of the host. 
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Approximately 50% of HCV cases in the USA can be traced to parenteral modes of transmission. 
The remaining half the cases are due to community-acquired or sporadic transmission. The 
epidemiology of community-acquired HCV is complicated by the various definitions and 
differences between studies. The percentages range from 40-50% (Alter MJ, 1991, Bortolotti et 
al., 1991) to lower than 5% (Hollinger and Lin, 1992, Pohjanpelto, 1992). It is often difficnlt to 
elucidate the source of infection, as it is unlmown whether, e.g., mucosal exposure is a possible 
route of transmission. Some reports (Abe et al., 1991b, Takamatsu et al., 1990, Wang et al., 
1992b, Couzigou, 1993) claim the presence of HCV-RNA in saliva, although others challenge this 
(Hsu et al., 1991, Fried et al., 1992). Infectivity of saliva was shown in experimental infection in 
chimpanzees (Abe et al., 1987) but whether HCV transmission via saliva is an important 
epidemiologic factor remains unknown. Mucosal transfer of HeV might explain the (limited) 
increased risk for health care workers, such as oral. surgeons and dentists (Jochen. 1993. Klein et 
al., 1991). The presence of HCV in bndy secretions, such as saliva, probably reflects a high level 
of viremia in the circnlation. The higher the virus load, the higher the risk of transmission of 
HCV via sexual or household contacts. HCV RNA could not be detected in semen of 6 men with 
HCV-RNA positive serum (Terada et al., 1992). 
Since the infectious titer of HCV is usually much lower than, e.g., HBV, the risk of 
transmission via needlestick accidents seems very low (Mitsui 1992), although repeated exposures 
to possibly low-level contaminated equipment, such as dialysis units, increase the risk of HCV 
transmission (Schlipkoter et al., 1992, Chan T.M. et al., 1992) 
Initial epidemiological surveys of HCV transmission used first generation ami-HCV tests. 
Since these tests proved insufficient, data should be interpreted with care. Now that second and 
third generation antibody assays, as well as sensitive HCV-RNA detection are available, 
epidemiological studies are more reliable. HeV seems to have a worldwide distribution. different 
from the distribution of HBV. Whether this reflects other or additional modes of transmission of 
HCV is not clear (Yano, 1992). 
In the near future the importance of the viral (sub)type in epidemiology will be studied 
extensively. Preliminary results show that type 1 is the most common HeV genotype worldwide 
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and subtype Ib is less sensitive to treatment with interferon-a. Also the putative correlation 
between prolonged HCV infection and the development of hepatocellular carcinoma (Kew et al., 
1990) must be investigated in more detail. 
The recent discovery of HCV and HEV and the availability of sensitive assays for hepatitis 
viruses A through E allows identification of most hepatitis cases. However, some cases still cannot 
be attributed to any of these viruses and remain undiagnosed (Favorov et al., 1992, Arankalle et 
al., 1993, Thiers et al., 1993, Azar et al., 1993). 
Diagnosis of Hepatitis C virus infection 
Specific diagnosis of HCV instead of diagnosis by exclusion is an important achievement since the 
discovery of HCV in 1987. Identification of infected individuals prevents them from donating 
blood and limits the spread of the disease. Elimination of contaminated materials, derived from 
human blood, such as factor VllJ, also prevents infection in recipients of these products. 
Furthermore. current diagnostic tools allow efficient monitoring of antiviral therapy. 
Detection of specific antibodies agalnst viral epitopes (Kuo et al., 1989) is an indirect 
indication of viremia. However. antibody detection is relatively cheap, easy to perform in large 
quantities and often correlates well with the presence of the virus itself (van der Poel et al., 1991, 
Reuter et al., 1992). However, there are also important limitations. Firstly, antibodies are only 
produced after a variable interval following infection. During this 'seronegative window' the 
patient is infectious and should be excluded from blood donations. Secondly, there are 
considerable differences between individual immune responses of patients, also affecting the length 
of this window. 
Several antibody detection systems were developed. during the past years, with increasing 
sensitivity and specificity. The first cloned antigen of HCV, designated CIOO-3, was produced in 
g. coli as a fusion protein with SuperOxide Dismutase (SOD; Kuo et al., 1989) and was used in 
the first generation anti-HCV assays, together with the smaller 5-1-1 protein. Both sensitivity and 
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specificity of this test were shown to be insufficient (van der Poel et aI., 1991, Yatsnhashi et aI., 
1992, Wong et aI., 1990, McFarlane et aI., 1990). Anti-ClOO-3 negative blood may still be 
infectious and transntit HCV to recipients (!naba et aI., 1991). This is probably due to 
immunological incompetence in some individuals (Hosada et al .• 1992) and to sequence variation 
in NS4. 
Second generation assays were developed to overcome these problems and additional HeV 
antigens were included in the tests, such as recombinant NS3/NS4 (C33c, C200) and core (C22c) 
proteins. These assays detect more true positives among various risk groups than the first 
generation assays (McHutchinson et aI., 1992). Routine diagnosis is performed by Enzyme 
Immunoassays (EIA) in nticrotiter plates. Initial positive samples can be further confirmed by a 
neutralization-based test or by immunoblot assays, such as RIBA (recombinant immunoblot assay; 
van der Poel et aI., 1991, Tanzi et aI., 1992) and LIA (Line Immuno Assay, Chan et aI., 1991, 
Peeters et al .. 1993). These confirmation assays are DecesSary to exclude false positive reactions 
(Chaudhary et aI., 1991) and also allow the discrintination of the immune response against distinct 
viral epitopes. An increasing number of anti-HCV tests are based on the use of synthetic peptides 
(Okamoto et aI., 1990b, Hosein et aI., 1991, Kotwal et aI., 1992, Ching et aI., 1992, Brown D. et 
aI., 1992) or chimeric recombinant antigens (Chien et aI., 1992), resulting in more efficient 
diagnosis of HCV infection. 
Anti-eore assays are particularly useful for HCV diagnosis, as these increase the detection 
rate and limit the 'seronegative window' after inoculation (Vallari et aI., 1992, Katayama et aI., 
1992, Okamoto et aI., 1990b). The nucleotide sequence of the core gene is relatively well 
conserved, allowing serological detection of different HCV genotypes. 
Detection of HBV surface and core antigens (HBsAg and HbcAg) in the bloodstream are 
important diagnostic tools. Direct detection of HCV proteins in blood seems possible (fakahashi et 
aI., 1992b) but due to the limited sensitivity and usually low HCV titers this is not applicable for 
routine diagnostics. 
The only method to deterntine viraentia is specific detection of HCV RNA. This can be 
achieved by direct detection of circulating HCV RNA by slot blot hybridization to radiolabelled 
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riboprobes (Hu et al .• 1992) or inside hepatocytes by in situ hybridization (Blight et al., 1992). 
However~ the sensitivities of these methods are limited. Currently. HeV RNA is assayed by a 
combined reverse transcription polymerase chain reaction CRT -peR). This method is extremely 
sensitive and allows detection of minute quantities of HeV RNA even in plasma pools. During the 
early phase of primary HCV infection, HCV-RNA is the only diagnostic marker of infection (Kato 
et al., 1993b). Although detection of HeV RNA correlates very well with viraemia. is superior to 
anti-HCV detection (Sugitani et al., 1992) and can predict infectivity, it is important to note that 
lack of PCR positivity does not absolutely rule out infectivity (Garson et al., 1990, Barbara et al., 
1993). 
A variety of RT-PCR assays for HCV RNA detection have been described and allow HCV 
RNA detection in plasma and liver samples (Weiner et al., 1990, Wolff et al., 1992). Most 
systems employ primers from the highly conserved 5' UTR (Cha et al., 1991), since these allow 
detection of all known genotypes with a single set of primers. To enhance sensitivity the size of 
the PCR product can be reduced (Garson et al., 1991) and nested PCR can be performed 
(Okamoto et al., 1990c, Lin et al., 1992, Gretch et al., 1993). The use of degenerated primers 
allows detection of all currently known genotypes (Stuyver et al., 1993b). Using sense cDNA 
primers, RT-PCR allows specific detection of antigenomic HCV RNA, indicative of viral 
replication (Takehara et al., 1992). 
Despite the availability of a wide range of RNA isolation protocols (van Doorn et al., 
1992, Ulrich et al., 1993) and PCR primer combinations, the reliability of RT-PCR for HCV 
RNA detection remains a problem (Zaaijer et al., 1993). Both sensitivity and specificity need to be 
improved considerably to compare experimental results from different laboratories. Furthermore, 
the handling and storage of blood samples, suitable for HCV RNA detection must be standardized 
to prevent degradation of HCV RNA (Busch et al., 1992, Wang et al., 1992a, Cuypers et al., 
1992). 
Quantitative analysis of HCV RNA can be achieved by two methods at present. 
Competitive PCR employs a modified RNA transcript or cDNA which is processed along with the 
sample of interest in serial dilutions (Kaneko et al., 1992, Hagiwara et al., 1993). This method is 
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tedious and very contamination prone. More importantly, competitive peR should use known 
quantities of control molecules not only during PCR but throughout the entire detection method, to 
assess influences from isolation and cDNA procedures. 
An alternative procedure is not based on RT -PCR, but uses specific capture and branched 
DNA to detect HCV RNA specifically (Urdea, 1993), Although the latter method is easy to 
perform, relatively contamination proof and omits exponential enzymatic DNA amplification, 
sensitivity is limited to approximately 350,000 equivalents/mL 
HCV RNA quantitation will become more important, since it can have significant clinical 
implications (Lau, 1993), such as the efficacy of interferon-a treatment in chronic HCV infections 
(Shindo et al" 1991, Weiland et al" 1993) and the relation between viral titer and infectivity of 
body secretions. 
Therapy of HeV infection 
In 1986, Hoofnagle et al, treated chronic non-A, non-B hepatitis patients with imerferon alpha-2b 
(Hoofnagle et al., 1986) and succeeded in inducing remission in eight of the ten patients. Several 
other trials with interferon treatment followed (Thomson et al., 1987, Davis et al., 1989, Di 
Bisceglie et al., 1989). Based on improvement of serum ALT, and liver histological abnormalities, 
these studies suggested a therapeutic effect of interferon. Interferon has pleiotropic effects that are 
antiviral and immunomodulatory. Long-term follow-up of interferon-treated patients showed that 
normalization of ALT levels is often accompanied by disappearance of detectable HCV RNA from 
the serum (Shindo et al., 1992b). Failure to normalize ALT levels during interferon treatment is 
consistent with resistant viral infection. Treated patients can be classified into different categories. 
Complete responders show complete normalization of ALT and disappearance of circulating HCV 
RNA. Partial responders exhibit a significant reduction, but not a complete normalization of AL T, 
and HCV RNA often remains detectable at a lower leveL Nomesponders do not reveal any 
improvement after interferon treatment. During posttberapy follow-up, a high percentage of the 
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initial responders show a relapse of disease. with returned elevated AL T and detectable serum 
ReV RNA (Shindo et al., 1992b, Douglas et al., 1993). 
The reported success rates of interferon treatment differ significantly. The relevances of 
the dose and administration schedule of interferon are not completely clear (DiBiceg1ie et al., 
1989, Benelux Multicentre Trial Study Group, 1993, Liang et al., 1993b). The severity of chronic 
HeV infection. assessed by liver histology. is negatively correlated with the outcome of interferon 
treatment (Uchida et al., 1993). Differences between ReV genotypes may also have important 
implications. Sensitivity of genotype I to interferon treatment seems lower than that of genotype 2 
(rakada et al., 1992, Yoshioka et al., 1992, Pozzato et al., 1991). This phenomenon is possibly 
correlated with the infectious titre of ReV before onset on treatment. Patients with a high quantity 
of ReV RNA in the serum are less likely to respond than patients with low ReV RNA 
concentrations (Lau, 1993, Ragiwara et al., 1993, Yamada et al., 1992). Levels of viremia of the 
different ReV genotypes seems to be significantly different (Kleter et al., unpublished 
observations). Furthermore, the mode of acquisition is found to be an important determimmt of the 
level of ReV viremia (Lau 1993). 
In conclusion, interferon therapy can lead to complete and sustained response. but the 
success depends on multiple virus~ and host-related factors. 
Developments 
In the past 5 years substantial progress has been made after the discovery of ReV. The virus itself 
has been characterized intensively and our insight in its biology increased tremendously. However. 
the picture is far from complete. Little is known about the mechanism of virus persistence during 
chronic infections, evolution of the viral genome. and response to antiviral treatments. 
The clinical diagnosis of ReV-RNA must be improved and standardized, and quantitative 
analysis should be included, given the recent indications of clinical importance. Antibody 
screening must be improved and should possibly lead to serolOgic typing assays to differentiate 
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between the various Hev genotypes. A special problem are seronegative samples that remain 
undiagnosed by the current screening assays. Direct detection by molecular biological methods 
could solve this problem but due to tecbnicallimitations. this approach seems not feasible yet. 
The question remains whether protective immunity against HCV can be achieved, and how 
vaccine strategies should be developed. Initial vaccination experiments pennit little optimism and 
progress towards an effective vaccine might take many years. 
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Outline of the thesis 
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This thesis describes several aspects of hepatitis C virus (HCy) infections. The first part focuses 
on the diagnosis of HeV viraemia, by detection of the viral RNA genome. Chapter 2 describes the 
development of a novel technique for isolation and purification of HCV RNA from blood samples. 
This RNA-eapture method is applied to investigate the presence of HCV RNA in chimpanzee 
plasma samples that were obtained at least 2 years after experhnental Non-A, non-B hepatitis 
(NANB) inoculations. HCV RNA results are compared with results from a Line Immuno Assay 
(LIA), which detects anti-HCV antibodies. Chapter 3 focuses further on the HCV RNA-eapture 
technique described in chapter 2. The method is optimized, and the performance is evaluated by 
comparing specificity and sensitivity with a highly sensitive standard HCV RNA detection 
technique in a coded panel of patient samples. HCV RNA results are correlated with anti-HCV 
determination by a Line Immuno Assay (LIA). 
The second part of this thesis (chapter 4) describes experimental HCV infections in a 
cohort of chimpanzees. The presence of HCV RNA is monitored by the optimized RNA-capture 
assay and anti-HCV is measured by the LIA in serial sertnn samples obtained before and during 
HCV infection. In order to determine the genomic stability of this particular HCV isolate during 
chronic infection or after transmission to other chimpanzees, sequence variation of the putative 
hypervariable region in the E2INS! region is studied. 
The third part of the thesis focuses on the recognition of HCV genotypes. HCV isolates 
can be classified into different genotypes based on sequence variation of the RNA genome. 
Whether the highly conserved 5' UTR allows sufficient discrhnination between HCV genotypes is 
studied in chapter 5. In chapter 6, 5' UTR based genotyping with a reverse hybridization Line 
Probe Assay (LiPA) is evaluated by comparison with sequence analysis. Furthermore, the 
correlation between the viral genotypes and detection of antibodies to specific HeV epitopes is 
investigated to assess the possibility of serological discrimination. To substantiate genotyping by 5' 
UTR analysis, a large cohort of HCV patients was genotyped by LiPA, as described in chapter 7. 
For each genotype several isolates were further characterized by sequence analysis of both the 5' 
UTR and the N-terrninus of the core region. Classifications of isolates based on the 5' UTR and 
on the core region are compared. 
Finally, chapter 8 summarizes and discusses the results and conclusions from this thesis. 
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CHAPTER 2 
Hepatitis C virus antibody detection by a 
line immunoassay and (near) fulliengtb genomic RNA 
detection by a new RNA-capture 
polymerase chain reaction 
Leen-Jan van Doorn, Alex van Belkum, Geert Maertens', Wim Quint, 
Ton Kos', and Huub Schellekens'. 
SSDZ Diagnostic Centre, Department of Molecular Biology, Delft, the Netherlands. 'Innogenetics 
N.V., Gent, Belgium. 'ITRI-TNO, Rijswijk, the Netherlands. 'Diagnostic Centre SSDZ, Dept. of 
Jnnnunology and Infectious Diseases, Delft, the Netherlands. 
Journal oj Medical Virology (1992), 38: 298-304. 
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Abstract 
A rapid and simple RNA-capture polymerase chain reaction assay (RCPA) for detection of 
hepatitis C virus (HCV) is described. The assay detects specifically the presence of (near) full 
length genomic RNA of HCV by capturing HCV-RNA at the 3' terminus on magnetic beads, 
followed by cDNA synthesis and PCR with 5' end specific primers. 
Sera were obtained from 30 chimpanzees inoculated with non-A, non-B hepatitis from 
various sources, 28-122 months after infection. The sera were tested for the presence of HCV-
RNA by RCPA and for HCV antibodies by the Line Immuno Assay (lnno-LIA). Both tests were 
compared and show a bigh degree of agreement. Screening of 30 chimpanzee sera revealed either 
clearing of the virus below detection level (22/30) or development of an HCV carrier state (8/30). 
Only I of II LIA-indeterminate samples was positive by RCPA. As the RCPA is more sensitive, 
it can be used to test for the presence of HCV in sera that are classified as indeterminate by the 
LIA. 
The outcome of the infection seems to be independent of the nature of the inocula, 
suggesting that the individual immune response could determine either clearing of the virus or the 
development of chronic infection. 
Introduction 
Hepatitis C virus (HCV) is the major cause of post-transfusion non-A, non-B Hepatitis (NANB) 
(Choo et aI., 1989; Kuo et aI., 1989). The virus possesses a positive-sense, single stranded RNA 
genome of about 9,500 nucleotides. and the genome organization closely resembles that of Flavi-
and Pestiviruses (Choo et aI., 1991; Miller and Purcell, 1990). As the virus is transmitted by 
blood and blood products, bighly sensitive methods for detection of the virus are important. The 
estimated average titre of HCV in blood is relatively low (Bradley et aI., 1983; Sinunonds et aI., 
1990; Bradley et al., 1985), and so far it has been impossible to assay vira1 proteins directly in 
serum. Specific amibodies against several viral protein components can be detected by ELISA. 
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These, however, provide indirect information about the presence of virus in the sample. On the 
other hand, viral RNA can be detected directly by cDNA synthesis and by PCR, 
Most protocols for isolation of viral RNA from serum involve phenol extractions and 
ethanol precipitation of total RNA, with considerable risk of contamination in the peR reactions. 
Furthermore, considerable amounts of material are lost during the process. These factors hamper 
routine testing of larger numbers of samples in clinical laboratories. A very simple method for 
specific purification of full length genomic HCV-RNA was developed by selective RNA-capture, 
with low risk of contamination. The purification process eliminates phenol-extraction and 
precipitation steps completely and requires minimal sample handling. Furthermore, the RCPA 
allows the specific detection of (near) full length HCV-RNA only. 
A number of chimpanzees have been used for NANB studies during the past decade. These 
chimpanzees, with well-documented NANB infections were tested for the presence of HCV. The 
aims of this study were to determine the current HCV status of these animals, and to evaluate the 
RCPA against the LIA, a confirmatory assay for detection of HCV antibodies. The results of both 
tests were compared and discussed. 
Material and methods 
Chimpanzee sera 
Chimpanzee serum samples were obtained 28-122 months after inoculation with NANB infectious 
material from various sources. Several animals have been infected by the material described by 
Tsiquaye et aI. (1980). Other chimpanzees (Hellings et aI., 1987) received inocula derived from 
either a Factor VITI pool, or human serum (personal communication J .A. Hellings, Organon 
Technika, Boxte1, the Netherlands). Since the majority of the inocula were derived from plasma 
pools, the presence of several types of viruses in one inoculum cannot be excluded. 
All animals developed clear symptoms of acute infection, including elevated serum alanine 
transaminase and gamma glutatnyltranspeptidase and appearance of characteristic alterations in 
hepatocytes visualized by electron microscopy. 
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RNA capture 
Using the RNA-capture PCR assay, as outlined in figurel, (near) full length HCV RNA was 
detected. Oligo LD 40 captures genomic RNA, released from viral particles, at the very 3' end. 
The captured RNA was reverse transcribed at the very 5' end and the cDNA was amplified by 
PCR using 5' end specific primers NCRI and NCR2. 
Capture oligo LD 40 (5'biotin- GAAAAAAAAAAAAGGGAATGGCCTATIGGC-3'; 
synthesized by Pharmacia, Woerden, the Netherlands) is complementary to the extreme 3' end 
sequence (position 9055-9086; numbeting starting at first codon of polyprotein) of the HCV 
genome, as published by Kato et aI. (1990). Reverse primer NCR2 (5'-
ATACTCGAGGTGCACGGTCTACGAGACCT-3', pos. -2 to -21) and primer NCRI (5'-
GTATCTCGAGGCGACACTCCACCATAGAT-3', pos. -324 to -304) were described by Garson 
et aI. (1990). Paramagnetic streptavidin-<:oated particles were from Promega (Streptavidin 
MagneSphere™ particles no. Z524). 
5' UTR 
---+ 
NCR1 
E1 E2jNS1 NS2 NS3 NS4 
+-
NCR2 
magnetic 
bead 
LD40 
NS5 
core 
Figure 1. Oligonucleotides LD40 are linked to magnetic beads by a avidin~biotin interaction. LD40 
sequence is complementary to the extreme 3' end of the HeV-RNA genome and therefore able to capture 
the RNA by specific hybridization. eDNA synthesis on purified HCV-RNA is primed by NCR2. 
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Biotinylated oligonucleotide LD 40 was coupled to the magnetic beads by mixing 100 ng 
of LD 40 with 0.1 mg beads (prewashed twice with one volume of 0.5xSSC) in 100 "I O.5xSSC at 
room temperature and left 30 minutes at room temperature. Uncoupled LD 40 molecules were 
removed by washing the beads three times with one volume of O.5xSSc. The beads were washed 
by attachment to the tube wall in a magnetic stand (Promega). Finally, the oligobeads were 
resuspended in O.5xSSC at a concentration of 0.1 mg/500 JLl and stored at 4°C. 
The actual RNA capture protocol was modified after Jakobsen et aI. (1990). Fifty "I of 
serum was diluted in SOO "llysisbuffer (0.5 M LiCI, 0.1 M Tris-HCI pH S.O, 0.01 M EDT A, 1 % 
SDS, 5 mM DTT) and incubated at 50°C for 20 min. 500JLl of the oligobeads suspension was 
added and incubated further on ice for at least 1 hour. mixing slowly every 15 minutes without 
vortexing. After RNA capture, beads were washed five times with 500 JLl volumes of ice-cold 
buffer; twice with LiCI washing buffer (0.15 M LiCI, 0.01 M Tris-HCI pH S.O, I mM EDTA, 
0.1 % SDS.), twice with O.5xSSC and once with O.lxSSC. After the last washing step, the tubes 
were centrifuged very briefly and all fluid was removed. 
eDNA synthesis, 
Immediately after RNA capture and washing, the beads were resuspended in 16 JLl of water 
containing dATP, dCTP, dGTP and dTTP and reverse primer NCR2, heated to 75°C for three 
minutes and snap-cooled on ice. 9 .ul of a mix:ture. containing buffer. RNasin and reverse 
transcriptase were added, giving a total volume of 25 JLl with finaI concentrations of 50 mM Tris-
HCI pH S.O, 75 mM KCI, 3 mM MgC]" 10 mM DTT, Soo"M each dNTP, 10 pmoles of reverse 
primer, 0.25 units/JLl RNasin (Promega) and Su/,,1 M-MLV reverse transcriptase (Gibco-BRL). 
After mixing. the suspension was incubated at 40°C for at least 1 hour, and mixed every 15 
minutes. 
eDNA amplification by peR 
From 5-10 "I of the cDNA reaction mix, including magnetic beads, were included in a 100 JLl 
PCR reaction, containing 10 mM Tris pH 9.0, 2 mM MgCI" 50 mM KCI, 0.01 % gelatin, 0.1 % 
Triton X-IOO, 10 pmoles of primers NCRI and NCR2 and 1.5 units of Taq DNA polymerase 
(promega). The sample was covered with mineraI oil. The PCR consisted of 40 cycles of I min 
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95°C, 2 min 42°C, 3 min 72°C, Fifteen "I samples were analyzed on 1% agarose gels, blotted to 
Hybond N+ membranes (Amersbam), hybridized to a labelled [NCRI-NCR2j 320 bp amplified 
DNA fragment and autoradiographed, according to standard procedures (Sambrook et aI" 1989), 
Line lmmuno Assays 
HCV antibodies were detected by the lnno-LlA (Line lnnnunoAssay, lnnogenetics N,V" Belgium; 
Pollet et al .. 1991). Assays were carried out according to the manufacturer's instructions. Briefly. 
10 ",1 of serum was diluted 11100 and incubated with a LlA antigen strip. which exposes several 
highly specific HCV antigens from the core, NS4 and NS5 regions of the polyprotein (see also 
figure 2). After staining. the antibody reaction against every line was read semi-.quantitatively. 
Three positive control lines consist of various amounts of human IgG whereas one line is anti-
human IgG as sample addition control. 
Results 
Thirty chimpanzee sera were tested for the presence of HCV, Using the LlA system, antibodies 
against highly specific antigens derived from the NS4, NS5 and core region of HCV were 
detected. With the new RNA-capture PCR assay, the presence of near full length HCV genomic 
RNA was assayed. Specificity of the RCPA was determined by using magnetic beads with or 
without oligo LD40 to capture RNA from an HCV containing serum sample. A positive signal was 
obtained in the presence of L040, whereas without LD40 a signal was not visible after 
autoradiography (results not shown). The results of both HCV antibodies and HCV-RNA tests are 
summarized in table L 
Figure 2 illustrates results of both LlA and RCPA for selected samples. Hybridization with 
a "P-Iabelled specific oligonucleotide probe yielded identical results. 
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Table 1. Results of LlA and RCPA on chimpanzee sern. 
chimpanzee NS4 NSS "'reI ",re2 core3 ",re4 UA RCPA cond. 
Inoculum EfOVided bv T~iguaxe et 31. {l980l 
Peggy(89) 2+ 2+ ± + + cl>ron. 
Phil(82) 2+ 2+ ± ± + + cl>ron. 
Hans{9S) 2+ ± + + ebron. 
Riet(9S) 1+ ;'d re,. 
Sophie(44) ± ± ;'d re,. 
Natnma(67) ± indo re,. 
Beatrix(46) ± ;'d re,. 
Walter(67) ± ;'d re,. 
human serum 1. 
Billy(84) ± 2+ + + chron. 
Factor VITI 
Randy(47) 2+ ± 3+ ± 1+ 2+ + + cl>ron. 
Thjjs(59) 1+ ± ± ± ;'d re,. 
Ton(S2) 1+ indo + cl>ron. 
human serum 2. 
Ruud(65) ± 2+ + + ebron. 
Cor(SO) ± 2+ + + ebron. 
Bam.Bam(89) ± IDd re,. 
Bic(72) ± ind =. 
Peer(93) ± ;'d =. 
Dirk(SO) ± ;ad m. 
Chimpanzees Socrates, Jaqueline, Agnetta, Anna·CIara, Zeef, Laurens. Marlies. Barney. Centa. Robin, 
Bart. and Oscar were negative by LIA and RCP A. indo ;;;0; indeterminate, res. = presumably resolved. 
ehron. = chronic carrier. conci. = conclusion. Numbers between brackets after chimpanzee names indicate 
how many months after infection the tested serum sample was obtained. Chimpanzees are grouped according 
to the inoculum they received. By comparing color intensity with the internal standards on the LIA strips, 
individual lines are scored -. ±. 1 +,2 +.3 + or 4+ according to the indications of the manufacturer, 
Samples are classified non-reactive if all lines have a negative scoring. Samples are classified reactive if 
either one line has a reactivity of 2 + or higher or if at least two lines have a reactivity of at least 1 +. A 
sample is considered indeterminate if it doesn't meet the criteria for non-reactive or reactive. A sample is 
classified RCPA positive if a NCRI-NCR2 amplified DNA fragment of the right size (320 bp) is detected by 
autoradiography in duplicate. 
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Figure 2. Example of results of Line lmmuno Assays (UA) and RNA-capture PCR assays (RCPA). (a) LlA 
strips contain 4 control and 6 HCV specific antigen lines. Incubation with serum and consecutive staining 
detects the presence of captured antibodies against these specific antigens. (b) 15 td peR samples are 
electrophoresed on a 1 % TAB-agarose gel. showing specific NCRI-NCR2 amplimers of 320 bp. (c) The 
same agarose gel was blotted to Hybond N+. which was hybridized to a random primed 32~p labelled NCR2~ 
NCRl fragment, followed by autoradiography for 30 minutes. 
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Discussion 
RNA-capture peR Assay 
A new method for detection of (near) full length HCV-RNA in serum is described by HCV-RNA 
capture specifically at the 3' end and amplifying the 5' end, This method, which resembles the 
sandwich ELISA in using two separate epitopes on one molecule, has several advantages. 
First, the RNA capture method is rapid and simple and eliminates the need for hazardous 
chemicals such as phenol or guanidiniumisothiocyanate. Secondly, although there is uncertainty 
about the exact termini of the viral RNA genome, the RCPA detects only HCV-RNA which is at 
least near full length. When using ccnventional RNA isolation methods (Chomczynski and Sacchi, 
1987), even separate detection of both 3' and 5' ends of the HCV-RNA is not a proof that they are 
derived from the same viral genome. So far, there is no evidence for the existence of defective 
HCV particles, carrying only a fragment of the genome. The capture assay described may also be 
a good method to investigate this issue. A third important advantage of the method is the relatively 
low risk of ccntamination during RNA purification with material amplified earlier. The specific 
isolation of HCV molecules is based on sequences not present in the amplified fragments, as the 
3' end sequence is captured, whereas the amplification primers are detecting the Yend of the 
HCV-RNA. A fourth advantage is the specific purification of HCV-RNA, whereas most other 
methods use total RNA or total nucleic acid from plasma, which may increase the number of 
nonspecific annealing reactions dwing eDNA synthesis and peR considerably. By using a specific 
capture oligonucleotide together with two specific PCR primers, the overall specificity of the test 
is very high. Positive samples indeed show very clean bands on gel with hardly any background 
and results may be improved further by increasing the stringency of washing of the HCV-RNA on 
the beads, e.g., by prolonged washing at elevated temperature. 
Another advantage is that the capture method can be used to purify selectively single 
stranded RNA or DNA from various sources, e.g., purification of specific messenger, genomic or 
subgenomic RNA from viruses in serum. The lithium and SDS present in the lysis buffer 
obviously inactivate the high levelS of nbonuc1eases present in serum very efficiently. 1bis method 
may therefore also be effective for whole blood or for biopsy material. 
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RCV diagnosis by {lfItibody detection 
Availability of a reliable and easy HCV detection method is of major importance for routine RCV 
screening. The first generation anti-HCV tests, detecting antibodies against c-lOO antigen only, has 
been shown to be inadequate (!naba et aI., 1991) and have now been replaced by more sensitive 
assays. LIA is a confirmatory assay similar to RIBA (recombinant immunoblot assay, Ortho 
Diagnostics), but using a larger number of other epitopes. with high sensitivity and specificity. 
It was shown previously that the LIA (pollet et al., in press), as well as other systems 
using synthetic peptides (Hosein et al., 1991), resulted in low numbers of false positive or false 
negative reactions. The predictive value of LIA for infectivity is therefore better than that of the 
anti-C-lOO test. Siguificant association between infectivity of anti-ClOO positive blood donors and 
persistence of antibody reactivity has already been established (van der Poel et al., 1990). 
Furthermore. LIA provides information on the presence of antibodies against specific epitopes. 
This might be useful for determination of relations between the LIA antibody profiles and clinical 
progression of the disease. 
LlA llIId RCPA results using chimpanzee sera. 
The data presented describe the outcome of RCV infection in a population of chimpanzees tested 
long after inoculation. Based on biochemical and electron microscopical data obtained before and 
after inoculation, it was concluded that all these chimpanzees have been infected with NANB 
hepatitis virus. 
The LIA can yield three possible results. 
1. Some of the animals reacred positive on LIA, and apparently developed a chronic 
infection (Billy, Hans, Peggy, Randy, Ruud, Cor and Phil). Phil has been a carrier for almost 10 
years now. indicating that a prolonged carrier state is possible without obvious clinical 
complications, in agreement with earlier reports (Tabor et al., 1980; Ogata et al., 1991). 
The agreement between positive LIA and positive RCPA is 100% in this population of 
chimpanzees. However. there are several remarkable differences between carriers with respect to 
the LIA antibody profile. Chimpanzee Billy has a low titre of anti-NS4, but a high level of anti-
NS5, whereas chimpanzee Hans shows the opposite. Chimpanzees Peggy and Phil have high 
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antibody levels against both NS4 and NS5. Chimpanzee Randy shows antibodies against all epito-
pes tested. 
Since identical or closely related inocula were used in several chimpanzees. the 
progression towards chronic infection seems to depend on variation among the chimpanzees. 
Individual differences in inunune response between animals might be reflected in the different LlA 
antibody patterns. 
2. Some chimpanzee serum samples show indeterminate reaction by LlA (e.g., Riet, 
Ton, and Thijs). These indeterminate results hamper definite classification by LlA only. Most 
(10/11) indeterminate sera were negative by RCPA; only chimpanzee Ton is positive. The animals 
are likely to be clearing the virus. Examination of Ton's serum dnring the next few years may 
provide information on whether clearance beyond RCPA detection level occurs. So far, Ton is still 
classified as a carrier. By testing earlier serum samples from this group of LlA-indeterminate 
animals by RCPA we should be able to estimate the average time required to clear the virus below 
detection level. To determine beyond doubt whether these sera are still infective, they would have 
to be inoculated into another chimpanzee. 
Another possibility is that the samples were taken at a time between two peaks of 
viraemia dnring chronic infection (Bradley et al., 1981), although this is less likely, because 
considerably higher titres of persisting antibodies are expected. 
HCV-RNA assays are therefore necessary. in addition to the antibody test, not only for 
sera showing borderline level antibodies, but also for sera from the acute phase of the disease, 
when antibodies are not yet detectable. Several samples, including acute phase sera, obtained 
throughout the course of infection of chimpanzees Socrates, Zeef and Sophie were all negative for 
anti-CIOO. However, RCPA shows that the virus was present dnring the acute phase of the 
disease. In Socrates. infectivity of this acute phase serum was proven by transmission to 
chimpanzee Sophie, resulting in infection. Acute phase serum from Zeef was also negative by 
LlA, but positive by RCPA (figure 2). 
3. The last group of chimpanzees was found negative by LlA. These sera were also 
negative by RCPA, indicating the clearance of the virus from blood beyond detection level. The 
agreement between negative LlA result and negative RCPA result is also 100%, indicating the 
high specificity of both tests. 
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By comparing results from both HCV antibody assays and HCV-RNA assays, it has been 
claimed that all 4 possible combinations of antibody and RNA findings are possible (Obkoshi et 
aI., 1990). In this study, however, samples negative by LIA and positive by RCPA were not 
found. This might reflect the specificity of both test systems. 
HCV subtypes 
There is heterogeneity among the reported 3' terminal sequences of HCV-RNA (Choo et aI., 
1991; Kato et aI., 1990; Han et aI., 1991; Takamizawa et aI., 1991) as summarized in figure 3. 
Based on this diversity two subtypes of HCV can be distinguished. The Kato (Kato et aI., 1990) 
and Takamizawa (Takamizawa et aI., 1991) sequences have a high degree of homology, but differ 
considerably from the sequences of Choo (Choo et aI., 1991) and Han (Han et aI., 1991), which 
are almost identical. Capture oligo LD 40 is based on the sequence published by Kato et aI. 
(1990). 
Kato 
Takam. 
Choo 
Han 
LD40 
3' -® eGG TTA Tce GGT AAG GGA AAA AAA AAA AAG 8 
5' III III III III III III III III III III , 
TGA ACG GGC AGe TAA eCA eTC CAG Gee AAT AGG eCA TTC eeT TTT TTT TTT TTC 3 
x x x x x X 
TGA ACG GGG AGA TAA ACA eTC CAG Gee AAT AGG eCA Tce eee TTT TTT TTT TTT 
x xx x x x x x x 
TGA AGG TTG GGG TAA ACA eTC eGG eeT 
TGA AGG TTG GGG TAA ACA eTC eGG eeT AAA 
Figure 3. Comparison of 3' terminal sequence of HCV-RNA as published by the indicated authors. Shown 
are sequences downstream of the last codon of the polyprotein. Mismatches are indicated by a cross. 
Position and sequence of capture oligonucleotide LD40 is shown. 
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Sequences of several amplified RCV-<:DNA fragments obtained from chimpanzee Phil 
convalescent serum. have a much higher degree of homology with the Japanese sequences than to 
the Choo subtype (data not shown). Therefore. the RCV-RNA derived from Phil was very likely 
to possess 3' terminal sequences complementary to LD 40, as confirmed by the results. Rowever, 
some of the chimpanzees, e.g .. Randy. Ton and Cor. were infected with other inocula. derived 
from the same factor vm preparation which was used by Choo et al. (1991), and Ran et al. 
(1991). RCV-RNA from these animals can also be captured by oligo LD 40, suggesting the 
presence of this common sequence at the 3' end of both subtypes of RCV. As LD 40 is a 31-mer 
and during RNA isolation the RNA-LD40 hybrid is washed with O,lxSSC, specificity of 
purification is high. Using other capture oligos might be useful for rapid discrimination between 
subtypes of RCV, simply by using a different oligo for capturing RCV-RNA of different subtypes. 
The cDNA and PCR reactions are based on highly conserved sequences at the 5'end, so these are 
effective for most SUbtypes. The RCPA system will be compared with other PCR assays and 
SUbjected to further modifications. Sensitivity might be increased, e.g., by capturing RCV-RNA at 
the S' untranslated region. by using random primers for reverse transcription and optimal primers 
for PCR amplification. The efficacy of the LIA will also be subject of further study. 
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Abstract 
A new diagnostic assay for hepatitis C virus RNA detection is described. HCV genomic RNA is 
captured onto streptavidin-coated magnetic beads by solution hybridization with biotinylated 
complementary oligonucleotides. The specificity of the capture assay is confirmed using different 
capture oligonucleotides as well as sera representing different types of HeV. Sensitivity was 
determined by testing serial dilutions of an HCV infected plasma. A panel of 50 sera was tested 
for anti-HCV by a Line lmmuno Assay (LIA) and for HCV-RNA by both a conventional gnanidi-
nium extraction method and the new capture assay. The specificity of the capture assay was 95.8% 
and the sensitivity was 92.3%, compared to the standard protocol. This method provides a fast and 
simple alternative for HCV-RNA detection in blood samples. 
Introduction 
Since the discovery of the Hepatitis C virus (HCV) as the main cause of non-A, non-B hepatitis 
(Choo et al .. 1989) numerous studies have rapidly increased insight in the biology of this virus. 
The viral genes have been mapped. leading to the classification of HeV as a new member of the 
Flaviviridae (Choo et al., 1991). From several isolates the entire sequence of the cDNA, obtained 
from the RNA genome of about 9400 nucleotides has been determined. (Kato et al., 1990; Choo et 
al., 1991; Takamizawa et al., 1991; Okamoto et al., 1991, 1992a; Chen et al., 1992a). Based on 
sequence comparisons, several types of HCV (Houghton et al., 1991; Chan et al., 1992; Cha et 
al., 1992; Okamoto et al., 1992b) can be identified, although no consensus about nomenclature has 
been reached yet. 
Antibodies against HeV epitopes can be assayed using expression products from partial 
cDNA clones (Chiba et al., 1991; Chen et al .. 1992b; Mori et al., 1992; Wang et al., 1992) or 
synthetic peptides (Kotwal et al., 1992; Ching et al., 1992; Hosein et al., 1991). It also seems 
possible to detect HCV antigen directiy in serum (Takahashi et al., 1992), although sensitivity of 
this method is low and relatively large quantities of plasma are needed. 
The detection of HCV-RNA in serum has been described by others (Kaneko et al., 1992; 
Widell et al., 1991; Bukh et al., 1992a; Cha et al., 1991; Schlauder et al., 1992; Novati et al., 
1992; Lazizi et al., 1992). Basically, total nucleic acids are isolated from serum by phenol and 
chloroform extraction and precipitation with ethanol. The RNA is reverse transcribed into cDNA, 
which is subsequently amplified by the Polymerase Chain Reaction (PCR), enahling detection by 
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Southern blotting and hybridization. Methods for preparation of viral nucleic acids for PCR are 
tedious, involve multiple manipulations and are a potential source of contamination. To reduce 
these problems. simplified procedures have to be developed. One of the possibilities is to isolate 
and purify the organism of interest by antigen capture, and subsequent detection of viral RNA by 
PCR, as described for Hepatitis A and Hepatitis E viruses (Jansen et al., 1990; McCaustland et 
al., 1991). Specific antibodies, preferably monoclonal, are necessary for effective and specific 
capture of the organism. At this moment sufficient quantities of antibodies. directed against HeV 
surface epitopes are not available. Direct capture of RNA from crude cell lysates has been 
described earlier. but sensitivity was limited because peR was Dot used (Albretsen et al., 1990; 
Thompson et al., 1989). 
Therefore, a combined HCV-RNA capture PCR assay was developed (van Doom et al., 
1992). This assay is based on hybridization of a complementary biotinylated oligonucleotide to 
HCV-RNA, followed by capture of the resulting hybrid onto streptavidin-coated paramagnetic 
particles. Further evaluation of the capture method for sensitivity and specificity is described in 
tltis paper. The applicability of the assay is detemtined by testing a coded panel of patient sera by 
both the conventional extraction method (Kleter et al., 1993) and the new capture assay. 
Materials and methods 
Plasma samples 
Fifty plasma samples were obtained by venapuncture. Aliquots were quickly frozen in liquid 
nitrogen and stored at _70°C. 
Diagnosis of non-A. non-B hepatitis (NANB) was based on classical parameters as 
elevated ALT. detection of histological indication of bepatitis in liver biopsies. absence of 
serological markers for hepatitis A or B, and exclusion of other possible causes. 
Based on HCV-RNA assays using the standard protocol, one of us (B.K.) prepared a 
coded panel for the HCV-RNA capture method. The panel was complemented with samples from 
7 HBV patients, 2 autoimmune patients and a healthy control. 
The efficiency of the capture assay for different types was exantined using human plasma 
samples containing either RCV type I, 2 or 3 sequences (classification according to Chan et al., 
1992). Sensitivity of both HCV-RNA assays was detemtined by testing diluted plasma samples 
from the Eurohep HCV-RNA panel, which was prepared by dr. P.N. Lelie (CLB, Amsterdam). 
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Oligonucleotides 
captur. ol.igo:c.ucl.eotid •• 
LD40E (9055 •• 90136) (~) S'vBvGGC eGG GG.C Gee CGC GM J>.AA AAA AAA AGO GAl\. TOO ccr ATT GGC v3' 
LDS7 (-29 •• 3) (_) S'-B-GGC CGC GGC GGC CGC CAT GIT GC7\. CGG TC1' ACG AGA ccr CCC GGG GC -3' 
:LOSS (-66.. -35) (-) 5' -B-GGC CGG GCC GGC CGC C1I.A GCA CCC TAT CAG GC7\. GTA CCA C1I.A GGC _3' 
LOS3 (-278 •• -248) (-) 5'-B-GGC CTT TGC GGC CGC 'l'AA CGC CAT GGC TAG ACG CTT 'rC'l" GCQ 'tGA -3' 
LOS;: (9261 •• 9200) (-) 5' -B-GGC CGG TGG ACT GAG '.t'l"l' A/GAG C/TrT G/TGT C/TC/TT C/'rAC C/TG': 
BGl. (16S l:'RNA) 
QpWo, -.n<1 peR p:d,m .. r_ 
NCR3 (-3l.4. •• -2SS) (+) 
LDG6 (-55 •• -79) (-) 
HCV'lS (-323 •• -304) (+) 
HCVJ.9 (-L .-20) (-) 
hybridizatiQ];!. p=b. 
HCVl.7 (-118 •• -69) (+) 
COl. GTT GM GAG -3' 
5' -B-C1I.G ACT GAG TAi\. GGA GGT GAT COl. ACC GC7\. GGT TCC CCT ACG GTT Ace 
TTG TTA CGA CTT -:)' 
5' - GGG Gee Gee Gee Ace ATA/G A/GAT CAe Tee CCT GTG AGe: -3' 
5' - Ace ACA AGe: eerie TTC GeG/A Ace CAlI. C -3' 
5' - GGC CAe ACT CCA CCA TAG AT -3' 
5' - GTG CAe GGT CTA CGA GAe CT -3' 
5' - GAG TAG '!CT TGG GTC GCG]>,A -3' 
Underlined sequences are additional and not complementary to the target. B indicates biotinylation. 
Polarity of the oligonucleotides are indicated in parentheses. 
Standard HeV-RNA assay 
RNA was isolated by a modified version of the guanidinium method (Chomczynski et al., 1987) as 
described elsewhere (Kleter et al., 1993). Briefly, 60 ",I of plasma was diluted in denaturing 
guanidinium thiocyanate buffer. extracted with phenol and chloroform. and precipitated with 
isopropanol. One third of the RNA was used for reverse transcription with primer HCVl9 in a 
volume of 25p.1. After heat inactivation of the reverse transcriptase. PCR ingredients including 
primer HCV18 were added to a final volume of 100 ",I. PCR consists of 40 cycles of 1 min. 
95°C, 2 min. 48°C, and 3 min. 72° C. 
RNA captaTe assay 
Chimpanzee serum from the acute phase of an HCV infection served as a positive control for the 
capture assay. This chimpanzee had been infected with type 1 HCV (Takamizawa et al., 1991; 
Kato et al., 1990) as was confirmed by sequence analysis (data not shown). 
Fifty ",I plasma was diluted in 800 pl1ysisbuffer (0.5 M LiC1, 1 % SDS, O,2M EDT A, 1 
mM DIT, 100 mM Tris-HCL pH 8,0) and incubated at 37°C for 10 minutes; 100 pl of 20x SSC 
and 50pl of 100x Denhardt's solution were added together with 100 ng of capture oligo. After 
careful mixing without vortexing. the sample was heated at SO°C for 5 minutes to denature the 
RNA, followed by 1 hour shaking at room temperature to hybridize the capture oligo to the RNA. 
Paramaguetic streptavidin-eoated particles (Dynabeads M-280 Dynal, Oslo, Norway) were 
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prewashed once with 0,5x SSC, Fifteen !'l of beads (0,15 mg) was added to each sample and 
incubated for 30 minutes at RT. Beads were concentrated at the tube wall using a magnetic 
separation stand, Fluid was removed by sterile disposable pastettes and 500 "I of fresh buffer was 
added. The beads were washed twice with 0.15M LiCI, 0.1 % SDS, O.OIM Tris-HCI pH 8.0, and 
twice with 0,5xSSC. After the last wash, the suspension was collected at the bottom of the tube by 
very brief centrifugation and fluid was removed completely. Beads were resuspended in 18 .ul of 
DEPC treated water, 0.75 "I 20mM dNTP's (pharmacia) and I !'l (0.2 "g) of random hexamers 
(pharmacia). After heating at 80'C for 5 minutes tubes were quickly chilled on ice and a mix of 6 
,,15x buffer (250 roM Tris-HCI pH 8.3, 375 roM KCI, 15 roM MgCI,), 3!'l 0.1 M DTT, 1,,1 M-
ML V reverse transcriptase (200 u) and 0.5 !'l RNAsin (20 u) was added. Suspensions were 
incubated at 37°C for 90 minutes, resuspending the beads every 30 minutes. The reverse 
transcriptase was inactivated at 95'C for 5 minutes. (Sellner et ai., 1992). Ten "I of the cDNA 
solution, including beads, were used in a 100,,1 PCR assay. Reaction conditions were: lOroM Tris-
HCI pH 9.0, 0.1% Triton X-IOO, 0.01 % gelatin, 200~ dNTP's, 50 roM KCI, 1.5 roM MgCI" 
0.25 units SuperTaq (Sphaero Q, Leiden, the Netherlands) and 10 pmoles of primers LD66 and 
NCR3. (Note that the cDNA solution already contains dNTP's, KCI and MgCI,). 
The PCR program consisted of I minute pre-incubation at 94 'c, followed by 40 cycles of 
I min 94'C, I min 45'C and 2 min n'c. After the last cycle an extra incubation for 5 min at 
72°C was carried out. 
Analysis of the PCR products 
PCR products (15 "I) were analyzed on a 1,5% TBE agarose gel, followed by blotting onto 
Hybond N+ membranes (Aroersham) and hybridization with ''P labeled HCVI7. Results were 
based on examination of autoradiographs. Outcome of an experiment was only accepted if 
duplicates showed comparable signals. If discrepant results were obtained. samples were retested 
in duplicate using the same sense primer (either NCR3 or HCV18) in both assays. 
HCVantibodyassay 
Each plasma sample from the coded panel was tested for the presence of antibodies against core, 
NS4 and NS5 epitopes by a Line immunoAssay Inno-LIA HCV Ab II (Innogenetics N.V., Gent, 
Belgium) according to the manufacturer's instructions. 
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Results 
Several aspects of the new HCV-RNA capture assay like sensitivity, specificity and practical 
applicability were analyzed. First, the efficiency of different oligonucleotides to capture type 1 
HCV-RNA was analyzed, as shown in figure I. Capture oligo's LD53, LD57 and LD58 are 
specifically capturing highly conserved sequences from the 5' untranslated region (5'UTR). LD52, 
containing 7 degeneracies, is aimed at the C-terminal part of NS5. LD40 is annealing at the 
extreme 3' end of some of the type 1 RNA (type Ib sequences; Kato et al., 1990; Talcatnizawa et 
al., 1991), which allows the specifiC detection of (near) fulllengtb HCV-RNA (van Doom et al., 
1992). Negative control was oligo BGI, specific for 16S rRNA sequences. There were clear diffe-
rences in capture efficacy of the various oligonucleotides (figure 1). LD40, LD58 and LD53 all 
efficiently captured HCV-RNA. Oligo LD53, which hybridizes between the annealing sites of the 
two PCR primers, did not seem to obstruct cDNA synthesis and subsequent amplification. LD57 
yielded consistently high signals. Because the target sequence for LD57 is highly conserved among 
all known HCV isolates (Bukh et al., 1992b), this capture oligo was used for further capture 
experiments. LD52 was less efficient, whereas negative control oligo BGI was Dot able to capture 
HCV-RNA at all. A combination of LD57 and LD58, to improve binding of HCV-RNA to the 
magnetic beads, resulted in a considerable reduction of signaL Results of capture assays on 
positive serum without any capture oligo were negative, illustrating the specificity of the capture 
(data not shown). 
Second, the capture system was evaluated on isolates from three different types of HeV. 
Three plasma samples containing either type I (Kato et al., 1990; Talcatnizawa et al., 1992; Choo 
et al., 1991), type 2 (HCJ-6, Okamoto et al., 1991), or type 3 (Lee et al., 1992; Chan et al., 
1992) HCV sequences were tested. HCV-RNA was captured with LD57, and amplified using 
primers LD66-NCR3. Each sample yielded PCR fragments of the right size. Direct sequencing 
confirmed the expected type specific differences in these 5' UTR fragments. (data not shown). 
These results illustrated that the capture method is able to detect RNA of distinct HCV types. 
The sensitivity of the capture assay was determined by testing 10-fold serial dilutions of a 
HCV RNA-positive human serum, provided as part of the Eurohep panel. The standard assay was 
shown to be approximately lO-fold more sensitive than the capture assay. The sensitivity of the 
standard protocol was approximately I Chimpanzee Infectious Dose (CID) per mi. 
A coded panel of 50 patient plasma samples was tested for the presence of HCV-RNA by 
both the standard protocol and the capture assay. Each sample was tested in duplicate. Plasma 
samples giving discrepant results in the two HeV-RNA assays were retested using identical sense 
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primers NCR3 or HCVI8 in both assays to exclude this as a cause of discrepancy. It was not 
possible to use HCV19 as antisense primer in the capture assay. because it overlaps with capture 
oligo LD57. Only one sample, found positive with NCR3 in the capture assay, was initially scored 
RNA negative by the standard protocol using HCVI8, but became positive when using NCR3. 
All sera were also tested for the presence of HCV specific antibodies by the Inno-LIA 
HCV Ab II assay. Table I sbows a summary of the results. Twenty-four samples were RNA 
positive in both assays; 21 of these are anti-HeV positive, 2 were indeterminate and 1 was anti-
HeV negative. Twenty-three samples were RNA negative in both assays. of which 19 were anti-
HeV negative, 2 were indeterminate and 2 were positive. Among the RNA negative and anti-HeV 
negative samples were the 7 HBV and 2 auto-immune patients and the healthy control sample. 
Two samples were HCV RNA negative by both assays but did contain antibodies against 
viral epitopes. One sample was only RNA positive by the capture assay and was also anti-HCV 
positive. Two samples were exclusively positive by the standard protocol, 1 being anti-HeV 
positive and I negative. The capture assay bas a specificity of 95.8% and a sensitivity of 92.3% 
compared to the standard protocol. Compared to both RNA assays, the LIA bad a sensitivity 
between 85-88 %. 
Table 1. 
Standard 
Protocol 
Comparison between the standard protocol and the 
HCV RNA capture assay in 50 patient plasma samples. 
HCV RNA capture assay 
+ anti-HCV anti-HCV 
21 + 1 + 
+ 24 2 indo 2 
1 - 1 -
1 + 2+ 
1 23 2 indo 
19 -
77 
A 
B 
c 
535857 52 40 
111 I 1 1 
...... peR primers +-
LD40 LD52 LD53 LD57 LD58 LD57 +58 
Figure 1. Different oligonucleotides were used for HeV RNA capture. The position of these capture oligos 
is shown in A. After capture. eDNA synthesis and PCR. samples were analyzed on agarose gel (B) and by 
Southernblot hybridization (C). 
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Discussion 
Detection of Hev -RNA in serum by the capture assay described here is an alternative for the 
more complex and laborious extraction and precipitation methods. Several advantages favour the 
capture method. It is less contamination prone, because the specificity of HeV-RNA isolation 
prevents co-purification of amplimers and it is essentially a I-tube assay. The method also omits 
the use of hazardous chemicals such as phenol, chloroform and guanidiniumthiocyanate. 
Furthermore, ethanol precipitation and multiple centrifugations are omitted. The method is fast; 
20-30 samples can be processed in duplicate by one person. Because this method specifically 
purifies the HCV RNA. it can be used to assay samples that contain substances that are inhibitory 
for PCR, like heparin. 
The efficiency of the capture assay was tested by using several oligonucleotides aimed at 
different regions of the HCV genome. Oligo's LDS3, LDS7 and LDSS are annealing at various 
S'UTR sequences. The target sequence for LDS2 is located at the C-terminal region of NSS, 
whereas LD40 hybridizes to the extreme 3' UTR. There were considerable differences in 
sensitivity among the tested HCV specific oligo's (figure I). This may be caused by the secondary 
structure of the RNA genome, which makes some sequences more accessible than others (Brown 
et al .• 1992). If a non HCV-specific capture Oligo like BGI was used, or no capture oligo at all. 
no positive signal could be obtained from an HCV-RNA positive plasma, which indicates the 
specificity of the capture system. The reduced efficiency of using both LDS7 and LDSS together in 
one assay was probably due to steric hindrance of the oligo's while capturing target sequences that 
are only a few nuc1eotides apart. Consequently, either the capture efficiency was low or the 
conformation of the captured RNA prevented proper cDNA synthesis. Oligo LDS2 was less 
efficient for RNA-capturing, and this target region also shows variation among isolates. Despite 
several degeneracies in the oligo, LDS2 apparently does not anneal well to this type I HCV-RNA. 
Oligo LD40 is interesting, because it hybridizes at the extreme 3' end of type Ib RNA. By 
subsequent amplification of S' end sequences it was possible to detect specifically full-length RNA 
efficiently. However, the 3' UTR shows a high degree of sequence variation (Han et al., 1991). It 
was therefore impossible to develop a consensus capture sequence for this region. 
Results from the lintiting dilution experiments performed on serum show that the capture 
assay is about 10 times less sensitive than the standard protocol. There are several factors that 
affect the overall efficiency of the assay, like degree of biotinylation of the capture oligo, and 
optimal hybridization conditions. Recent experiments have shown that use of proteinase K to 
release HCV-RNA from the viral particles considerably improves the sensitivity (data not shown). 
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Further studies are aimed at increasing the sensitivity of the system. 
Although the sensitivity of the capture assay at the moment is slightly lower than the 
standard protocol. the method can be very useful as a screening test. Most infected individuals 
have high enough HeV titers to be detected by the capture assay, as shown by results of the 
comparison of the two methods using the patient panel. 
To determine the applicability of the capture assay for routine diagnostics, the results of 
the capture assay were compared with those of the standard protocol. The sensitivity and speci-
ficity of our srandard assay have shown to be very high (Kleier et aI., 1993). 
There were only three discrepancies in the entire patient panel. One serum sample was 
positive by capture assay ouly and did contain HeV antibodies. Two serum samples were 
exclusively positive by the srandard protocol and only one of those contained detectable HeV 
antibodies. The discrepant results are probably due to sequence variation among HeV types. As 
stated. there is a difference in anti-sense peR primer between the two tests. Sequence variations in 
the target sequences for these antisense primers might explain different test results. although this 
region is extremely conserved among reported HeV isolates (Bukh et aI., 1992b). Based on the 
strong signals obtained from the 3 samples, it seems not likely that the discrepancies are due to 
low HeV titers. The real cause for the 3 discrepancies remains obscure. 
The sample. exclusively positive by the capture assay was obtained from a hemophiliac. 
with cllnlcal symptoms of hepatitis. No histological data of liver biopsies are available. This 
sample also contained HeV antibodies, which indicates at least previous contact with HeV. Of the 
2 samples. exclusively positive by the standard protocol, 1 was LIA negative, and was derived 
from a patient which was innnunosuppressed. The other sample was anti-Hey positive. 
As shown previously (van Doorn et aI., 1992) for chimpanzee serum samples there is a 
very good correlation between the presence of Hev antibodies detected by the LIA and the 
detection of HeV-RNA. One patient was RNA positive by both methods, but did not contain 
detectable HeV antibodies, which can be explained by the severe immunosuppression in this 
patient after receiving a heart transplant. Generally, a small fraction of all HeV antibody positive 
samples are peR negative, but up to 30% of HeV-RNA positive serum samples are not detected 
with cttrrent antibody assays (Sugitani et aI., 1992). The sensitivity of the LIA, compared with 
both HeV-RNA assays in our patient panel, was approximately 85%. Two sera are RNA positive 
and LIA indeterntinate, and 2 are RNA negative and LIA indeterntinate, which emphasizes the 
necessity of HeV-RNA assays to complement serological tests. 
Among 23 RNA-negative samples, two are LIA positive. This may reflect stages of 
infection where the virus concentration bas dropped below detection level, and antibodies are still 
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detectable. The only sample exclusively positive by the capture assay does contain Hey 
antibodies, an indication that this patient had been infected with Hey. 
In the future, subtyping of Hey will become an important issue, because of possible 
clinical implications (yoshioka et aI., 1992; Pozzato et aI., 1991). Therefore, the Hey capture 
assay, combined with methods for rapid analysis of the amplified eDNA like reverse hybridization 
assays (Stuyver et aI., 1993), will provide powerful tools in Hey diagnosis and analysis. 
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Abstract 
Hepatitis C virus (HCV) infections in a cohon of chimpanzees were studied retrospectively. All 
animals had been inoculated intravenously with materials derived from a single source chimpanzee 
plasma implicated in non-A, non-B hepatitis, prepared by extensive ultracentrifugation. Anti-HCV 
and HCV RNA were monitored by the confirmatory Line Immuno Assay and by a RNA-capture 
PCR method, respectively. In a chronically infected chimpanzee, HCV RNA was first detectable 
after 32 days, throughout the acute phase, dropped transiently below detection level, and became 
positive again. In three other chimpanzees with acute resolving infections. ReV RNA was 
detected 7-11 days after inoculation, and became permanently undetectable after AL T 
normalization. Various anti-HCV profiles were detected among the chimpanzees. Analysis of the 
hypervariable region in E2/NS I in seven chimpanzees suggested genome stability upon 
transmission, revealed different mutation frequencies during chronic infection and suggested the 
importance of immune selection during chronic ReV infection. 
Introduction 
Hepatitis C virus (HCV) has been identified as the major etiologic agent of posttransfusion non-A, 
non-B hepatitis (NANB; Choo et al., 1989, Kuo et al., 1989). The virus, classified as a distinct 
relative of the Flavi- and Pestiviruses. contains a positive-sense. single-stranded RNA genome of 
approximately 9400 nucleotides and encodes a single large open reading frame of about 3010 
amino acids. The viral polyprotein is processed into several structural and non-structural proteins. 
Antibodies against several viral" proteins can be detected in the serum of infected individuals and 
are used in routine diagnostic screening assays. Serum ReV-RNA can be detected by reverse 
transcriptase polymerase chain reaction CRT-PCR) and provides a direct measure of virentia 
(Weiner et al., 1990). Several HCV types have been distinguished among HCV isolates 
worldwide, and at least 5 types have been identified so far (Simmonds et al., 1993, Kleter et al., 
1994, van Doorn et al., 1994a, Cha et al., 1992, Chan et al., 1992, Okamoto et al., 1991, 1992). 
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During the past twO decades, NANB hepatitis was studied in vivo in the only susceptible 
animal, the chimpanzee. (Bradley et al., 1979, 1981). Experimental infections of these animals 
provided data and material that were crucial for the molecular characterization of HCV (Bradley et 
al., 1985). Several retrospective studies in chimpanzees have elaborated our understanding of this 
virus and its interaction with the infected host (Beach et al., 1992, Shindo et al., 1992, Farci et 
al., 1991, 1992a,b, Abe et al., 1992). In this study, experimental HCV infections were examined 
retrospectively in chimpanzees via biochemical. serologic and virologic parameters. The animals 
had been inoculated with processed infectious chimpanzee plasma material from a single source. 
containing genotype lb HCV (typing according to Simmonds et al., 1993). Several sequential 
passages are included in this study, and the hypervariable region of HCV (Weiner et al., 1991, 
Kato et aI., 1992a.b) was analyzed by direct sequencing in a total of 7 chimpanzees, in order to 
assess genetic drift of this particular HeV isolate. 
Materials and methods 
Preparation of inocula 
The original NANB inoculum was obtained from an acute phase plasma from chimpanzee George 
(Tsiquaye et al., 1980). This chimpanzee had been infected with hepatitis A and hepatitis B viruses 
and had recovered from acute NANB hepatitis induced by an implicated factor IX preparation. 
Subsequently. this animal was challenged with an implicated factor VITI preparation. which was 
kindly supplied by Dr. Daniel Bradley (Bradley et al, 1979). The chimpanzee developed a severe 
acute NANB hepatitis after an incubation period of only 12 days, when a volume of acute phase 
plasma was obtained. Samples (5.0 ml) from this plasma were centrifuged at 52,000 rpm. 
(200,000 x g) for 18 h at 4°C. Aliquots of the supernatant (4.0 ml), collected from the top of the 
tube were pooled, distributed to new tubes and centrifuged again under the same conditions. This 
procedure was repeated twice more in new tubes. At the end of the 4th cycle of centrifugation. an 
aliquot (100 pL.) was carefully collected from the surface layer of the supernatant, diluted in 9.9 
ml of PBS pH 7.4 and labeled "Top Fraction". About 3 ml of the first supernatant was collected 
from below the meniscus (top to the middle part of each tube) and ultracentrifuged again. After 18 
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h centrifugation at 200,000 x g, a second aliquot of 100 JLL was collected at the meniscus of the 
supernatant and added to 9.9 ml of PBS. This diluted sample was labeled "Middle Fraction". 
]1UJcu/ation of chimpa1lZl!es 
All chimpanzees were inoculated intravenously, and the infection schedule is represented in figure 
I and table 1. Chimpanzee Phil received 2.5 ml of the "Top Fraction" in December 1982. Three 
ml of the diluted "Middle Fraction" were inoculated into chimpanzee Peggy. Furthermore, 0.3 ml 
of the "Middle Fraction" were mixed with 2.7 ml plasma obtained from chimpanzee Phil at 165 
days after infection and inoculated into chimpanzee Hans. At 165 days after infection, chimpanzee 
Phil had biochemical and histological signs of recovery and it was presumed that this plasma 
might coutain neutralizing antibodies. Chimpanzee CoeD, who had been inoculated previously with 
HlV -I, was inoculated in 1983 with I ml plasma from Phil obtained at 35 days after infection. 
Chimpanzee Socrates was inoculated in 1985 with 0.1 ml plasma from Phil obtained at 62 days 
after infection, which was mixed with 0.9 ml plasma from Coen obtained at 192 days after 
infection. Antibodies would possibly neutralize the infectious virions and anti-human IgG was 
added to generate large immune complexes. Briefly. plasma samples from Phil and Coen were 
mixed, incubated at 37°C for I h, and then with anti-IgG, overnight at 4°C. After clarifying the 
mixture at 2,500 rpm for 10 min, I ml was inoculated into Socrates. Sophie was infused in 1987 
with 40 ml acute phase plasma from Socrates obtained 74 days after infection. Serial blood 
samples were obtained from the chimpanzees by venipuncture and serum was stored at -20°C. 
Infections were monitored by testing serum samples for alanine antinotransferase (ALT), aspartate 
antinotransferase (AST), and gamma-glutamyltranspeptidase (g-GT) activity. 
HCV-RNA capture assay 
HCV-RNA was purified from serum samples by a modified version of the HCV-RNA capture 
assay d=ibed earlier (van Doom et aI., 1992, 1994b). Serum (50-100 JLL) was diluted in 200 JLL 
lysis buffer (50tnM Tris-HCI pH 8.0, 5 mM EDTA, 0.5% SDS, ImM Dithiothreitol, I % Triton 
Xloo) containing 0.5 mg/ml proteinase K, 10 p.g carrier tRNA and incubated at 55°C for 30 
minutes. Afterwards, proteinase K was heat-inactivated by incubation of the mixture at 80°C for 5 
min. Biotinylated capture oligo LD57 (table 2) was coupled to streptavidin-coated paramagnetic 
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"Top Fraction" 
(RNA -, infect +) 
George 
"Middle Fraction" "Pellet" 
(RNA +, infect +) (RNA -, infect -) 
1 r---I -----+Ii ~ 
Hans Peggy 
Coen Socrates 
1 
Sophie 
Figure 1. Inoculation scheme of chimpanzees. Underlined chimpanzee name indicates chronic Hev 
infection. 
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particles (Dynabeads M280, Dynal, Oslo, Norway), Beads were prewashed twice with 0.5 x SSC 
(20 x SSC is 3 M NaCl, 0,3 M Na-citrate pH 7,0) and LD57 was coupled (250 ng LD57/0,15mg 
beads) by mixing with the beads in 5 x SSC, After 30 min, the oligobeads were washed twice with 
5xSSC to remove uncoupled LD57, Fifteen I'L oligobeads and 100 )'L 10 x SSC were added to 
the lysate. To denature the RNA and facilitate hybridization to the capture oligo, samples were 
heated to 80°C for 5 min and shaken for 60 min at ambient temperarure. Beads were washed twice 
with 5 times diluted lysis buffer and twice with 0.5 x sse using a magnetic stand. eDNA 
synthesis was performed as described (van Doom et al" 1992, 1994b) using random primers, Ten 
)'L eDNA was amplified by PCR using primers derived from the 5' untranslated region (5' UTR; 
all primers are represented in table 2), NCR4 and NCR3 were used as outer primers, Two )'L 
from the first PCR mixrure was transferred into nested PCR reactions with LD55 and LD56 as 
inner primers. Fifteen J..'L samples were analyzed by agarose gel electrophoresis and Southern blot 
hybridization, using HCV17 as a probe. The sensitivity of the capture assay is slightly lower than 
the conventional assays, using extractions with organic solvents and precipitation of the ReV 
RNA, The detecrion limit has been estimated at between approximately 150 and 1500 HCV RNA 
genomes (unpublished data), 
Anti-HCV assay 
Antibodies to core, NS4 and NS5 epitopes were determined by a confirmatory Line Immuno Assay 
(Inno-LIA HCV AbII, innogenetics NV, Gent, Belgium) according to the manufacrurer's 
instructions. 
Sequence analysis of the hypervarioble region 
The hypervariable region was analysed by direct sequencing of nested. biotinylated peR products 
(van Doom et al" 1994a). HCV36 and HCV31 served as outer primers in the initial PCR, The 
product was reamplified with primers HCV38B and HCV37, resulting in a biotinylated DNA 
fragment of which 356 bp were sequenced, Sequences of both strands were determined by the T7-
DNA sequencing system (pharmacia, Uppsala, Sweden) using PCR primers and internal 
sequencing primers LD79 and LDSO, 
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Table 1. HCV inocula and transmissions 
inoculum passage year of infection 
George factor VIII concentrate 0 1982 
Phil George 12 dpi, 
top fraction 1 1982 
Coen Phil 35 dpi 2a 1983 
Socrates Phil 62 dpi + Coen 192 dpi 
+ anti Human IgG 2b + 3 1985 
Sophie Socrates 74 dpi 3 1987 
Peggy George 12 dpi, middle 
fraction 1 1983 
Hans George 12 dpi, middle 
fraction + Phil 165 dpi 1 + 2c 1983 
Dpi indicates number of days after infection. 
Table 2. Oligonucleotides 
oligo pol. pos. sequence (5'-3') 
LD57 ·29 . .3 Bio-GGCCGGGGCGGCCGCCATGiT 
GCACGGTCTACGAGACCTCCCGGGGC 
NCR3 + ·314 .. ·288 GGGGCGGCCGCCACCATARRATCACTCCCCTGTGAGG 
NCR4 ·66 .. -47 CACTCTCGAGCACCCTATCAGGCAGTACC 
LD55 -99 .. -81 CRCTACTCGGCTAGCAGTCT 
LD56 + ·263..·241 CTAGCCATGGCGTTAGTATGA 
HCVI7 + ·88 .. ·69 GAGTAGTGTTGGGTCGCGAA 
HCV37 1874 .. 1852 AAGCAATACACYGGRCCACAYAC 
HCV36 + 1281..1290 GGTCAYCGCATGGCWTGGGA 
HCV38b + 1287 .. 1298 Bio-CGiATGGCiTGGGAiATGATG 
HCV31 1894 .. 1864 CTGCAGGCATGCGGGCTBGGRGTGAAGCARTA 
LD79 + 1414 .. 1435 TCCATGGTRGGGAACTGGGC 
LD80 1746 .. 1727 TGATGGGACCCCACCCCTG 
+ indicates sense. - indicates antisense orientation. Positions are according to Choo et al .• 1991 
[24J. Underlined sequences are non·HCV specific R= G or A, Y = Cor T, W = A or T, i= 
inosine, Bio = 5' -terminal biotin. 
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Results 
HCV injections in chimpanzees 
COlony-bred chimpanzees were experimentall~ infected with NANB hepatitis (see figure I and 
table I). The inocula for chimpanzees Phil, Peggy and Rans were prepared by extensive 
ultracentrifugation of infectious chimpanzee George plasma. All chimpanzees developed hepatitis 
with elevated levels of liver-specific enzymes in the serum. In chimpanzee Phil, infection was also 
proven by light- and electronmicroscopical investigation of liver biopsies, which revealed 
characteristic histological and ultrastructural changes in hepatocytes (data not shown). Serial blood 
samples from 4 chimpanzees. Phil. Coen, Socrates. and Sophie, were tested for the presence of 
RCV-RNA and anti-RCV. Results are summarized in figure 2A-D and table 3. 
Chimpanzee Phil (figure 2a) received a diluted low-density fraction of the centrifuged 
plasma and clearly developed a chronic RCV infection. A biphasic AL T profile was observed 
during the acute phase. g-GT showed only one peak. which coincided with the second AL T peak. 
Enzyme elevations were relatively low compared to levels observed in the other chimpanzees, and 
the infection seemed mild. RCV-RNA was first detected at 32 days after infection, remained 
detectable till 84 days after infection, followed by a transient period during which RCV-RNA was 
undetectable. Later, RNA became and remained detectable for more than 10 years. Anti-NS4 was 
first detected at day 53 and was the only serologic marker for at least several months. Anti-NS5 
was not detected during the first 5 months and anti-core positivity was observed for the first time 
at day 2527. Infectivity of Phil's acute-phase plasma was proven by inoculation of other anintaIs. 
Chimpanzee Coen (figure 2b) was inoculated with acute-phase plasma from Phil. RCV 
RNA was detected in the first available sample after inoculation at day II. RNA became 
permanently undetectable immediately after the AL T peak at day 67 suggesting complete resolution 
of the infection. Anti-core antibodies were first detected at day 40 and titers increased till day 74. 
At day 54 anti-NS4 was also detected, but anti-NS-5 remained consistently undetectable throughout 
the entire infection. 
Chimpanzee Socrates (figure 2c) experienced an acute resolving RCV infection, after 
inoculation of mixed sera from Phil (34 days after infection) and Coen (192 days after infection), 
which bad been complexed with anti-human IgG. At 192 days after infection, Coen serum 
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contained antibodies against NS4 and various core epitopes while HeV RNA was undetectable. In 
Socrates. HeV-RNA was below detection level at day 4 but was positive from day 8 till the ALT 
peak at 88 days after infection. Between day 89 and 92 the HeV-RNA concentration rapidly 
dropped till below the detection limit of ODr HeV-RNA assay. This change coincided with the 
sharp decline of the AL T levels in the serum. At day 54 antibodies against one core epitope were 
first observed. Levels of antibodies to core epitopes remained low. whereas anti-NS4 was 
undetectable in all tested samples. Anti-core antibodies gradually diminished until they became 
completely undetectable. 
Chimpan;zee Sophie (fignre 2d) was infused with a large volume of acute phase plasma 
from Socrates. The infectious dose of this inoculum was Dot determined but peR results suggested 
the presence of a high virus titer. The serum g-GT level reached a very high peak of 740 ulL at 
day 57. whereas AL T elevations were relatively mild. This chimpanzee also experienced only 
transient viremia. HeV-RNA was detected in the first available sample after inoculation at day 7. 
RNA was not detected after day 56. As observed in Socrates, the sharp decrease of the RNA 
concentration coincided with normalization of ALT levels. Anti--core antibodies were first detected 
at day 49, and titers diminished till almost complete seronegativity at 140 days after infection. 
(The sample at 140 days after infection would be scored as indeterminate on LIA). Later, ouly 
antibodies against the second core epitope were detectable from 407 to 1127 days after infection. 
Chimpan:zee Hans was inoculated with fractioned HeV positive plasma from George 
that had been mixed with plasma from Phil (165 days after infection), in an attempt to neutralize 
the virus by antibodies against essential epitopes. Hans developed a chronic HeV infection. The 
acute phase plasma from George was positive for both HeV-RNA and anti-HeV antibodies 
detected by second generation ELISA (Tsiquaye KN, unpublished data). Phil plasma at 165 days 
after infection does contain antibodies against non-strnctnral NS4 epitopes (fignre 2a) but not 
against NS5 or core epitopes. The antibody status against EI and E2 proteins is not known. The 
overall anti-HeV response in Phil was poor. and therefore it is not likely that Phil antiserum at 
165 days after infection could neutralize virus. HeV-RNA was undetectable in Phil at 165 days 
after infection, but dnring chronic HeV infection, infectivity of this plasma sample cannot be 
completely excluded (Beach et al., 1992). After inoculation of the mixture, Hans developed a 
chronic HeV infection. 
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Chimpanzees Peggy and Hans were not included in the longitudinal HCV-RNA and 
anti-HCV analysis. Both animals developed acute hepatitis with elevated ALT levels. Samples 
obtained in 1990 were tested positive by RT-PCR previously (van Doorn et al .• 1992), indicating 
chronic HCV infections. Genetic drift was also studied in these animals. 
Sequence analysis 
HCV genomes from Phil and Socrates were characterized by sequencing of amplified cDNA 
fragments derived from 5' UTR, E2INSI and NS5, and revealed the presence of genotype Ib (data 
not shown). Isolates from Phil (1983, 1987, 1989, 1993), Coen (1983), Socrates (1985), Sophie 
(1987), Peggy (1983, 1986, 1987, 1990), and Hans (1986, 1989) were used for sequence analysis 
of the hypervariable region. Furthermore, the original plasma sample from George as well as the 
derived "Middle Fraction", used to inoculate the chimpanzees Peggy and Hans, were analyzed. 
The sequences determined from the EI-E2/NSI boundary (nucleotides 1016-1372, encoding amino 
acids 339-457), including the hypervariable region, are represented in fignre 3. Sequences of 
cDNA fragments obtained during the early acute phase of hepatitis in Phil, Coen, Socrates and 
Sophie are completely conserved. Genetic drift of HCV during the chronic HCV infection in Phil 
between 1982 and 1993 is remarkably low. Three mutations were observed in the 356 bp fragment 
and only one located in the postulated hypervariable region. The deduced amino acid seqnences of 
the 1982 and 1993 sequences differ in only 2 positions. Viral genetic drift in Peggy and Hans is 
much higher in this region. (The 1983 sample from Peggy was obtained after the acute phase, 4 
months after inoculation). In both animals 17 nucleotide mutations. mainly Don-silent mutations 
were observed, resulting in significant amino acid replacements in the putative hypervariable 
region. Sequence from the "Middle Fraction" showed some sequence ambiguities but was almost 
identical to the sequence obtained from the acute phase plasma from George (fignre 3a). It was 
consistently impossible to detect HCV RNA in the original "Top Fraction", and therefore could 
not be subjected to sequence analysis. 
Figure 2. Schematic representation of longitudinal analysis of HCV infections in Phil (a). Coen (b). 
Socrates (c) and Sophie (d). Dpi "" days after infection. AST= aspartate amino transferase. ALT= alanine 
aminotransferase. g-GT~ gamma-g!utamylttanspeptidase. 
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Table 3. Clinical and serological data of HCY infection in experimentally infected chimpanzees 
Chimpanzee Acute phase Outcome LIA anti -HCY HCV RNA PCR detection 
start' peak ALT peak ALT NS4 NS5 core first duration 
(dpi) (dpi) (units/L) (dpi) (dpi) (dpi) (dpi) 
Phil 30 35' 194 chronic 53 2051 2527 32 > 10 years 
68 211 
Coen II 54 560 resolving 54 -' 40 II' 51 days 
Socrates 25 88 294 resolving 54 8 80 days 
Sophie 22 51 126 resolving 49 1 49 days 
1 Start of acute phase illness is defined as the day post-infection where either ALT (alanine aminotransferase), AST (aspartate aminotransferase), or g-GT (gamma 
glutanlyltC<lffipeptidase) is above nOID13.1 values. 
2 A biphasic ALT profile was observed during the acute phase. 
3 _ indicates absence of antibodies. 
4 first available sample after inoculation. 
LIA = Line Immuno Assay. Dpi indicates number of days after infection. 
Figure 3a. Nucleotide sequence alignments of El~E2INSl region 
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GATCCCGCAAGC'roTCATOOACATGG1XlGCOOGGGCCCACI'GGGGAG'tCCI'GGCGOOCC'ITGCCTACI'ATICCATGGI'GGGOAACI'GGGCTAAGGTT'IT 
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GGGGCGCAGCAAAAAGTCCAGCTCATAAACACCAACGGCAGCTOOCACATCAACAGAACTGCCCroAACTGCAATGAC"rCCCTCCAGACTGGGTTCCTCG 
1316 
CTGCGCTGI'TCTACACGCACAAGITCAACGCG'ICCGGATGCTCGOAACGCATGGCCC 
----- --- --------------- -- --- --- -- --- --- -- -- ----
------------------------------AT---------A--------R------
--- --- --------- --- --- -AT--
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Alignments of EI-E2/NSI sequences (nt 1016-1372), including the hypervariable region from 7 cWmpanzees. 
Middle fro represents sequences from the ftMiddle Fraction". Sequences obtained during the acute phase of the disease are indicated. 
Figure 3b. Deduced amino acid sequence alignment EI-E2INSI region 
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Deduced amino acid sequences (residues 339-457). Underlined amino acid sequence indicates tbe hypervariable region. Italics indicates the possibility of the presence of 
both the original and the indicated amino acid, due to sequence ambiguity. >I< indicates the possible presence of multiple amino acids. 
Discussion 
The courses of NANB hepatitis infections in chimpanzees were studied retrospectively by detection 
of Hev RNA and anti-Hey. All chimpanzees described in this study were infected with inocula 
from, or derived by passage of, a single acute phase plasma from chimpanzee George, containing 
genotype Ib ReV. It is important to note that George previously went through 2 distinct episodes 
of NANB hepatitis, caused by contaminated Factor IX and Factor VIII preparations respectively 
(Tsiquaye et al., 1980). Therefore, it is difficult to trace the real source of the predominant HeV 
variant as detected in George. 
Chimpanzee Phil showed a biphasic AL T profile, considered characteristic for a specific 
Factor VIII preparation (Bradley et al., 1979, Beach et al., 1992. HeV-RNA was first detected 32 
days after infection in Phil~ in contrast with the much earlier detection in the other 3 chimpanzees 
involved in this and other studies (Shimizu et al., 1990). This phenomenon has been reported 
earlier (Hilfenbaus et al., 1992) but the amount of inoculated HeV and the first detection of 
viremia did not seem to be correlated. 
Chimpanzee Coen had been infected by HIV-l before inoculation with HeV containing 
acute phase plasma from PhiL It is unlmown how the replication of these viruses may interfere. 
although an increased risk of vertical transntission has been reported (Giovannini et al., 1990). 
Chimpanzee Sophie received a large inoculum of possibly high-titer material, obtained 
during the acute phase of infection in Socrates. The incubation period in chimpanzee Sophie did 
not differ significantly from the other animals, although a shorter incubation period after 
inoculation of a high titer HeV preparation in a chimpanzee has been suggested (Beach et al., 
1992). The peak level of g-GT observed in Sophie was much higher than in the other chimpanzees 
and there may be a correlation betvleen the infectious dose and the g-GT level. indicating the 
severity of primary infection. 
In all animals, RNA levels dropped below detection level inunediately after the sharp 
decline of the serum ALT level, a phenomenon that has been observed earlier (Beach et al., 1992, 
Shindo et al., 1992, Farci et al., 1991, 1992b). The level of seturn ALT is considered to be a 
direct measure of hepatic injury (Ohosone et al., 1992). During acute illness, HeV-infected 
hepatocytes are lysed, releasing large quantities of liver specific enzymes in the blood. After a 
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massive destruction of infected hepatocytes, the number of infected hepatocytes producing HeV 
virions will be reduced significantly. causing very low levels of HeV RNA in the serum 
hmnediately after the AL T peale, It is unknown whether development of chronicity depends on an 
extrahepatic reservoir of HeV such as lymphocytes (Hellings et aI" 1988, Milller et aI" 1993) 
during this primary hmnune response, 
Antibody profiles 
Antibody patterns in the 4 chimpanzees showed significant differences, and were unpredictive for 
the development of chronicity, Remarkably, anti-NS5 has been observed only in 3 samples from 
Phil, obtained more than 5 years after infection, This result was unexpected since NS-5 epitopes in 
the LIA are derived from homologous genotype 1 sequences and anti-NS5 has been observed in 
chimpanzees and humans infected with various genotypes (van Doom et al., 1992, 1994a). Anti-
core antibodies were the first evidence of immune response in chimpanzees eoen. Socrates and 
Sophie, but were not detected in the chronically infected chimpanzee Phil up till 176 days after 
infection. The remarkably delayed anti-core response in Phil may have facilitated the development 
of chronicity in this animal. 
Neutralization experiments 
Neutralization experiments were clearly unsuccessful in Socrates and Hans. Although virus and 
antibody titers in the various sera may have been incompatible. this result and other reports (Farci 
et al., 1992b) suggest, that protective antibodies against HeV are not produced. Farci et al. 
(1992b) also reported that antibodies against core, NS3 and NS5 epitopes could not prevent 
reinfection in chimpanzees. This phenomenon may also partly explaln the high percentage of 
chronic HeV infections. On the contrary, recent experiments (Hijikate 1993) suggested that 
association of antibodies with HeV virions is correlated with a reduction of infectivity. but these 
results remain to be validated in vivo. 
Genetic drift of the hype11lariable region 
The N-terminal part of E2INSI has been designated as a hypervariable region (E2 HV; Weiner et 
al., 1991, Kato et al., 1992a,b, Hijikata et al., 1991, Oshima et al., 1991, Tanaka et al., 1992). 
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The sequence of E2 HV differed considerably (data not sbown) from earlier reported genotype Ib 
isolates (Kato et al .• 1990, Takamizawa et al., 1991). Putative consensus amino acids (Lesniewski 
et al., 1993) at positions 385 (threonine), 406 (glycine), 409 (glutatnine) and 413 (leucine) are also 
conserved in these isolates. No variations in HeV sequence were observed between George and 
early acute pbase isolates from Phil, Coen, Socrates and Sophie. This indicates the relative 
stability of the HCV bypervariable region during passage of the virus in another bost, and is in 
accordance with previous reports (Farci et al., 1992b). 
The observed mutation rate of the E2 HV region during chronic infection in chimpanzee 
Phil was remarkably low. Mutation of the viral RNA, caused by errors of the RNA polymerase, 
may result in appearance of new sequences in the virus population. These mutants may experience 
different selective pressure than the wildtype. Also, if an inoculum already contained multiple 
coexisting sequence variants, both mutation and selection can account for the detection of multiple 
sequences at different timepoints during infection. Sequence analysis by either cloning or direct 
sequencing of amplified cDNA bas limited sensitivity to detect variants with a low abundancy. The 
low mutation rate of the E2 HV region observed in Phil may be due to the inoculation of a very 
limited number of different HCV genomes. In several reports, the buoyant density of HCV virions 
(Carrick et al., 1992, Miyamoto et al., 1992, Takahashi et al., 1992, Bradley et al., 1991) was 
estimated and results varied considerably. Association of HCV with 6-lipoprotein (Tbomssen et 
al., 1992) will cause a mucb lower density, and may explain the observed 'floating' of the virus, 
whereas formation of immune complexes can cause an increase in density (Hijikata et al .• 1993). 
Preselection of a specific population of HeV virions by fractionation of the George plasma by 
ultracentrifugation cannot be excluded. On the other band, it is more likely that bypervariability is 
caused by selective inunune pressure (Weiner et al., 1992, Kato et al., 1993). If a predominant E2 
HV epitope is neutralized by specific antibodies, mutations may lead to escape mutants, whicb 
evoke a new immune response that again selects for novel escape mutants. If such an antibody 
response is absent, there will be no driving force for selection of escape mutants. Thus, the low 
mutation frequency observed in Phil may be due to the absence of selective inunune pressure 
against E2 HV. We bave not yet studied the antibody response against epitopes from the E2 HV 
region. Interestingly ~ far more replacement changes than silent mutations are observed. in Peggy 
and Hans, suggesting the importance of immune selection of E2 HV epitopes. 
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Since the hypervariable region is located in a putative envelope protein. sequence variation 
may have important clinical implications, such as the efficacy of interferon therapy (Okada et a1., 
1992). Therefore, analysis of sequence variation should be accompanied by a thorough 
investigation of the immunological implications of host factors such as the HLA genotype. 
Understanding the interaction between virus and host will be crucial for the future development of 
vaccines or antiviral therapies. 
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Abstract 
The RNAs of Hepatitis C virus (HCV) isolates from 62 patients with chronic HCV infection were 
analyzed by direct sequencing of the S' untranslated region. Two important sequence motifs were 
recognized; one between position -170 and -155 and the other between -132 and -117. These 
motifs are partly complementary. All three previously published genotypes were observed: 34 
(55%) isolates were classified as type 1 (including prototype [from the United States] and HCV-
BK [from Japan] sequences), 11 (18%) as type 2 (including HC-J6 and HC-J8), 12 (19%) as type 
3 (including EBl), and one patient was coinfected with genotype 1 and 2. Four (6%) isolates 
showed aberrant sequences and were therefore provisionally classified as genotype 4. These results 
indicate the Significance of S' UTR sequence variation among different HeV genotypes, and the 
possibility to use this region for consistent genotyping of HeV isolates. 
Introduction 
Since the discovery of hepatitis C virus (HCV), a flavi-like virus with a positive-sense, single 
stranded RNA genome of approximately 9.400 nucleotides (Choo et al., 1989), several full length 
sequences have been obtained from various isolates (Choo et al., 1991, Kato et al., 1990, 
Okamoto et al., 1991, Okamoto et al., 1992a, Takamizawa et al., 1991) and proposals have been 
made to classify HCV isolates into different (sub)types (Cha et al., 1992, Chan er al., 1992, 
Enomoto et al., 1990, Houghton et al., 1991, Mori et al., 1992, Okamoto et al., 1992c). Based on 
all available sequence information, Chan et al., (1992) distinguished 3 HCV genotypes. Type I 
isolates include the prototype HCV-I (Choo et al., 1991), the HCV-H strain (Ogata er al., 1991), 
HCV-Kl (Enomoto et al., 1990), HCV-J (Kato et al., 1990) and HCV-BK (Takamizawa et al., 
1991); type 2 includes HCV-K2 (Enomoto et al., 1990), HC-J6 (Okamoto et al., 1991) and HC-J8 
(Okamoto et al., 1992a); type 3 includes HCV E-bl (Chan et al., 1992), HCV-T (Mori et al., 
1992) and HCV1196 (Lee et al., 1992). 
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HCV genotyping is of interest in viral transmission studies and HCV epidemiology. 
Furthermore, the success of interferon treatment (pozatto et al., 1991, Yoshioka et al., 1992) may 
be (sub)type related. 
There are several reasons to choose the 5' untranslated region (5' UTR) for genotyping: 
(a) analysis of a large number of HCV isolates resulted in similar phylogenedc trees for the 5' 
UTR, the core, NS-3 and NS-5 regions (Chan et al., 1992); (b) the observed mutation rate of the 
5' UTR is extremely low (Ogata et al., 1991, Okamoto et al., 1992c); (c) sequence variation 
within the conserved 5' UTR is mainly limited to specific regions; and (d) the putative secondary 
structure of the 5' UTR, as established on biochemical and phylogenetic data (Brown et al., 1992), 
suggests (functional) conservation of this region. 
In the study described here, 62 HCV isolates from patients in the Netherlands with a 
chronic Hev infection were investigated to determine whether HeV genotyping by sequence 
analysis of PCR products derived from the 5'UTR could be performed. 
Materials and methods 
Patients 
Sixty-two patients from the Netherlands, between 26 and 74 years of age with elevated alanine 
aminotransferase (ALT) levels, a biopsy-proven chronic non-A. non-B hepatitis, antibodies to 
hepatitis C virus, and no recent history of infection with hepatitis B virus, hepatitis A virus, 
Cytomegalo virus or Epstein-Barr virus, were analyzed. 
Anti-HeV 
Antibodies to HCV were tested by a second generation enzyme immuno assay (EIA) (Abbott, 
North Chicago, IL, USA) and confirmed by the recombinant immunoblot assay (RIBA-4, Ortho 
Diagnostics, Raritan, NJ, USA) according to the instructions of the manufacturer. 
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Blood plasma 
For HCV RNA detection, EDTA-blood was collected by venipuncture and plasma was prepared 
witlrin 2 hours after sampling. One ml aiiquots were quickly frozen in liquid nitrogen and stored at 
_70°C untiI use. 
HCVRNAPCR 
HCV RNA was isolated from 100 JLl plasma by a modified version of the guanidinium method as 
described previously (Chomczynski et ai., 1987). cDNA synthesis was performed on one-third of 
the isolated RNA in a 25 JLl reaction volume (Kleter et ai., 1993) using 20 pmol antisense primer 
HCV19 (GTGCACGGTCTACGAGACCT, position -1 to -20), 200 units Moloney murine 
leuketnia virus reverse transcriptase (M-MLV, Gibco-Bethesda Research Laboratories, 
Gaithersburg, Md, USA), 30 units RNAsin (Promega, Madison, WI, USA), 0.5 mM of each 
deoxyribonucleotide (Boehringer, Mannhehn, Germany) at 42°C for 30 min after brief 
denaturation at 80°C. PCR was performed (40 cycles, 1 min 94°C, 2 min 48°C, 3 min 74°C) 
with antisense primer HCV19 and sense primer HCV18 (GGCGACACTCCACCATAGAT, posi-
tion -304 to -324) or sense primer HCV35 (TTGGCGGCCGCACTCCACCATGAATCACTCC-
ce. position -296 to -318; underlined sequences are Dot complementary to HeV). For diagnosis. 
the first round PCR products were analyzed by Southern blot hybridization with probe HCV 17 
(GAGTAGTGTTGGGTCGCGAA, position -86 to -67), followed by washing at low stringency. 
Direct sequencing of PCR products 
For direct sequencing (Hultman 'et ai., 1991), a second round of PCR (40 cycles, 1 min 94°C, 2 
min .48°C, 3 min 74°C) was performed with sense primer NCR3 (GGGGCGGCCGCCAC-
CATRRATCACTCCCCTGTGAGG, position -288 to -314) and antisense primer LD58 (5' bio-
GGCCGGGGCGGCCGCCAAGCACCCTATCAGGCAGTACCACAAGGC, position -37 to -64). 
LD58 is biotinylated at the 5' end. Biotinylated PCR products (estimated by agarose gelelee-
trophoresis at approximately 100 ng) were captured onto streptavidin-roated paramagnetic particles 
(Dynabeads M-280, Dynal, Oslo, Norway). Single stranded DNA was prepared by denaturation of 
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the captured amplification product by alkaline treatment according to the instructions of Dynal. 
Separate strands were sequenced using the T7 DNA sequencing kit (pharmacia, Uppsala, Sweden) 
and [a-"Pj-dATP (Amersham, Buckinghamshire, UK). NCR3 served as a sense primer on the 
minus strand captured on the beads, and NCR4 (CACTCTCGAGCACCCTATCAGGCAGTACC, 
position -57 to -29) was used as antisense primer on the plus strand in the supernatant. DNA 
sequences were read manually from autoradiographs and analyzed with the PC/Gene computer-
program (Intelligenetics Inc., Mountain View, CA, USA). 
Results 
Sixty-two patients with chronic HeV infection were anti-Hey positive by EIA, confirmed by 
R1BA-4, and were HCV RNA positive by RT-PCR aimed at the 5' UTR. Sense primer HCV18, 
based on the first published HeV sequences (Garson et al., 1990, Okamoto et al., 1990) was 
initially used for diagnosis of HCV viraentia by PCR. In the case of low yields of PCR products, 
sense primer HCV35 improved PCR results considerably (data not shown), and in these cases, 
PCR products obtained by HCV35 were used for sequence analysis. 
Nested PCR products were directly sequenced, and the results are represented in fignre 1. 
If identical sequences were obtained from a number of isolates, only one representative is shown. 
Several sequences have been reported previously. and are identified by their original names. 
Limited sequence variations were observed essentially in 2 motifs: motif 1 is located between nt -
170 and nt -155, and motif 2 between nt -132 and nt -117 (fignre 1). Based on these motifs, 58/62 
isolates could be classified into the 3 genotypes as proposed previously. Thirty-four (55%) isolates 
were classified as type 1, which includes the prototype HCV sequence HCV-I. Isolate HCI-N8 
showed a single nucleotide insertion at position -138. In one patient (isolate HC1/2) a double 
infection with type 1 and 2 was observed, as deduced from bands with identical mobility in two 
different lanes on the gel (fignre 2). Type 2 sequences, like HC-J6, were observed in 11 (18%) 
patients. These isolates are also recognized by the presence of a T at position -72 and a C at 
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position -80. HC2-N2 contains a mutation at nt -127 in motif 2. Within genotype 2, sequence 
heterogeneity was observed at position -119. showing either a T or C. Type 3 sequences were 
detected in 12 (19%) patients. In addition to the type-specific sequence motifs, type 3 isolates can 
also be identified by a TCA sequence at positions -93 to -95. HC3-N2 contains a point mutation at 
position -118 in motif 2. Fout (6%) isolates were provisionally classified as type 4. These isolates 
showed additional sequence heterogeneity between position -238 and -235, compared to types I, 2, 
and 3. 
Comparison between obtained (nt -262 to -66) and all previously reported 5' UTR 
sequences (Bukh et aI., 1992), Cha et aI., 1992, Chan et aI., 1992, Han et aI., 1991), revealed a 
nutnber of new 5' UTR mutations within all genotypes (figute I). 
Table 1. 
(A) 
Type 
2 
3 
4 
(B) 
I 
2 
3 
4 
Mean nucleotide variation among fout HCV genotypes in (A) 
the entire 197 bp 5' UTR fragment and (B) motifs I and 2. 
Nutnber nucleotide variation (%) 
of isolates' I 2 3 4 
34 0.Q25 
11 0.071 0.020 
12 0.071 0.112 0.010 
4 0.041 0.061 0.061 0.020 
0.000 
0.280 0.025 
0.280 0.355 0.003 
0.125 0.235 0.158 0.015 
113 
Figure 1. Alignment of 5' UTR sequences from different genotypes. 
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Figure 1. (continued) 
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Alignment of 5' UTR sequences from 62 patients. Sequences between position -262 and -66 were classified 
into genotypes 1. 2. 3 (as proposed by Chan et al .. 1992). and 4. Previously published sequences are 
identified by their original name: HCV-I (7): DK7. SAlO. USlO. SAl. and DK!3 (2): HCV-BK (26): HC-
J6 (21): EB-12 and EB-7 (4) and HCV1196 (17). Numbers in parentheses indicate the number of isolates 
with that sequence. Hyphens indicate presence of identical nucleotides as in prototype. Sequence motifs 1 
and 2 are boxed. HeV-l underlined nucleotides are involved in the putative dsRNA stem structure (1). 
Abbreviations: M (A or C): R (A or G); Y (T or C): W (A or T) and S (G or C). 
The overall sequence heterogeneity among the 4 genotypes in this study ranged from 4 % 
between types 1 and 4 to 11 % between types 2 and 3. whereas heterogeneity within each type was 
less than 2.5% (Table la). Mutations are not randomly distributed along the 5' UTR. but are 
clustered in motifs 1 and 2. Comparison of these motifs among the four genotypes revealed strong 
conservation within each genotype and showed significant differences between the genotypes 
(Table Ib). Further analysis of the sequence variation in motifs 1 and 2 revealed the presence of 
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covariants, i.e., complementary mutations in each motif, maintaining the postulated secondary 
structure of the 5' UTR genomic RNA (Brown et a1., 1992), The P-values for the occurrence of 
one, two, or three covariant mutations in motifs I and 2 to have arisen by chance were very low 
(P= 0.06, P=O.OO4, P=0.OOO2, respectively). Covariance occurred at positions -164, -163, -161 
and -ISS in motif I, and positions -132, -124, -122, and -121 in motif 2. This covariance was 
consistently observed in all 62 sequences, indicating the importance of this phenomenon. 
CAT C 
l 
motif 2 
J 
l 
motif 1 
J 
Fignre 2, Direct sequence analysis of the 5' UTR from isolate HCI/2 with sense primer NCR3. 
Abbreviations: S (G or C); W (A or T); Y (f or C); R (A or G) and M (A or C). 
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Discussion 
Sequence analysis of the 5' UTR of HCV isolates from 62 patients with a chronic HCV infection 
allowed consistent and efficient genotyping. Fifry-eight (94 %) isolates could be classified into the 3 
different genotypes as proposed by Chan et aI., (1992). Identification of the genotypes is 
essentially based on the sequence variation in the defined motifs 1 and 2. 
All three genotypes reported so far were observed in this patient population in the 
Netherlands. Coexistence of HCV genotypes in several geographic regions has been indicated 
earlier (Cha et aI., 1992, Chan et aI., 1992. However, little is known about the distribution of 
HCV genotypes in Europe. The majority of published isolates belong to type 1 (Cuypers et aI., 
1991, Kretnsdorf et aI., 1991). Types 2 and 3 were detected in European isolates only recently 
(Bukh et aI., 1992, Chan et aI., 1992). 
Although at a low frequency, isolates belonging to a new genotype, tentatively desigoated 
as genotype 4, were observed in the Netherlands. Similar sequences were first found in isolates 
from South Africa (Cha et aI., 1992) and Denmark (Bukh et aI., 1992). To justify classification of 
these isolates as a new genotype 4, sequence analysis of coding regions is necessary. Preliminary 
results (data Dot shown) indicate significant nucleotide sequence differences between the core 
region from type 4 isolates and corresponding sequences from types I, 2. and 3. One sequence 
(SAl), classified here as type 4, showed minor differences with the other type 4 sequences, and 
might be classified as a separate genotype 5 (p. Sinnnonds et aI, unpublished observations). 
Probably, all genotypes have a worldwide distribution but relative abundances per geographic 
region may differ considerably. 
In one patient a double infection was found involving genotype 1 and 2. This is in 
accordance with the reported frequency of double infections which has been observed by others 
(Okamoto et aI., 1992b, Yoshioka et aI., 1992) using type-specific primers or probes. 
New 5'UTR sequences were observed in 21 of the 62 anaIyzed isolates. The distribution 
of the sequence variation is not random. Recently. the putative secondary structure and possible 
functional elements of the 5' UTR of the HCV genome were postulated (Brown et aI., 1992, 
Tsukiyarna-Kohara et aI., 1992, Yoo et aI., 1992). The defined sequence motifs 1 and 2 show 
partiaI complementarity and are able to form a stahle stem-loop structure, e.g., nt A at pos. -170 
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is complementary to nt T at pos. -115 and the nt C (or T for type 2) at pos. -155 is complemen-
tary to nt G (or A for type 2) at pos. -132. Covariance in motifs 1 and 2 consistently preserve the 
secondary structure. Therefore. mutations are more likely to be tolerated in single stranded 
regions. This is confirmed by the relatively high mutation rate in the ssRNA loop between position 
- 136 and -151. Most of the point mutations are located outside the defined sequence motifs and do 
not affect classification. Only 2 isolates showed single point mutations within the 2 motifs: HC2-
N2 contains a G at position -127, and HC3-N2 contains a C at position -118. Despite these variati-
ons. classification of HC2-N2 and HC3-N2 as type 2 and 3 respectively, was obvious. 
The overall sequence variation between the 197 bp 5' UTR fragments is not statistically 
significant. as only 6--21 mutations were observed among the four genotypes. Since the mutations 
are not randomly distributed along the 5' UTR, it is impossible to apply regular statistical methods 
to this problem, as these require random distribution of events. The secondary structure. i.e. the 
stem-loop structure formed by partial complementarity of motifs 1 and 2, must be maintained (with 
a sufficiently low free energy) to function properly as an internal ribosomal entry site (Tsukiyarna-
Kohara et al., 1992). Therefore, mutations in these motifs have functional restrictions. Comparison 
of the 5' UTR sequences as described in this paper, reveals the existence of covariants. These 
complementary mutations in motifs 1 and 2 indeed completely conserve the secondary structure. 
indicating the significance of covariance. Based on these findings. classification of HeV isolates 
should preferably be based on covariance in motifs 1 and 2. 
In conclusion. consistent genotyping based on 5" UTR sequence analysis is possible and 
may complement studies on antiviral treatment and transmission of HeV. 
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Abstract 
In order to determine the (sub)type of Hepatitis C virus (RCV) the 5' untranslated regions (5' 
UTR) derived from 54 patients with a chronic HCV infection were analyzed. Biotin-labelled PCR 
products from the 5' UTR were used for reverse hybndization in a Line Probe Assay (Inno-LiPA) 
and results were vaiidated by comparison with direct sequencing data. Five different genotypes 
could be distinguished based on 5' UTR sequence diversity. Results of typing by LiPA and direct 
sequencing were similar. Antibody responses against core, NS-3. NS-4 and NS-5 epitopes were 
detected by RIBA-4 and Inno-LIA HCV Ab II confirmatory assays. There was no clear correlation 
between genotype and anti-HCV response, aithough types 2 and 3 HCV isolates show poor 
reactivity with NS-4 epitopes. 
Introduction 
Hepatitis C virus, the main etiological agent of post-transfusion hepatitis, is a small enveloped 
virus and contains a positive sense, single-stranded RNA genome of approximately 9400 nucleo-
tides (Choo et ai., 1989). Based on genomic (Miller et ai., 1990) and physico-chemical characte-
ristics (Bradley et ai., 1985) of the virus, HCV is classified as a distinct member of the Flavivi-
ridae. From HCV isolates, obtained worldwide, severai full length (Kato et ai., 1 990a, 
Takamizawa et ai., 1991, Choo et ai., 1991, Okamoto et ai., 1991, 1992a, Chen et ai., 1992) and 
numerous partial sequences (e.g. Chan et ai., 1992, Han et ai., 1991, Ogata et ai., 1991, Takeuchi 
et ai., 1990, Kato et ai., 1990b, Mori et ai., 1992, Enomoto et ai., 1990, Weiner et ai., 1991, 
Lee et ai., 1992) have been obtained. Based on sequence diversity, severai proposais were made to 
classify the different HCV isolates (Chan et ai., 1992, Enomoto et ai., 1990, Okamoto et ai., 
1992b, Houghton et ai., 1991, Cha et ai., 1992), but there is no consensus in HCV nomenclature 
so far. A useful HCV classification was proposed recently (Stuyver et ai., 1993), based on 
phylogenetic trees determined by Chan and collogues (Chan et ai., 1992), differentiating between 
types (approx. 68% average sequence homology) as well as between subtypes (approx. 79% 
sequence homology). Homologies between isolates belonging to the same subtype are about 88%. 
This system was further extended with new types, provisionally designated as types 4 and 5 
(Simmonds et ai., 1993). 
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There are indications that infections caused by different HCV (sub)types may bave diffe-
rent clinical implications (Okamoto et aI .• 1992b). The effectiveness of antiviral treatment (Kana! 
et aI., 1992, Pozatro et aI., 1991, Yoshioka et aI., 1992), efficiency of viral transmission, distri-
bution among various patient populations and the development of hepatocellular carcinoma may 
also be subtype related. Preliminary results urge HCV subtyping which complements the routine 
diagnostic antibody and RT-PCR assays. 
All available sequence data were used to develop type and subtype-specific probes for the 
reverse hybridization Line Probe Assay (LiPA), which has been described in detail recently 
(Stuyver et aI., 1993). The assay is based on the observation that variation within the 5' UTR is 
mainiy restricted to 2 short (sub)type specific sequence motifs. 
In this study HCV isolates were analyzed from 54 patients by the novel LiPA which 
allows classification of isolates into genotypes 1,2 and 3 (Chan et aI., 1992, Stuyver et aI., 1993), 
and the new types 4 and 5 (Simmonds et aI., 1993). Results of reverse hybridization were 
compared with data from direct sequencing of the 5' UTR. Furthertnore HCV antibody proflles, 
deterutined by RIBA-4 and Inno-UA HCV Ab II, were compared with the 5 genotypes. 
Materials and methods 
Patient sera 
Blood samples from 54 patients were obtained by venipuncture. EDT A-plasma was prepared 
within 2 hours afrer collection, aliquotted, quickly frozen in liquid nitrogen and stored at -70°C. 
All patients bad a chronic HCV infection with elevated ALT levels, biopsy-proven liver 
abnormalities and were anti-HCV and HCV-RNA positive (Kleter et ai, 1993). 
RNA isolation, and reverse transcriptase PCR (RT-PCR) 
HeV-RNA was isolated from freshly frozen plasma samples by a modified version of the acid 
guanidinium-phenol-chlorofortn method as described (Kleter et aI., 1993). Briefly, cDNA was 
synthesized using antisense primer HCV19 (pos. -I to -20; 5'-GTGCACGGTCTACGAGAC CT-
3') and amplified by PCR using HCVI9 and sense-primer HCVI8 (pos. -323 to -304; 5'-
GGCGACACTCCACCATAGAT-3') or HCV35 (pos. -318 to -296; TTGGCGGCCGCACTCCA-
CCATGAATCACTCCCC). Fourty PCR cycles were perfortned, consisting of I min. 94°C., 
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min. 55°C. and 1 min. 72°C. Amplification products were analyzed by agarose gelelectrophoresis 
and Southern blot hybridization using probe HCVI7 (pos -88 to -69; 5'- GAG-
TAGTGTIGGGTCGCGAA-3'). 
Line Probe Assay (LiPA) 
Based on all available 5' UTR sequences, several type-specific sequence motifs were recognized 
(see also Stuyver et aI., 1993). Motif I is located between positions -170 and -ISS, and motif 2 
between -132 and -117. These motifs already allow discrimination between the different genotypes, 
are partially complementary and can form a stable dsRNA stem structure (Brown et aI., 1992). A 
number of positions displaying more subtle~ but consistent variations allow consolidation of typing 
by means of motif I and 2, or enable more detailed sUbtyping. Type I can be divided into 
subtypes la and Ib, by the presence of an A or G at position -99, respectively. At pos -99 a G has 
been observed in all type Ib isolates studied so far, but is also present in most type 3 and some 
type 4 isolates. Type 2 isolates are also recognized by a T at -72 and a C at -80. Further sUbtyping 
into subtypes 2a and 2b is based on nucleotides at pOSitions -161 (G or A respectively) and -124 
(C or T respectively). Therefore, motifs I and 2 can be used for both typing and subtyping of type 
2 isolates. Type 3 is also identified by the presence of a TCA motif at positions -95 to -93. 
The LiP A is based on the hybridization of labelled PCR amplification products to specific oligomr-
cleotides directed against the variable regions of the 5' UTR. These probes were immobilized as 
parallel lines on membrane strips (reverse hybridization principle). During nested PCR. the 
product is biotinylated, which allows detection of hybrids by alkaline phosphatase labelled 
streptavidin. The HCV-LiPA (figure I) contains IS probe lines, exposing 18 different 16-mer 
probes. Sixteen probes specifically recognize HCV genotypes, and 2 (no. 21 and 22) are general 
HCV probes (location of the probes in the 5' UTR sequence is shown in figure 2.). The 
development of the LiPA was described in detail recently (Stuyver et aI., 1993). 
From the first round PCR, 0.5 f'l product was transferred into a new, 50 1'1 nested PCR 
reaction, containing primers HC3 (sense; -264 to -238; 5'-TCTAGCCAT 
GGCGTIAGTRYGAGTGT-3'), HC4 (antisense; -29 to -54; 5'- CACTCGCAAG-
CACCCTATCAGGCAGT-3') and biotinylated "dUTP. These biotinylated nested PCRproducts 
were used as probe on the LiPA strips. Briefly, biotinylated DNA was denatured by mixing 10-20 
f'l of the nested PCR reaction with an equal volume of 400mM NaOH, 10mM EDTA, and 
incubating for 5 min. at room temperature. The denatured fragment was hybridized to the probes 
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on the LiPA in the presence of tetramethylammoniumcbloride (TMACI, Merck) at 42'C for 2 
hours. Strips were washed at 52 'C and alkaline phosphatase conjugated streptavidin was added and 
coloured by NBTIBCIP substrate (4-Nitroblue tetrazolium cbloride and 5-bromo-4-cbloro-3-
indolylphosphate) for 15-30 min. at room temperature in the dark. Strips are finally rinsed in dis-
tilled water and air-dried. The results of the LiPA were determined by scoring the presence or 
absence of hybridization with each probe line. 
Direct sequencing 
PCR products were reamplified using sense primer NCR3 (pos. -314 to -288; 5' -
GGGGCGGCCGCCACCATARRATCACTCCCCTGTGAGG-3'; underlined sequence is non-HCV 
specific) and LD58 (pos -66 to -35; 5'-Bio-GGCCGGGGCGGCCGCCAAGCACCCTA-
TCAGGCAGTACCACAAGGC-3') carrying a 5' biotin moiety. Biotinylated nested PCR products 
were used as template for direct sequencing, using the protocol suggested by the manufacturer of 
the Dynabeads (Dynal, Norway). Briefly, nested PCR products were mixed with streptavidin-
coated paramagnetic particles (Dynabeads M280, Dynal, Norway) in binding and washing (B&W) 
buffer (Ix B&W buffer is 10 mM Tris-HO, pH 7.5, I M NaCI, I mM EDTA), to allow the 
binding of the biotinylated DNA. Complementary strands were separated by addition of NaOH, 
and sequenced using the T7 DNA sequencing kit (pharmacia, Uppsala, Sweden) and [Ct-"P]-dATP 
(Amersham, Buckiugharnshire, UK). DNA attached to the beads or in the supernatam was 
sequenced with either NCR3 as a sense primer on the captured minus-DNA strand or NCR4 (pos.-
66 to -47; 5'-CACTCTCGAGCACCCTATCAGGCAGTACC-3') as an antisense primer on the 
plus strand in the supernatant. Sequencing products were separated on an 8% polyacrylamide:bi-
sacrylamide gel (19: I w/w). DNA sequences were read manually from autoradiographs and 
analyzed with the PC/Gene computer program (Intelligenetics Inc., Mountain View, CA, USA). 
Anti-HCV assays 
Antibodies to HCV were assayed by an Enzyme Inununosorbent assay (ElA; Abbott Chicago, n, 
USA) and confirmed by RIBA-4 (Ortho diagnostics, Raritan, NJ, USA) and Inno-LlA HCV Ab II 
(Innogenetics, Gent, Belgium) according to the manufacturers instructions. 
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Results 
HCV-RNA was isolated from 54 patients with a chronic HCV infection, and amplified by RT-PCR 
using 5' UTR specific primers, These PCR products were analyzed by direct sequencing as 
described elsewhere (KIeter et al" 1994), Biotinylated amplification products from nested reactions 
were used as probe in the reverse hybridization LiP A system. The location of the probes on the 
LiP A strip and typical LiP A results are shown in figure I. 
Figure 1~ 
3 4 5 1b + 2b 50 20 48 neg 
-15 
-,. ~17 
'-. "18 ~19 
20 
type 3 
J type 4/5 
Figure 1. Positions of the probe lines on the LiPA strip and typical results. Probes 21 and 22 are general 
probes to identify general 5' UTR sequences. Probes 5-20 distinguish different types and subtypes of HeV 
as indicated. Representative results of isolates containing types la, lb, 2a, 2b. and 3 are shown. together 
with. all type 4 and 5 isolates. Furthennore. isolates 50 and 20. displaying sequence~specific var'...ation and 
the single discrepant isolate 48 are shown. 
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All labelled nested PCR products hybridized to general probes 21/22 and with a subset of 
genotype-specific probes. Results of LiPA analysis of 54 patient isolates are summarized in table 
1. Five different genotypes were detected and there were no isolates that could not be typed by 
LiPA. Observed hybridization patterns were consistent and classification into types and subtypes 
was obvious in all isolates, including one double infection with subtypes 1b and 2b. 
Table 1. Genotypes of 54 patient HCV isolates determined by the LiPA 
Type # of isolates % 
la 7 13 
1b 24 44 
2a 7 13 
2b 1 2 
3 10 18 
4 3 6 
5 2 
Ib+2b 2 
Probes 17 and 18 were aimed to discrintinate further between type 3 isolates, based on the 
presence of a G or A at -139 respectively. However, most type 1 isolates cross-reacted with probe 
17, and to a lesser extent with probe 18. Overall background staining on the strips was very low 
or completely absent. 
Reverse hybridization results from LiP A were compared with data obtained from direct 
sequencing. Sequences were determined on nested products derived from the sarne first round PCR 
products as used for LiPA. 5' UTR sequences and locations of LiPA probes are shown in figure 2. 
Comparison of LiP A and direct sequencing results revealed a small discrepancy in only one 
sample. Amplified HCV.;:DNA from this isolate (no. 48, containing the DK7 sequence figure 2.) 
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hybridized with probe 7 (figure I), indicating the presence of a G at pos. -99, but direct 
sequencing showed only an A. This isolate is therefore classified as Ib by LiPA but as la by 
direct sequencing. On the other hand. some aberrant hybridization patterns observed in LiPA were 
validated by direct sequencing results. Isolate 50 (HC2-N2) failed to hybridize with probe 9. This 
is in perfect agreement with the presence of a G at -127. Isolate 20 (HC3-N2) hybridized only 
very weakly to type 3-specific probe 15, which can be explained by the presence of a C at -118. 
The presence of such mutations in regions used for typing never hampered the classification 
because 2 or 3 type-specific probes are present in the LiP A. Probe 9 contains a crr degeneracy at 
-167, which allows hybridization to both type 4 and type 5 sequences. Probe 20 does not hybridize 
to the type 5 sequence. In a number of isolates additional sequence variation outside the defined 
motifs I and 2 was detected by direct sequencing, but this did not affect the classification by the 
LiPA. 
Antibodies against various HCV epitopes were assayed by RIBA-4 and LIA. Results are 
shown in table 2. 
Table 2, 
type # pat. 
la 8 
Ib 23 
2a 7 
2b 
3 10 
4 3 
5 
1+2 
Anti-HCV profiles of 54 patient isolates determined by RIBA-4 and Iono-HCV 
LIAHCVAbll 
RIBA-4 
511 C-100 C33c C22-3 
(NS4) (NS4) (NS3) (core) 
8 8 8 8 
22 19 22 22 
2 7 7 
0 0 
0 4 10 10 
0 3 3 
0 0 
Iono-LJA 
total NS-4 NS~5 core total 
8 8 5 8 8 
22 22 13 22 22 
7 2 5 6 6 
0 I 
10 2 7 10 10 
3 2 2 3 3 
0 
Anti-HCV detection by RlBA and LiA. 5-1-1 and C-100 are derived from the NS-4 region. C33c contains 
NS-3 and C22~3 covers core epitopes. Numbers in columns represent samples with a positive reaction 
against the specified epitope. 
129 
One patient was negative by RIBA and LIA. One was indeterminate by LIA, as only weak anti-
core reaction was detected. From the single anti-HCV negative sample, weak HCV-RNA signals 
were obtained. However. a sample from this patient, obtained one month earlier, was anti-HeV 
positive in RIBA. Only one patient specifically lacked core antibodies in both confirmatory assays, 
all other anti-HeV positive isolates were anti-core positive in both assays. All patients contained 
anti-NS-3 antibodies as determined by RIBA. 
Type 2 and type 3 infected patients show a low response rate against NS-4 epitopes, both 
in RIBA and LIA. NS-5 antibodies are detected by LIA in the majority of patients. The single 
isolate with a coinfection did not contain antibodies against NS-4 epitopes. 
Figure 2. Aligument of 5' UTR sequences. 
HCV-~ 
TYPE l.a 
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Figure 2. (continued) 
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Alignment of 5· UTR sequences (pos. -265 to -(8) and positions of LiPA probes. Sequences between pos. -210 and 
-170 are completely conserved and omitted from the figure. Sequences are grouped into 5 different genotypes. 
HCV-1 is the prototype sequence (Choo et al. 1990). DK-7. SAIO. USIO. and DK13 (Bukh et al. 1992). HC-J6 
(Okamoto et al 1992). EB-7. EB-12 (Chan et al 1992) were previously repotted and identified by their original 
ruune. 
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Discussion 
This study describes the use of a novel reverse hybridization Line Probe Assay to determine the 
(sub)type of HCV in 54 well characterized patient plasma isolates. The system was evaluated by 
direct sequeuing and results are highly similar. 
There are several reasons to use the 5~ UTR of the HeV RNA genome for genotyping. 
Firstly, the 5' UTR is geuerally used in diagnostic PCR assays to detect viremia by universal pri-
mers. Therefore it is convenient to perform subsequent typing analysis on the resulting DNA 
product. Secondly, the sequence variations within the 5' UTR are limited to specific regions, such 
as motifs 1 and 2, located betweeu highly conserved flanking sequences, allowing the application 
of general PCR primers as well as (sub)type-specific probes. This relatively high degree of 
conservation in the 5' UTR ontits the necessity of type-specific primers to classify HCV using 
more variable coding regions of the genome (Okamoto et aI., 1992b). A large number of 5' UTR 
sequences bas been published so far (Chan et aI., 1992, Stuyver et aI., 1993, Bukh et aI., 1992). 
Discrintination betweeu types has been described using amplified cDNA derived from the 5' UTR 
for restriction fragment length polymorphism (RFLP, Simmonds et aI., 1993, Nakao et aI., 1991, 
McOntish et aI., 1993). Furthermore, the overall mutation rate of HCV bas beeu estimated at 
approximately 1.5 x 10" base substitutions per site per year (Okamoto et aI., 1992c, Ogata et aI., 
1991). However, mutations occur unevenly along the genome. A hypervariable region located at 
the N-terntinus of E2/NSI bas a high mutation rate, whereas the 5' UTR has a very low rate. 
Studies on genetic drift of HCV for more than 8 years in a chronically infected chimpanzee 
(Okamoto et aI., 1992c) and over 13 years in a chronic patieut (Ogata et aI., 1991) showed 
complete conservation of the 5' UTR. Finally, the putative secondary structure of the 5' UTR 
(Simmonds et aI., 1993, Brown et aI., 1992, Tsukiyama-Kohara et aI., 1992) implies functional 
conservation with respect to initiation of translation of the single open reading frame and genome 
replication (Yoo et aI., 1992). Therefore, it is expected that there is a high selective pressure on 
the function of this region. This is indicated by the existence of paired mutations (co-variants) in 
the complementary strands in the stem of the putative RNA-hairpin. This covariance, observed 
among different genotypes, conserves secondary RNA structure of the region (Simmonds et aI., 
1993). Finally, extensive sequence comparisons have shown (Chan et aI., 1992) that sequence 
heterogeueity in the 5' UTR displays similar phylogenetic relationships betweeu HCV genotypes as 
other regions such as core, NS3 and NS5. Therefore, sequence analysis of the 5' UTR should 
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allow consistent discrimination of Hev types. 
HCV-RNA isolates from 54 chronic HCV patients were genotyped by 5' UTR analysis, 
Amplified cDNA from the 5'UTR was biotin-labelled during nested PCR and nsed as a probe for 
reverse hybridization in the LiP A, Reverse hybridization offers a fast method to screen for the 
presence of specific sequences in a PCR product, The probes used in the LiP A described here 
cover a considerable part of the entire 5' UTR sequence, The LiPA contains both general and 
(sub)type specific probes and therefore allows detection of known as well as unknown HCV 
genotypes, Each of the 54 isolates described here hybridized to the general probes and could be 
further (sub)typed by LiPA. New HCV types will fail to hybridize with the current (sub)typing 
probes on the strip, but will hybridize to the general probes. Also aberrant hybridization patterns 
can be observed on the LiPA, as shown in isolates 20 and 50 (figure 2.). Therefore the LiPA 
provides an instrument for rapid identification of new HCV types or subtypes. The entire LiPA 
post-PCR procedure takes only 5 hours and can be performed easily in a routine setting. If new 
types are identified, the sequence can be determined and corresponding probes can be added to the 
strip, making it a very versatile system. In contrast. the efficacy of RFLP analysis entirely 
depends on the presence of useful restriction sites within the variable regions. 
To evaluate the efficiency of the LiPA system. the presence or absence of hybridization to 
each probe was compared with the corresponding results from direct sequencing. Single nucleotide 
differences were efficiently detected, e.g. to disctirninate between type 2a and 2b by probes 10, 
II, 12, and 13. In addition to published sequences, new variations were also detected by LiPA and 
confirmed by direct sequencing, as observed in isolates HC3-N2 and HC2-N2. There was only I 
discrepancy between LiPA and direct sequencing. PCR fragments from isolate 48 (DK7 sequence) 
weakly hybridized with probe 7, suggesting the presence of a G at -99. However direct sequencing 
showed the presence of an A exclusively. The question remains whether this isolate contains la or 
Ib sequences, although hybridization with probe 7 is much weaker than in all other Ib isolates. A 
possible explanation is a co-infection with types la and lb. A large excess of la sequences over Ib 
sequences could explain the failure of direct sequencing to detect both A and G at -99 and the 
weak hybridization of the PCR product with probe 7. The directly obtained sequence represents 
the major sequence present in an isolate. Furthermore the LiPA does identify subtype la based by 
absence of hybridization with probe 7. Positive identification of each subtype could further 
improve the reliability of the LiPA. Probes 17 and 18 cross-reacted with most of the type I isolat-
es. The reason for this is unclear. The value of probes 17 and 18 in discriminating between the 
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presence of a G or A at position -139. is doubtful. The target sequence for these probes is located 
in the region forming a single stranded RNA loop in the putative secundary structure of the 
genomic RNA (Brown et aI., 1992). This might also explain the relatively high frequency of 
mutations detected in this region, including the insert in HCI-N8. 
A single double infection with subtypes 1 b and 2b was detected (figures 1 and 2; isolate 
HC1I2) both by LiPA and direct sequencing. It is much easier, both to detect and (sub)type the 
double infection by LiPA than by direct sequencing. Interpretation of double signals at one 
nucleotide position by direct sequencing can be difficult and may require advanced experience in 
reading sequence autoradiographs. 
Although the version of the LiP A described here did not yet contain type 5 specific 
probes, it was possible to discriminate between type 4 and 5 sequences because probe 19 contains 
a degeneracy. Addition of type 5 specific probes onto the LiP A strip will further facilitate 
recognition of this genotype. 
Profiles of amibodies against specific HCV epitopes were determined. Two confirmatory 
immunoblot assays, capable to detect antibodies against epitopes from core, NS-3, NS-4 and NS-5, 
could not discriminate between different genotypes. RIBA-4 uses expression products of recombi-
nant cDNA clones, derived from various parts of the HCV genome, whereas the luno-LIA exposes 
a number of synthetic peptides. All epitopes are based on sequences derived from type 1 HCV 
isolates, because no data from other genotypes were available at the time these tests were 
developed. At present much more data are available from genotypes 1, 2 and 3, and reveal 
significant sequence heterogeneity in various parts of the genome (Chan et aI., 1992, Cha et aI., 
1992). Consequently, infection with other HCV genotypes may evoke antibodies against type 
specific epitopes, which are not optimally recognized by type 1 epitopes in the RIBA and LIA. 
This is illustrated by the absence of antibodies against NS4 epitopes in most type 2 and 3 isolates 
(Chan et aI., 1991, table 2). Antibodies against 5-1-1 are even completely absent in type 3 
isolates. The single indeterminate LIA result on an isolate classified as type 2a may be partly 
explained by genotype-specific immune reactions. 
Antibodies against core and NS-5 epitopes show a higher degree of cross-reactivity. It was 
possible to distinguish a number of type 1 and 2 isolates by assaying anti-core antibodies, directed 
against 2 different type-specific core peptides (Machida et aI., 1992), although specificity was 
limited. Type-specific serological assays would facilitate discrimination between different HCV 
genotypes considerably. Sequence information of antigenic regions is still limited. Therefore. much 
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more sequence data from all different genotypes must be obtained, in order to develop (sub)type-
specific antigens for antibody assays. However. considerable differences in immune reactivity 
among individual patients exist. In some patients. antibody responses are poor; e.g. in isolate 23. 
antibodies against core were undetectable. Also in immunocompromised patients serological testing 
is difficult. due to lack of sufficient antibody titers. These conditions would prevent serological 
HCV typing. 
In summary, sequence analysis of the 5' UTR of HCV allows consistent genotyping of all 
HeV isolates presendy known. Furthermore. reverse hybridization systems in a strip test format 
like the described LiPA, provide fast and reliable typing of HCV isolates and identification of new 
HCV types. This assay allows the nse of the amplification products from 5' UTR and therefore 
conveniently complements the routine diagnostic RT-PCR assays. Screening of large patient 
populations is feasible, and could lead to rapid identification of new HCV genotypes. 
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Abstract 
Hepatitis C virus (HCV) isolates were genotyped by means of the Inno-LiPA HCV genotyping assay. 
From a large cohort of 278 patients with a chronic HeV infection, 31 isolates representing different 
genotypes (la, Ib, 2a, 2b, 3a, 4a, and the novel type 5a) were analyzed. 5' UTR sequences as well as 
partial sequences from the core region (nucleotides 1 to 326) were determined. 5' UTR sequence analysis 
confirmed LiP A results. including several aberrant sequences. Nucleotide distances among N-terminal core 
regions were 0.0265 ± 0.0136 within each subtype, 0.0867 ± 0.0162 between different subtypes, and 
0.1695 ± 0.0296 between types. Genotype 2 seqnences showed more intratypic heterogeneity compared 
to reported Japanese isolates. Discrimination between HCV genotypes by 5' UTR analysis was completely 
justified by phylogenetic analysis of the core region and indicated maintenance of genotypic variation 
throughout the viral genome. However, HCV genotypes 2a and 4a, as identified by 5' UTR analysis, may 
be further subdivided by analysis of the core region and other coding regions. Comparison of the deduced 
amino acid sequences of all N-term.inal core regions revealed the presence of several type-specific amino 
acids and a heterogeneous region between residues 68 and 78. 
Introduction 
Hepatitis C virus (HCV) is the major etiological agent of parenterally transmitted non-A, non-B hepatitis 
(Choo et aI., 1989, Kuo et aI., 1989). Based on physico-chemical properties and genomic organization, 
the virus is classified as a separate genus within the Flaviviridae (Choo et aI., 1991, Miller and Purcell, 
1990, Houghton et aI., 1991). Since the discovery of HCV, an increasing amount of sequence data 
became available of isolates obtained from nmnerous geographical areas (e.g., Okamoto et aI., 1992a, 
Kato et aI., 1990, Takamizawa et aI., 1991, Chen et aI., 1992). Sequence comparisons revealed the 
existence of multiple HeV strains or genotypes. Initial attempts to classify the different isolates were 
based on limited data from different regions of the genome (Mori et aI., 1992, Okamoto et aI., 1992b, 
Cha et aI., 1992) and associated nomenclature was confusing. A more useful classification system was 
proposed recently (Chan et aI., 1992, Simmonds et aI., 1993, Stuyver et aI., 1993a) and is expected to 
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be generally accepted. This system differentiates between types and subtypes. Overall sequence homology 
is higher than 88% within each subtype, approximately 79% between subtypes and about 68% between 
different types (Okamoto et aI., 1992a, Stuyver et aI., 1993b). 
Phylogenetic studies suggested that different regions of the genome could be used to distinguish 
HCV genotypes (Chan et aI., 1992). Genotyping of HCV isolates has been described, employing either 
the core region (Okamoto et aI., 1992b), the NSS region (Tsukiyama-Kohara et aI., 1991, Enomoto et 
aI., 1990, Chayama et aI., 1993) or the S' UTR (Stuyver et aI., 1993a, Sinnnonds et aI., 1993). 
A reverse hybridization Line Probe Assay (LiPA) has been developed for genotyping of HCV 
isolates by S' UTR analysis (Stuyver et aI., 1993a) and evaluated by direct sequencing (van Doorn et aI., 
1994b). The S' UTR is highly conserved, and shows limited sequence variation. Two small regions (nt. 
132 to ·117 and nt ·170 to ·ISS) were identified as (sub)type·specific sequence 'motifs' (Kleter et aI., 
1994, van Doorn et aI., 1994a). These motifs are partially complementary and are able to form a stable 
RNA stem·loop structure, which is considered to be functionally important for the irdtiation of translation 
(Brown et aI., 1992, Yoo et aI., 1992, Wang et aI., 1993, Sinnnonds et aI., 1993). Genotyping by S' 
UTR analysis would be convenient, since this region is generally used to deterntine HCV viraemia by the 
reverse transcriptase polymerase chain reaction (RT·PCR). Moreover, the higher level of variability in 
several coding regions can hamper the use of type-specific motifs for genotyping. 
In this study, 31 isolates, representing at least seven different (sub)types, were randomly selected 
from a large cohon of patients, that had been genotyped by LiPA. Selected isolates were subjected to 
sequence analysis of the 5' UTR and N-terminal core region. in order to substantiate the classification by 
S' UTR analysis and to confirm such classification between (sub)types in a coding region. 
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Materials and methods 
HCV isolates 
HCV isolates described in this study were obtained from participants in the trial for treatment with 
interferon-a, organized by the Benelux Study Group on the treatment of hepatitis C (Brouwer et al., 
1993). The relationship between HCV genotypes and biochemical, epidemiological, serological, 
demographical and clinical parameters within this cohort of patients will be described in detail elsewhere 
(Kleter et al., manuscript in preparation). Plasma or serum samples were obtained by venipuncture, 
aliquotted and stored at _70°C. Informed consent was given by all patients. 
RNA isolation and reverse transcriptase PCR (RT-PCR) 
HCV RNA was isolated by a modified version of the guanidiniumthiocyanate method (Chomczynski and 
Sacchi, 1987, Kleter et al., 1993). A small number of heparanized plasma samples were analyzed by an 
HCV RNA capture method as described earlier (van Doorn et al., 1994a) as these samples could not be 
analyzed by conventional methods (Willems et al., 1993). DetectionofHCV RNA was performed byRT-
PCR with primers HCV35 (seose, pos -318 to -296; 5'-TTGGCGGCCGCACTCCACCATG 
AATCACTCCCC-3'; underlined sequence is non-HCV specific) and HCVI9 (antisense, pos. -1 to -20; 
5'-GTGCACGGTCTACGAGACCT-3'). Core analysis by RT-PCR was cartied out with primers HCV 
983 (antisense, pos. 963 to 983; 5'-GGiGACCAGTTCATCATCAT-3'; i=inosine) and biotinylated 
LD58C (sense, pos -57 to -34; 5'-Bio-GGTACTGCCTGATAGGGTGCTTGC 3'). cDNA synthesis was 
primed with antisense PCR primers. 
The PCR program for 5' UTR amplification consisted of 40 cycles of 1 min. 95°C, 2 min. 48°C, 
and 3 min. noc. The PCR program for the core region comprised 40 cycles of I min. 95°C, 2 min. 
45°C and 5 min. noc. 
Genotyping by the Line Probe Assay (Inno-LiPA) 
Amplification products from the 5' UTR were subjected to nested PCR with primers HC3 (sense: -264 
to -238: 5'-TCTAGCCATGGCGTTAGTRYGAGTGT-3') and HC4 (antisense: -29 to -54: 5'-
CACTCGCAAGCACCCTATCAGGCAGT -3') in thepresenceofbiotinylated "dUTP. Biotinylated nested 
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PCR products were used as target for the probes on LiP A strips (prototype version of !nno-LiP A, 
!nnogenetics, Gent, Belgium, see also figure I) as described previously (Stuyver et aI., 1993a). Briefly, 
biotinylated DNA was denatured by a1kaline treatment. After hybridization and stringent wash in the 
presence ofTMACI (Tetramethyl ammoniumch!oride), alkaline phosphatase conjugated streptavidin was 
added. Results of the LiP A were determined by scoring the presence or absence of signal at each probe 
line. (This prototype version still contained probed 17 and 18, which are no longer present in the first 
generation Inno~LiPA.) 
Direct sequencing 
First round PCR products from 5' UTR (HCV35-HCVI9) were reamplified in a nested PCR with primers 
NCR3 (sense, pos -314 to -288; 5'-GGGGCGGCCGCCAACCATARRA TCACTCCCCTGTGAGG-3'; 
R= A or G) and LD58B (antisense, pos -35 to -64; 5'Bio-GGCCGGGGCGGCCGCCAAGCACCCTA-
TCAGGCAGTACCACAAGGC-3'). First round PCR products ftom the core region were reamplified 
with LD58C and 186c (antisense, pos 410 to 391; 5'-ATiTACCCCATGAGiTCGGC-3') in a semi-nested 
PCR. In order to obtain single stranded DNA for sequencing, biotinylated PCR products were bound onto 
paramagnetic streptavidin-wated beads (Dynabeads M280, DynaI, Oslo, Norway) as described earlier 
(KIeter et aI., 1994, van Doom et aI., 1994b). Briefly, the PCR product was mixed with paramagnetic 
beads and strands were separated by a1kaline treatment, resulting in the release of the unbiotinylated 
strand in the supernatant. The biotinylated strand remained bound to the beads. Separate strands were 
subjected to standard dideoxy-temtination sequencing. 5' UTR fragments were sequenced with NCR3 and 
NCR4 (antisense, -66 to -47; 5'-CACTCT CGAGCACCCTATCAGGCAGTACC 3'). Core fragments 
were sequenced with 186c and LD58s (sense, pos. -51 to -34; 5'-GCCTGATAGGGTGCTTGC-3'). 
Phylogenetic analysis 
Sequences were read manually from autoradiograrns and analyzed by the PC-Gene software 
(Intelligenetics, Moutain View, CA, USA). 
Phylogenetic trees were constructed by a number of computerprograrns from the PHYLIP package 
(version 3.5; Felsenstein, 1993). Nucleotide distances between individual isolates were determined and 
represented in unrooted phylogenetic trees. To assess the reliability of specific sequence clusters, 100 
bootstrap steps were performed. 
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Results 
5' UTR analysis 
A cohort of278 HeV infected patients were genotyped by LiPA. Thirty-one isolates including randomly 
selected representatives for each (sub)type, as well as those showing an aberrant, but interpretable LiPA 
pattern, were further analysed. Typical LiPA results are shown in figure 1. The LiPA has at least 2 probe 
lines for recognition of types 1 to 3 as well as several probe lines for subtypes la, Ib, 2a, and 2b (see 
figure 1). Genotype 4 sequences hybridize with probes 19, 20 and sometimes probe 7. In a nttmber of 
isolates the signals with probes 6 and 9. used to recognize type 1 and 2 respectively. were very weak or 
absent. Since there are at least 2 probe lines to identify these types, classification was not hampered in 
these cases. 
Rgure " 
Ii conI, contr. 
1 2 • 4 5 6 7 8 9 10 11 12 1. 14 neg ji2j/22 
T ~: ] type 1 ~: l::'2 
~'" ~ 10/11 2a 
__ 12/13 2b 
_14 
1 type 3 
"j 
-15 , 
-'6 , ~17 
I 
I ~'. ~19 ] type 4/_ 
20 
Figure 1. Representative LiPA results for each HeV (sub)type, and several aberrant results. Isolates numbers are: 
l~ HCI,nl, 2~ HCI-N6 , 3~ HCl-N7, 4~ HCI-N8, 5~ HCI-NlO, 6~ HC2-NI, 7~ HCZ-N2, 8~ HC2-N6. 
9~ HC2-N4, IO~ HC3-N3. 11~ HC3-N2. 12~ HC4-N4. 13~ HC4-N2. 14~ HCS-N2. neg~ neganvecontrol. 
showing positive conjugate control line. Positions of LiP A probes are indicated in figure 2. 
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The 5' UTRs from 31 isolates, representative for a (sub)type or showing an aberrant LiPA 
pattern, were investigated by direct sequencing. Obtained sequences and the positions of the LiP A probes 
are shown in figure 2. 
Genotype I is recognized by hybridization to probes 5 and 6. Subtype I b sequences also hybridize 
to probe 7, whereas this is absent for subtype la. A number of isolates (HCI-N8, HCI-N1O, and HCI-
Nil) are classified as genotype I b by probe 7 but hybridization to probe 5 is absent, caused by a T at -
159. Isolate HCI-N7 also contained this T mutation and,like isolate HCI-N9, a C at -94, which prevents 
hybridization to probe 7. Therefore, these two isolates were provisionally classified as type "I", but could 
not be subtyped by LiPA (figure 2). 
Genotype 2 sequences are identified by hybridization to probes 8 and 9. Subtype 2a and 2b are 
recognized by hybridization to probes 10 + II and 12 + 13, respectively. Only two subtype 2b isolates were 
identified in the entire cohort of patients. PCR products from isolate HC2-N2, one of the 18 isolates 
classified as type 2a by hybridization to probes 8 and 10+ II, failed to hybridize to probe 9, due to a AlG 
transition at pos. -127. Isolate HC2-N6, classified as type 2 by hybridization to probe 8, did not hybridize 
to any of the other type 2 probes. Sequence analysis showed that this LiP A result is caused by novel 
covariant mutations at positions -163 and -122. Therefore HC2-N6 was provisionally classified as subtype 
"2?". 
Genotype 3 isolates can be identified by hybridization with probes 14 to 18. Isolate HC3-N2 
shows only very weak hybridization with probe 15. This was confirmed by the presence of a C at position 
-118 in motif2. Isolate HC3-N4 did not hybridize to probe 16, which was again confirmed by the absence 
ofa G at -99. 
Nineteen isolates, hybridizing to probe 19 and/or 20 were SUbjected to 5' UTR analysis, in order 
to investigate discrimination between genotypes 4 and 5a (KIeter et al., 1994, van Doom et al., 1994a, 
Bukh et al., 1993, Stuyver et al., et al., 1994). Twelve type 4 isolates were recognized by probes 19 and 
20, all containing a T at -238 and sometimes an A at -235. HC4-N5 also contains an insertion at -138. 
Sequence motifs I and 2 were completely conserved within this type (not all sequence data shown). The 
remaining seven sequences closely resembled SA-I (Bukh et al., 1992) and BE95 (Stuyver et al., 1994) 
and are classified as type 5a. This genotype can be identified by the LiPA with probes 19 and 7, in the 
absence of reactivity to probe 20. All investigated type 5a isolates contained a double A motif at pOSitions 
-236 and -235. 
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Figure 2.5' UTR nucleotide sequence alignment ofHCV (sub)types. 
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Figure 2. (continued) 
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Figure 2. Nucleotide sequences alignment from the 5' UTR (positions -256 to -63) • Sequences between positions 
219 and -179 are completely identical to HCV1 o.equences among all isolates and are not shot..rIl. Boxed and underline' 
nucleotideo. indicate the positions of corresponding probes on the LiPA strip (eee also figure J.). R= G or A, l 
m A or C, Y = C or T, N. not deter.mined. Universal probe 22 io. located between positions -J.95 and -J.80. Th. 
origins of the reported ioolates are; HCV1 (Choo, 1991); HCV-J (Kato, J.990); HCV-BK (Takamizawa, 199J.), HCJ-· 
(Okamoto, 199J.); HCJ-8 (Okamoto, J.992) £B-1 (Chan J.992); HCV-Tr (Chayouna J.993); EG-29 (Simmond>3 J.993); BE9~ 
(Stuyver J.993c) . 
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Core sequences 
The 31 isolates, selected from the patient cohort based on 5' UTR analysis were also subjected to 
sequencing of the N-terminal core region (nt 1-326). Nucleotide and amino acid sequences are shown in 
figure 3 and 4, respectively (Classification in these figures was performed according to initial 5' UTR 
analysis). Nucleotide distances among the defiued (sub)types are presented in Table l. Based on the 
bootstrap results,S different groups could be confidently distingnished, corresponding to genotypes la, 
Ib, 2b, 3a, and Sa. Within these subtypes, nucleotide distances are 0.0265 ± 0.0136, whereas in 
genotypes 2a and 4a, these distances are 0.0813 ± 0.0123 and 0.0815 ± 0.0189, respectively. 
Nucleotide sequences from the two type "1" isolates (BCI-N7 and 9) are highly homologous to 
subtype 1 b sequences and can be classified accordingly. These isolates indeed exhibit the subtype I b-
specific G at position -99 in the 5' UTR. 
Nucleotide sequences from isolate HC2-N6, provisionally classified as subtype "21", resembles 
genotype 2a (0.0688 ± 0.0135) sequences more than 2b (0.1006 ± 0.0066). 
Phylogenetic analysis of core sequences is represented as an unrooted tree in figure 5. A higher 
degree of heterogeneity among genotypes 2a and 4a isolates can he observed compared to other subtypes, 
of which the isolates can he clustered by bootstrapping analysis. 
Amino acid homolOgies among the core sequences (figure 4) range from approximately 90% 
bet\Veen types to almost 100% within a SUbtype. Several type-specific amino acid residues can be 
identified, e.g., Val at position 36 in type 3, and Asn at position 106 in type 5 isolates. The region 
bet\Veen residue 68 and 78 seems the most variable part of the N-terminus of the core protein. 
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Figure 3. N-terminal core region nucleotide sequence alignment HeV genotypes 1-5. 
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Figure 3 (continued 1) 
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Figure 3 (continued 2) 
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----------------T--G-----C--A--------------G-----AT-------A---T-------A-----A--A 
-------A---- ____ T __ C __ G- ___________________ G __ C ___ T ____ -------T-----------------
----------------T--G-----------------------A----AAT-T-----A---T-----------------
-------A--------T--C--G--C--A--------------G--C---T-----------T-------C---------
-A-- - --- - -- - _C_ -T- -AC-G- -- - -- - -- --T-- - -- -- -G- -C-A- -- -AC-- --C--T- - -- - -G- --A-- _ ---
-A-----------C--T--AC-G-----------T--------G--C-A-----C----C--T-----_G ___ A _____ _ 
-A-----------C--T--AC-G--C- _______ T ________ G __ C __ A ___ AC----C--T-----_G ___ A _____ _ 
-A-----------C--T--AC-G--C--------T--------G--C-A----AC----C--T------G---A------
-A-----------C--T--AC-G--C-- ______ T ________ G __ C_A ____ AC----C--T------G---A------
-A-----------C--T--A,C-G--C--------T--------G--C-AAT--AC----C--T------G---A------
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Figure 3 (continued 3) 
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HCl.-N2 
HCl.-N3 
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,b 
HCV-J 
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HC1-NS 
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HC1-N7 
Bel-Na 
BC1-N9 
Hel-mo 
HC1-NJ.1 
2a 
BCJ-6 
HC2-NJ. 
HC2-N2 
BC2-N3 
,b 
HCJ-S 
BC2-N4 
HC2-NS 
"2?~ 
HC2-N6 
3a 
EB' 
BC3-NJ. 
Be3-N2 
HC3-ID 
BC3-N4 
HCV-Tr 
, 
HC4-N1 
HC4-N2 
HC4-N3 
HC4-N4 
HC4-N5 
sa 
BE95 
HCS-NJ. 
HCS-N2 
HCS-Nl 
HCS-N4 
HCS-NS 
2" 
TACCCT'l'GGCCCCTCTATGGCAATGAGOOC'I'GCGGGTGGGCGGGATGGcrCCTG'I'CTCCCCGTGGCTCTCGGCC'IAGCTGGGGCCC 
_________________ C _______________________ A _________ T __ --c-----------------------------
-----------------------------1'--------------------------------------------------------
-----------------C-----C-----------------A---------T----c-----------------------------
- ______________________ c ______________________________ --C--------------------T--------
-----------------------C-----orATG--------A--------------A--------------------T--------
-----------T-------------------TA--------A--------------A-----C-----C--------T--------
--- ____________________________ TG ________ A _____________ -A-----C-----------------------
-T---C------------------------ATG--------A--C-----------G-----------C ________ T _______ _ 
-------------------------------TG--------A--------------A-----------C--------T--------
------------------------------CTG--------A--------------A---A----T-----------T--------
--- ___________________________ ATG ________ A _____________ -A-----C--------------T--------
------------------------------CTG--------A--------------A--T--------C--------T--------
------------------------------ATG--------A--------------A-----------C--------T--------
-----C--------A--C--G--------ACT--CC-----A--------------C-----A--T--C--T--CTCT--------
--T---------T-G-----G--------GCT---T-----A--G----------TC-----A-CT-----C---TCA--------
--T--C--------G-----G--C-----GCT---C-----A--------------C-----A--------C---TCA--------
--------------G-----G--C------Cl"r--T-----A---------T----C--T--A-------CC-GCTCA--------
--T-----------G--C--A--C-----T-----C--------T-----------C-----C--G-----T----CT--------
--T-----------G-----A--C-----------C-----A--T-----------C-----C--G-----T----CT--------
- -T-- - - - -- -T--G--C--A- -C- -- - - - -- - --T-- -- -A- -T-- - -- -- -- - -C-- -- -c- -G- -- --T-- --CT- - -- - ---
--------------G--C--G---------CT---C-----A--G-----------C-----A--------C--GTCA--------
-----G--------------T--C-----------------A--G-----------C--A--C-----C--T--ATCT----- __ _ 
--------------------T--C-----------------A--G-----------C--A--C-----C--T--ATCT--------
--------------------T--C-----------------A--G-----------C--A--C-----C--T--ATCT----- __ _ 
--------------------T--C-----T-----------A--G-----------C--A--C-----C--T--ATCT--------
--------------------T--C-----------------A--G-----------C--A--C--T-----C--A-CT---- ___ _ 
-----------------C--G---A-------T----T---A---------T----C--------T-----C-----T--------
--T--------T--T--C--------------------------------------A-----C-----------GTCT--------
--T--A-----T--T--C--T--------T-----------ANN-------T----C-----C--T-----A--GTCT------ __ 
--------------T--C--------------T--- _____ A __ G _________ --C-----C--T--CA----ATCT--------
-----A-----T--T--C--T--------------------A--------------A-----C--------A--GTCT-----T--
-----A--------T--C--T--C--A--T--------------G-----------C-----C-----------GTCT--------
--------------T--C-C----------CT---------A--G-----G--C--C--T--A----- ________ AT _______ _ 
--------------T--C-C---y------CT---------A--G-----G--C--C--T--A-------------AT------ __ 
--------------T----C----------CT---------A--G-----G--C--C-----A-----C-------AT----- __ _ 
--------------y--y-C----------CT---------A--G---T-G--C--C-----A-------------AT--------
--------------T--C-C----------CT---------A--G---T-G--C--C-----A-------------AT------ __ 
--------------T----C---C------CT---------A--G-----G--C--C-----A-------------AT--------
Figure 3. Core region nucleotide sequence alignment of the analyzed fragment (nt 1 to 326). For 
designation and origin of reported isolates see legend figure 2. 
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Figure 4. Deduced amino acid sequences from the N-terminal core region genotypes 1-5. 
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--------R-T-------------------------------------------------------------------------------------------------
--------R-T-------------------------W-----------------------------------------------------------------------
--------R-T-------------------------------------------------------------------------------------------------
-------- - ------------------------------------------- _____________________________________________________ _ 
--------R-T-------------------------------------------------------------------------------M-----------------
--------R-T-------------------------------------P-----------------------------------------L-----------------
--------R-T---------------------------------A-----------------------------A---------------L-----------------________ - - ___________________________ -K- _____________________ -R- -QH- _ - - ___ F ______ -M- _______________ _ 
--------RQT--------------------------------------------L-------------Q-G------------------L-----------------
--------R-T----------------------------------------------------------X----A---------------L---------S-------
--------RQT---------------------------------------------------------------A---------------M-----------------
--------R-T------------------------------------T------------------------------------------L-----------------
--------R-T-------------------------------------------------------------------------------M-----------------
--------R-T--------------------------------------------------------D--ST-KS-GK------------LA----------------
---- ----R-T--- --------Q- ------- ------------------------------------0- -ST-KS-OR- -------- ---L- - - - - -- F--A- -- - --
--------R-T- ----------- --- ------------ ------------------ -----------O-XAT- -S -GR-- --- -------L- - - - - - - - - - - - - - - --
------ --R-T- ------ ----------------- ---------------------------- ----0- -ST-KS-GR- -----------L- -----------PR- --
--------R-T--------------------------------------------------------D--ST-KS-GK---------------------------T--
--------R-T- --__ ---------------- ------------------------- ----------0- -ST-KS-OK- -------- -------------- -- --T--
--------R-T- ---C- ----------- ------------ ------------------ ---------0- -ST-KS-OK-- --------------- ------ ----T--
--R-T----I-------------------V----------C-----------------------S---S---------------------------------
---L----R-T----I-------------------V---------------------------------QS---S---------------------------------
---L----R-T----I-------------------V----------------------------------S---S---------------------------------__ -- __ R-T- ___ I __________________ V- ________________________________ so s- _______________________________ _ 
---L----R-T----V------R------------V-----------T----------------------S---S------------------------------T--
__ - - __ RQT- __ -L- __ -N ____________ v ___________ v-- ______ -KQ-HL ___ SR- __ $ _____________ K- __ L _________ --
--------R-T--------M-------------------------------------------------Q----S---------------------------------
--------R-T--------M--------------------------------------------------S---S-------------------x-------------
--------R-T--------M--------------------------------------------------S---S---------------------------------
--------R-T--------M-------------------------------------------------QS---S---------------------------------
--------R-T--------M--------------------------------------------------S---S---------------------------------
::::::::t~::::::::~:::::::::::::::::::::::~:::::::::::::::::::::::::§:~::i:r=:::::::~:::t=::=::::::::::ll:: 
::::::::~:i:::::::::::::::::::::::::::::::::::::~::::::::::::::::::::g:i::~:g:::::::::~:::t::::::::::::::~:: 
--------R-T- -------- ---------------------------- ------------- ---- ----QST- -S-G--- --- ---A- --L- ------ -------N--
Discussion 
Hepatitis C virus isolates from a cohort of 278 patients with a chronic HeV infection were analysed. 
Since phylogenetic studies have suggested that comparison of different regions from the HCV RNA 
genome resulted in similar classifications (Chan et aI .• 1992), and since genotype-specific motifs can 
be observed in the 5' UTR (Stuyver et aI., 1993a). analysis of this region should allow consistent 
genotyping. This paper describes the correlation between5' UTR (sub )type-specific sequence variation 
and sequences from the core region. Although the overall sequence conservation within the 5' UTR 
is very high, there is significant sequence variation in two lintited regions (motif I and 2 figure 2; 
Stuyver et aI., 1993a, Simmonds et aI., 1993, Kleter et aI., 1994, van Doom et aI., 1994b). 
Genotyping of the patient isolates was performed with the !nno-LiP A. The specificity of this assay 
has been described earlier (Stuyver et aI., 1993a, van Doom et aI., 1994b). The LiP A contains probes 
against (sub)type-specific regions in the 5' UTR and almost all (>98%) of the 278 isolates could be 
genotyped and displayed a consistent hybridization pattern on the strip (KIeter et aI., manuscript in 
preparation). 
A very lintited number of isolates failed to produce a clear signal at the probe 6 (type I b 
isolates HCI-N8, HCI-NIO) or probe 9 (type "2?" isolate HC2-N6) lines, while hybridization is 
expected based on the seqnencing results. Degeneration at pos -127 in isolate HCI-N8 can only partly 
explain such result. Although errors during PCR and sequencing cannot be excluded, the reason for 
these aberrant results rentains unclear. The great majority of LiP A results, including some exceptional 
aberrant patterns (HC3-N2, HC2-N2, see figure I) were in complete accordance with the determined 
sequences. 
Several isolates from each (sub)type, as classified with LiPA, were selected randomly for 
further analysis and were SUbjected to direct sequencing of the 5' UTR. The core region is less 
conserved than the 5' UTR and seqnence comparisons should clearly distinguish between (sub)types 
(Chan et aI., 1992). 
Figure 4. Deduced amino acid sequences from the analyzed N-terminal core region (residues 1-108). X indicates 
that the amino acid could Dot be specified. due to nucleotide sequence ambiguity. For origin of reported isolates 
see legend figure 2. 
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Figure 5. 
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Whereas the 5' UTR is a non-coding region containing a highly conserved, presumably functional, 
element such as an internal ribosomal entry site (IRES, Yoo et al" 1992, Wang et al., 1993), the core 
gene encodes the putative nucleocapsid protein. and might be under different selective pressure than 
the 5' UTR. Since the mutations are not randomly distributed along the 5' UTR (figure 2), it is not 
useful to calculate the percentage of homology and standard deviation. Nucleotide mutations along the 
N-terminal core region are much more evenly distributed. Nucleotide distances within subtypes la, 
Ib, 2b, 3a, and 5a are all below 0.050. Within types 1 and 2, distances are between O.OS and 0.11. 
Nucleotide distances between different types can increase to 0.2237 (between genotypes 2a and 3a. 
see table 1). 
Five isolates (HCI-N7, HCI-NS, HC1-NlO, HCl-Nll, and HCI-N9;) showing a slightly 
aberrant LiPA pattern, were further investigated because of the presence of a T at -159 andlor a C 
at -94. These mutations were shown not to be involved in covariance. Analysis of nucleotide 
sequences from the core region (table 1. figure 5) indicate that these isolates are indistinguishable from 
subtype lb. Conclusively, these HCV isolates should all be classified as subtype lb. This underscores 
the importance of the G at position -99 in the 5' UTR to identify subtype Ib isolates. 
Isolate HCI-N6 was classified as subtype Ib by 5' UTR analysis, and this was confirmed by 
core analysis, despite the greater nucleotide distance to other 1b isolates in the core region (figure 5). 
Nevertheless. considering the amino acid sequence variation (figure 4), this isolate is an interesting 
candidate for further analysis of other coding regions. 
Discrimination between subtypes 2a and 2b is based on covariance at positions -123 and -160 
in the two 5' UTR complementary sequence motifs (Sinunonds et al., 1993, Kleter et al., 1994, 
Stuyver et aI., 1993a). Nucleotide distances in the core region among isolates classified as subtype 
2a by LiPA (O.OS13 ± 0.0123) are remarkably higher than within other subtypes, except genotype 
4a. Isolates classified as subtype 2a by LiP A did not reach the confidence level by bootstrap analysis. 
Figure S. Phylogenetic UDIOOted tree of nucleotide sequences (nt 1-326) in the core region. Individual sequences 
are nwnbered according to figures 2 and 3. Circled sequences indicate clusters that were confirmed by bootstrap 
analysis. Isolate codes are: Type 1a:1~HCV1, 2~HC1-Nl, 3~HC1-N2, 4~HC1-N3, 5~HC1-N4. Type 
Ib:6~HCV-J, 7~HCV-BK, 8~HC1-N5, 9~HC1-N6, IO~HC1-N7, !1~HC1-N8, 12~HC1-N9, 13~HC1-
NIO, 14~HC1-N11. Type 2a:15~HCJ-6, 16~HC2-Nl, !7~HC2-N2, 18~HC2-N3. Type 2b:19~HCJ-8, 
20~HC2-N4, 21~HC2-N5. Type "2?":22~HC2-N6. Type 3a:23~EB1, 24~HC3-Nl, 25~HC3-N2, 
26~HC3-N3, 27~HC3-N4. Type 3a:28~HCV-Tr. Type 4:29~HC4-Nl, 30~HC4-N2, 31~HC4-N3, 
32~HC4-N4, 33~HC4-N5. Type 5a:34~BE95, 35~HC5-Nl, 36~HC5-N2, 37~HC5-N3, 38~HC5-N4, 
39=HCS-NS. Hatched region represents uncertainty limit in bootstrapping analysis. 
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Isolate HC2-N6 contained a novel combination of covariants in both S· UTR typing motifs and was 
therefore classified as "2?". To avoid confusion. no letter was used to indicate a novel subtype within 
type 2. Based on nucleotide distances among core region sequences. this isolate was indistinguishable 
from the subtype 2a isolates (figure S). Taken together, these results indicate that type 2a isolates are 
more heterogeneous than previously reported (Okamoto et aI .• 1991. 1992a, b) and may need further 
differentiation intO several new subtypes. Due to limited sequence data from subtype 2a and the rarity 
of "2?" isolates, such division is not yet possible. Subtype 2b seems to be a highly homogeneous 
group. although only 2 isolates could be analysed. Similar small nucleotide distances within the 2b 
subtype have also been observed in the NS5a region (Stuyver et aI., unpublished observations) 
The selected type 3 isolates appear to be a homogeneous group, with intratypic nucleotide 
distances of only 0.0243 ± 0.0104. Therefore all these type 3 isolates can be classified within subtype 
3a. Existence of subtype 3b (Chayarna et aI .• 1993; isolate HCV -Tr) was not shown in this population. 
If any type 3b isolates had been present these would have been identified by hybridization to probe 
lines 16. 19 and 20 in LiPA (figure 2). 
Among nineteen isolates that hybridized with probes 19 and/or 20. two genotypes (4 and Sa) 
could be recognized by LiPA. Genotype 4 sequences have been described recently (Sinnnonds et aI .• 
1993, Stuyver et aI .. 1993a). Nucleotide distances among type 4 core region nucleotide sequences are 
0.081S ± 0.0189, and like for subtype 2a, these sequences could not confidently be assigned to a 
single subtype by bootstrap analysis. However. amino acid sequence homologies within type 4 (98.4 
± 0.82%) are considerably higber than within subtype 2a (94.0 ± 1.74%). 
The existence of genotype Sa has been suggested previously after analysis of the S· UTR from 
the South African isolate SA-l (Bukh et aI., 1992, 1993) and Belgian isolate BE9S (Stuyver et aI .• 
1994). Among type Sa isolates described in this study, core sequences from isolate HCS-Nl are 
slightly different from the other type Sa sequences (figure S). althougb within the limits to be 
classified within a single subtype. The S· UTR sequence from HCS-Nl is indistinguishable from the 
remaining type Sa isolates. 
Recently. an HCV typing system based on type-specific primers in the core region was 
described (Okamoto et aI., 1992b). Different genotypes yield fragments of specific lengths, allOwing 
classification after agarose gel electrophoresis of PCR products. Comparison of core sequences 
described in this study and type-specific primers as described by Okamoto (Okamoto et aI., 1992b) 
revealed that primers for subtype la and Ib should perform properly. However. subtype 2a specific 
primer no. 134 (nt 302 to 321) had a perfect match to HC-J6 only. Other 2a sequences contained up 
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to 6 mismatches. Subtype 2b sequences also showed mismatches to the type-specific antisense PCR 
primer no 135 (nt 251 to 270). !solate HC2-N5 showed a perfect match, whereas HCZ-N4 contained 
3 mismatches. Experimental results showed that isolate HCZ-N5 yielded a fragment of the expected 
length, whereas HCZ-N4 failed to produce any fragment after nested PCR (results not shown, K1eter 
et al., manuscript iu preparation). Conclusively, the described typiug system does not allow efficient 
genotypiug of type 2 isolates with this system. Type-specific PCR primers for genotypes 3a, 4 and 
Sa have not yet been described and can be designed, based on this study. However. there is a 
considerable risk that nested PC~ in the presence of multiple different type-specific primers, and the 
diversity of viral genomes. may produce erroneous results. 
Serologic differentiation between HCV genotypes 1 and 2 was described recently (Machida 
et al., 1992). Two distinct type-specific peptides comprised antino acid residues 65 to 85 and detected 
type-specific antibodies agaiust the core proteiu. Our results (figure 4) iudicate that the antino acid 
sequences between res. 65 to 85. even within a genotype, are more heterogeneous than described. 
which may account for the limited specificity and sensitivity of the method (Machida et al., 1992). 
Siuce the number of completely (sub)type-specific antino acids iu this region is limited, it is unlikely 
that correspondiug peptides will be sufficiently specific to serologically discrimiuate between all HCV 
genotypes. The El proteiu (Maertens et al., 1994) and the NS4a!b region (Stuyver et al., 1993b, 
Simmonds et al., 1993) may be more promisiug regions for serotypiug. 
Sequence analysis of either the S' UTR or the core region results in similar classifications of 
HCV genotypes 1 to 5. This iudicates that, as described earlier for types 1, 2 and 3 (Chan et al., 
1992, Cha et al., 1992) the genotypic differences are iudeed maiutained throughout the HCV genome. 
Recent studies (Bukh et al., 1993) revealed that 12 genotypes can be distinguished by analysis of the 
El region. However, only 9 of those could be recognized iu the 5' UTR. Our study iudicates a similar 
situation when compariug 5' UTR with core region analysis. Most HCV genotypes can be 
distinguished by differences iu the highly conserved 5' UTR. Further discrimiuation between variants 
is possible by analysis of the relatively well conserved core region as shown in this study_ 
Subsequently, the more variable El region may reveal additional differences. Finally, the 
hypervariable region present at the 5' end of the E2INS 1 region allows discrimiuation between almost 
everysiugle HCV isolate (Weiuer et al., 1991). Our current knowledge of genotypic variation ofHCV 
is still limited. 
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Although the number of HCV subtypes will probably increase, and the clinical significance 
of genotyping remains to be substantiated, 5' UTR analysis by the LiPA provides a reliable system 
to discriminate between genotypes of HCV. 
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CHAPTERS 
SlImmary and general discussion 
(samenvatting en discussie) 
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In this thesis, several aspects of a hepatitis C virus infection are studied. The first part focuses on 
the detection of HCV viraemia by molecular biological tools. Recent quality control studies 
revealed considerable variability among HCV-RNA detection results in different laboratories. This 
indicates the need for simple and reproducible methods that are less prone to contamination. 
In chapter 2, a novel HCV RNA-capture assay is described. This method is based on the 
selective hybridization of the HCV genomic RNA to a complementary oligonucleotide, which is 
immobilized on paramagnetic beads. The captured RNA is subsequently detected by reverse 
transcription polymerase chain reaction (RT-PCR), almed at the highly conserved 5' untranslated 
region (5' UTR). The capture technique provides a tool for rapid isolation of HCV RNA from 
blood, and enables specific detection of (near) full length HCV genomic RNA. HCV is selectively 
purified from possible inhibitory substances in blood. Furthermore, this RNA isolation method 
omits the use of hazardous chemicals. is less prone to contamination with peR amplimers. and 
might be automated in the future. Similar RNA-capture from serum is also applied in the Chiron 
b-DNA assay to quantitate HCV RNA. A combination of HCV-RNA capture onto magnetic beads 
and the b-DNA detection technology might improve sensitivity of this quantitative assay. 
Application of the HCV -RNA capture assay was shown by analysis of chimpanzee serum 
samples. The presence of RNA correlated very well with the presence of anti-ReV in samples 
from the convalescent phase of the disease. This indicates that during chronic HCV infection, both 
HCV RNA and anti-HCV are present, whereas after acute-resolving HCV infection, both markers 
become eventually undetectable. During the acute phase of infection HCV RNA detection is the 
only method to determine viraemia, since no anti-HCV antibodies are detectable. 
The HCV RNA-capture assay was further optimized and evaluated in human samples, as 
described in chapter 3. Comparison of the capture assay with a highly sensitive conventional RNA 
isolation method revealed similar specificity (95.8%) and sensitivity (92.3%) by testing a coded 
panel of 50 human plasma samples. The sensitivity of the CUrrent capture method is slightly less 
than the standard assay. Further adaptations, such as capturing of HCV RNA at multiple 
conserved sites may increase the sensitivity considerably. As observed for the chimpanzee sera. 
also in these samples a very good correlation between the presence of HCV RNA and anti~HCV 
was found. 
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The second part of this thesis describes experimental HCV infections in the only known 
susceptible animal, the chimpanzee (chapter 4), 
First, results indicate the efficacy of the HCV RNA-capture assay for monitoring of the 
infection, HCV RNA is detectable within one week after inoculation in three chimpanzees but only 
after more than 4 weeks in another animal, HCV RNA becomes undetectable immediately after the 
normalization of ALT levels in the serum. This considerable decrease in serum HeV RNA 
concentration after the major ALT peak indicates that in acute hepatitis C a large portion of HCV 
infected hepatocytes are destroyed as a result of direct viral cytopathic effect, action of the host 
immune system or by a combination of both. In the chronically infected chimpanzee, the decrease 
of the HCV RNA level in the serum is transient and returns to detecrable levels. 
Secondly, results from anti-HCV assays show that the antibody profiles vary considerably 
among different chimpanzees, although a closely related HCV inoculum was used in all anintals. 
Anti",ore antibodies were first detected after 40-54 days post-infection in 3 chimpanzees with acute 
resolving infections. but in one chimpanzee with a chronic infection., these antibodies were 
detected more than 5 years after inoculation. Acutely infected chimpanzees showed prolonged 
reactivity against one of the core epitopes. Whereas nODe of the sera from these animals reacted 
with NS-5 peptides, anti-NS-5 antibodies were first detected in the chronically infected anintal 
after 5 years. This underscores the imponance of the host immune system for the course and 
outcome of HCV infection. 
Thirdly, sequence analysiS of the postulated hypervariable region, located in the 5' 
terminus of the E2INSI region, was performed to assess genetic drift of the particular HCV isolate 
used in all chimpanzees. Follow-up samples from 3 chimpanzees with a chronic infection and 
acute-phase samples from 3 animals with acute-resolving infection were studied. Results indicate 
genomic stability of the HeV genome upon transmission into another chimpanzee. However. 
genetic drift of the hypervariable region differed considerably during chronic infections. Two 
chimpanzees show considerable nucleotide and amino acid sequence variation during 6 years of 
follow-up. whereas one chimpanzee shows almost complete conservation of the region during more 
than 10 years of follow-up. Hypothetically, new sequence variants are immune-escape mutants. 
When the wild-type strain virions are neutralized and eradicated by specific humoral and/or 
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cellular immune responses, variant strains, originating from random mutations. emerge in the 
circulation and become predominant. If immune pressure is absent, the original strain remains 
predominant and new variants will presumably not reach detectable levels in the circulation. 
Future research will be aimed at further elucidation of the interactions between HCV and 
the immune system of the host. This is of particular interest for antiviral therapy with 
immunomodulating agents such as interferon-a. 
Genomic sequence variation between different HCV isolates to determine viral genotypes 
was subject of the third part of the thesis. Sequence comparisons of HCV isolates from the United 
States and Japan first indicated the existence of multiple strains or genotypes. Genotypes can be 
defined by consistent and significant differences between isolates both at the nucleotide and amino 
acid level. Different genotypes presumably originated from a common ancestor by sequential 
processes of mutation and selection. Each new mutant will be under a different selection pressure. 
Mutations that lead. to a stop codon or frame shifts in the large open reading frame will have a 
dramatic impact on the function of the resulting virion, and are obviously lethal for the virns. 
Other mutations that are advantageous for the replication of the virns, will lead to an increase in 
relative abundancy of these mutants. Comparisons of complete sequences revealed that different 
levels of homology exist. This is reflected in the nomenclature and classification. Isolates with an 
overall sequence homology of ± 88 % are defined as the same SUbtype. Sequences with 
approximate homologies of 79% belong to the satne type and when homology is about 68%, 
isolates are classified into different types. However. it is not feasible to analyze complete viral 
genomes. Therefore, small regions are studied and compared between isolates. 
Chapter 5 describes the use of the 5' UTR to discriminate between genotypes by RT -PCR 
amplification and direct sequencing. Results show that the 5' UTR sequence is highly conserved. 
Sequence variation is mainly restricted to two "motifs", that are part of an important secondary 
RNA structnre. Variation in these motifs is often type-specific and can be used effiCiently to 
differentiate (sub)types of HCV. A reverse hybridization method to detect sequence variation in 
the 5' UTR, the Line Probe Assay (LiPA) is described in chapter 6. LiPA results correlate very 
well with data from direct sequencing. Furthermore, there was a correlation between genotype and 
anti-HCV antibody responses against various viral epitopes, although discrimination between 
genotypes by serological tests is not yet possible. Initial reports had suggested that certain HCV 
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genotypes were restricted to a specific geographical area. e.g .• the "American type", the "Japanese 
type", and the "South-African type". In the Netherlands, 5 genotypes with several subtypes were 
recognized. These results, and other recent reports, indicate that probably all HCV genotypes have 
a worldwide distribution, although the relative abundancy of each (sub)type may vary considerably 
berween different geographical areas. 
To substantiate the possibility of genotyping by 5' UTR analysis, a large cohort of patients 
was genotyped with the LiPA. Several isolates. representing the five different genotypes were 
randomly selected from this population and subjected to analysis of the N-termlnal core region 
(chapter 7). Core sequence analysis revealed that this region is relatively well conserved among 
the HCV genotypes. Nucleotide sequence homologies within each subtype exceed 95%, although 
type 2 and 4 isolates were less homogeneous and may be further divided in several subtypes. 
Differentiation between core sequences resulted in identical classification as the initial 5' 
UTR analysis. This justifies HCV genotyping by 5' UTR analysis and indicates that genotypiC 
variation is maintained throughout the genome. Since a large amount of HCV isolates obtained 
worldwide have been analyzed, it is expected that the most important genotypes of HCV have been 
identified by now. New (sub)types may be discovered, but presumably with a very low incidence. 
Sequence data from different HCV genotypes will lead to the improvement of both serological and 
molecular biological diagnostic tools. Furthermore, this knowledge will be essential for the 
development of an effective vaccine. 
Clinical relevance of genotyping will be subject of further studies, but it is likely that 
discrimination berween (sub)types 1 to 5 will be sufficient in the majority of HCV cases. 
An advantage of 5' UTR based genotyping is the fact that this region is used for 
determination of HCV viraerula by RT-PCR already in most laboratories. Therefore, 5' UTR 
genotyping provides a convenient complementary tool in routine settings. 
Detailed knowledge of the RNA genome of HCV is required for efficient diagnosis of 
HCV viraemia by various molecular biological and serological methods. Investigations described 
in this thesis contributed to the reliable and efficient detection of HCV RNA and discrimination 
berween various HCV genotypes. Studies on the natural course of HCV infections in chimpanzees 
and determination of genetic drift of the viral genome during cbronic infections has increased our 
insight in the biology of this fascinating virus considerably. 
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Samenvatting en discussie 
Dit proefschrift beschrijft een aantal aspecten van Hepatitis C virus (HCV) infecties. In 
hoofdstuk 1 wordt een samenvatting van de literatuur gegeven. 
Het eerste deel van dit proefschrift handelt over de moleculair biologische detectie van 
HeV viremie. Gezien de verschillen tussen resultaten van HeV-RNA detectie door verschillende 
laboratoria is de noodzaak voor de ontwikkeling van simpele en reproduceerbare detectiemethoden 
die minder gevoelig zijn voor contaminatie duidelijk. In hoofdstuk 2 wordt een nieuwe HeV-RNA 
capture assay beschreven. Deze methode is gebaseerd op de selectieve hybridisatie van het 
enkelstrengs HCV RNA genoom aan een complementaire oligonucleotide, die geImmobiliseerd 
wordt op paramagnetische deeltjes. Het weggevangen en gezuiverde RNA wordt vervolgens 
gedetecteerd door de reverse transcriptase polymerase chain reaction (RT-PCR), gericht op het 
zeer geconserveerde 5' onvertaalde gebied (5'UTR), De capture tecbniek biedt een merhode voor 
snelle isolatie van HCV RNA nit bloed en maakt specifieke detectie van het complete, intacte 
genoom (full length RNA) mogelijk, HCV RNA kan bovendien selectief worden gescheiden van 
mogelijke storende factoren in bloed, zoals beparine. Deze nieuwe RNA isolatiemethode vergt 
geen extracties met fencl/chloroform en ethanolprecipitaties. Door capture van HeV RNA op 
sequenties die buiten bet amplificatietarget liggen is de methode minder gevoelig voor contaminatie 
met PCR amplimeren gedurende de isolatiefase. Ben soortgelijke RNA capture methode wordt 
toegepast in de Chiron b-DNA assay om HCV RNA te quantificeren. Een combinatie van de in dit 
proefschrift beschreven HCV -RNA capture techniek met behulp van paramagnetische deeltjes en 
bet b-DNA systeem zon een gevoelige qnantitatieve assay op kunnen leveren. 
Ret capture systeem is toegepast voor de analyse van ReV RNA in cbimpansee 
serummonsters. De detectie van HeV RNA correleerde zeer goed met de aanwezigbeid van anti-
HeV antilicbamen in deze sera. die minstens twee jaren na de acute fase waren afgenomen. Dit 
geeft aan dat tijdens een chronische infectie, HCV RNA en anti-HCV aantoonbaar blijven, terwijl 
bij een acute infectie beide markers uiteindelijk verdwijnen. Gedurende de acute fase van de 
infectie is HeV RNA detectie de enige mogelijkbeid om vireniie aan te tonen. omdat dan (nog) 
geen anti-HCV is gevormd. 
De HCV RNA capture assay werd verder geoptimaliseerd en geevalueerd in een gecodeerd 
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panel van humane serummonsters. zoals beschreven in hoofdstuk 3. Er werd een vergelijking 
gemaakt tussen de Hey capture assay en een zeer gevoelige conventionele methode. Seide 
methoden hebben een vergelijkbare specificiteit (95.8%) en sensitiviteit (92.3%). Evenals in de 
chimpansee sera werd ook hier een duidelijk verband waargenomen tussen de aanwezigheid van 
HCV RNA en anti-HCV. De absolute detectiegrens van de huidige versie van de RNA capture 
assay ligt echter ongeveer een factor 10 boger dan die van de conventionele assay. Yerdere 
aanpassingen. zoals simultane capture van Hey RNA op verschillende plaatsen. zouden de 
gevoeligheid aanzienlijk kunnen vergroten. 
Het tweede deel van dit proefschrift bescbrijft experimentele HCV infecties in het enige 
bekeude infecteerbare dier, de chimpansee (hoofdstuk 4). In 4 chimpansees werden regelmatig 
serum monsters afgenomen voor en tijdens de Hey infectie. Daarin werden HeV RNA en anti-
HCV gemeteu. Met behulp van de capture assay was HCV RNA binnen I week detecteerbaar in 
drie chimpansees. maar pas na ruim 4 weken in de vierde chimpansee. Opvallend is dat direct na 
norntalisatie van het ALT niveau in het serum, HCV RNA in alle chimpansees tot onder de 
detectiegrens daalde. Dit duidt op de simultane vernietiging van een groot aantal HCV 
geinfecteerde hepatocyten ten gevolge van een intense immuunrespons van de gastheer. Daardoor 
stijgt de ALT concentratie in het serum tijdelijk sterk. Na de massale vernietiging van 
geinfecteerde hepatocyten zal de produktie van HCV sterk verminderd zijn, hetgeen de daling van 
HCV RNA in het serum verklaart. In eon chimpansee was de concentratie HCV RNA slechts 
tijdelijk verJaagd en steeg daarna weer tot boven de detectiegrens, hetgeen wijst op de 
ontwikkeling van een chronische HCV infectie. In de dde andere chimpansees daarentegeu was de 
daling van de HCV RNA concentratie permanent, hetgeen duidt op volledige klaring van het virus. 
Resultateu van de anti-HCV bepalingen toonden aan dat de humorale immuunrespons 
aanzienlijk kan verschillen tussen verschillende dieren, zelfs wanneer een identiek of sterk verwant 
inoculum wordt gebruikt. Anti-core antilichameu werden in dde chimpansees met een acute 
infectie 40-54 dagen na inoculatie voor het eerste gedetecteerd, maar in een chimpansee met een 
chroniscbe infectie pas ruim 5 jaar na inoculatie. De dieren met een acute infectie bleven nog 
lange tijd antilichamen tegen eon van de core epitopen behouden. Chimpansees met een acute 
infectie ontwikkelden geen meetbare antilichaamrespons tegen NS5 epitopen. Anti-NS5 werd weI 
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aangetoond in de chimpansee met een chronische infectie, hoewel pas 5 jaar na inoculatie. Deze 
resultaten onderstrepen het belang van de individuele immuunrespons van de gastheer voor het 
verloop van de HeV infectie, onafhankelijk van het virus. 
Vervolgens werd binnen een groep van zeven chimpansees~ die elk met een identiek of 
nauw verwant inoculum waren geinfecteerd. de genetiscbe variane in de loop van de tijd C genetic 
drift') onderzocht. Daartoe werden sequentieanalyses uitgevoerd op het zgn. hypervariabele gebied 
(HVR), gelegen in de N-terminus van E2INSL De resultaten van deze studie toonden aan dat 
transmissie van HeV vanuit e6n chimpansee naar verschillende andere geen onmiddellijke invloed 
had op de sequentie van het hypervariabele gebied tijdens de acute fase. De mate van variabiliteit 
tijdens een chronische HeV infectie in drie cbimpansees verschilde echter aanmerkelijk. In twee 
chimpansees werden binnen een periode van 6 jaren significante sequentieverschillen 
waargenomen. Daarentegen bleken in een andere chimpansee gedurende een periode van 10 jaar 
nauwelijks sequentieverschillen op te treden. Op grond van deze resultaten is de volgende 
hypothese ontwikkeld. Virusgenomen met gemuteerde HVR sequenties ontstaan tijdens een 
chronische HeV infectie door random mutaties ten gevolge van RNA replicatiefouten. Sommige 
van deze mutanten kunnen ontsnappen aan de immunologische response van de gastheer die, in 
eerste instantie, specifiek gericht is tegen het wildtype virus. Deze ~escape mutanten' kunnen 
vervolgens het onderdrukte wildtype virus verdringen en daarna een nieuwe specifieke 
immuunrespons veroorzaken hetgeen kan leiden tot nieuwe 'escape mutanten'. Indien de 
inunuunrespons regen het wildtype virus echter uitblijft, vindt er geen selectie plaats en kan het 
wildtype virus blijven domineren. Vervolgonderzoek zal moeten uitwijzen of deze hypothese kan 
worden bevestigd en zal gericht zijn op de interactie tussen HeV en het inunuunsysteem van de 
gastheer. Dit is in het bijzonder van beJang voor de toepassing van antivirale therapie met 
immunomodulerende steffen. zeals interferon-a. 
Sequentievariatie vormde tevens het onderwerp voor het derde gedeelte van dit 
proefschrift. Verschillende HeV isolaten kunnen op grond van sequentieverschillen van elkaar 
worden onderscheiden. Eerdere onderzoeken toonden aan dat er verschillende genotypen van HeV 
bestaan. die kunnen worden herkend aan consistente en significante sequentieverschillen, zowel op 
nucleotide- als aminozuurniveau. Deze verschillende genotypen stammen waarschijDlijk via 
mutaties en selecties af van een gemeenschappelijk prototype virus. Mutaties kunnen belangrijke 
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gevolgen bebben voor de overleving van de mutant. Mutaties die leiden tot een stopcodon of 
verschuiving van het leesraam rollen veelal niet leiden tot levensvatbare virussen. Andere mutaties 
zullen daarentegen een efficientere virusreplicatie tot geyoig bebben en zorgen yoor een sterke 
verspreiding van deze mutant. 
Vergelijkingen russen complete genoomsequenties toonden aan dat er verschillende mate 
van homologie tussen de diverse isolaten bestaat. Dit komt tot uiting in de huidige nomenc1atuur 
en classificatie van de genotypen. Isolaten met een totale genoomhomologie van ongeveer 88% 
worden geclassificeerd binnen hetzelfde subtype. Sequenties met ongeveer 79% homologie behoren 
tot hetzelfde type maar een verschillend subtype en isolaten met een gentiddelde homologie van 
68% worden als verschillende typen geciassificeerd. Het is echter onmogelijk om complete 
virusgenomen efficient te analyseren. Om isolaten te classificeren worden ldeinere delen van het 
genoom met elkaar vergeleken. Hoofdstuk 5 beschrijft het gebruik van het 5' onvertaaJd gebied (5' 
UTR) om d.m.v. RT-PCR en directe sequentieanalyse van het amplificaat verschillende typen en 
subtypen te onderscheiden. Het 5' UTR is sterk geconserveerd en de beperkte sequentieYariatie 
komt voornamelijk voor in twee 'motieven', die een onderdeel Yormen van een functioneel 
belangrijke secundaire RNA sttuctuur. Type-specifieke covariaties binnen deze motieven kunnen 
op efficieme wijze gebruikt worden om onderscheid te maken tussen verschillende HCV 
genotypen. Een 'reverse hybridizatie" methode om diezelfde variaties te detecteren is de basis voor 
de Line Probe Assay (LiPA). De resultaten van deze test staan beschreven in hoofdstuk 6. LiPA 
resultaten correleerden zeer goed met de sequentiegegevens van het 5' UTR. Bovendien werd een 
verband gelegd tussen bepaalde HCV genotypes en de aanwezigheid van anti-HCV antilichamen 
tegen verschillende virale epitopen, zoals gemeten m.b.v. de LIA-2 en de R1BA. Het bleek 
hiermee ecbter niet mogelijk een consistent serologiscb onderscbeid tussen de verschillende 
genotypes te maken. 
Eerder gepubliceerde onderzoeken suggereerden een sterke relatie tussen een specifiek 
genotype en de geografische verspreiding daarvan. Zo werden isolaten bestempeld als ' Amerikaans 
type' en 'Japans type'. Binnen Nederland echter werden bijiJa aile tot nu toe beschreven genotypes 
waargenomen. Deze resultaten duiden op een wereldwijde verspreiding van alle HCV genotypen, 
hoewel de relatieve incidentie op verschillende lokaties aanzienlijk lean verschillen. 
Om verder bewijs te verzamelen dat het 5' UTR voor genotypering kan worden gebruikt, 
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werd een grote groep parientenisolaten met behulp van de LiP A getypeerd. Uit deze groep werd, 
na genotypering. een aantal representanten van elk (sub)type gese1ecteerd en verder geanalyseerd. 
Dit is bescbreven in hoofdstuk 7. Allereerst werden door sequentieanalyse van het 5' UTR de 
LiP A resultaten bevestigd. Daarnaast werd van dezelfde isolaten een gedeelte van het core-gebied 
(nt 1-326) gesequenced. Deze core sequenties zijn relatief goed geconserveerd. De homologie 
binnen een subtype is in het algemeen meer dan 95 %, hoewel types 2 en 4 iets meer intratypische 
variatie vertoonden. Classificatie van isolaten op grond van 5' UTR was volledig identiek aan de 
indeling gebaseerd op core sequenties. Dit bevestigr de resultaten van de LiPA en duidt op 
handhaving van genotypische variatie in verschillende delen van het HeV genoom. Wei is het 
waarschijn1ijk mogelijk om op grond van core sequenties binnen een aantal genotypen een 
verfijnder indeling te maken in meerdere subtypes die op grond van 5' UTR alleen niet mogelijk 
is. Vergelijkbare resultaten zijn zeer recent ook gevonden bij de vergelijk:ing van bet 5' UTR met 
de El regio. Een voordeel echter van genotypering op grond van het 5' UTR is het feit dat dit 
deel van het HeV RNA genoom in de meeste laboratoria gebruikt word! voor de bepaling van 
Hey virentie met behulp van RT -peR. Daarom vormt de Hey genotypering op grond van 5' 
UTR een aanvulling op de routine diagnostiek. 
Aangezien reeds een grODt aantal HeV isolaten. verkregen vanuit wereldwijde verspreide 
regio's, zijn geanalyseerd, is de verwachting dat de belangrijkste Hey genotypes inmiddels zijn 
geldentificeerd. Indien nog nieuwe (sub)types worden ontdekt, zul]en die waarschijnlijk een lage 
incidentie hebben. Gedetailleerde kennis van de verschillende Hey genotypes zal leiden tot een 
verbetering van de serologische en moleculair biologische Hey diagnostiek. Bovendien zal deze 
kennis onontbeerlijk zijn v~~r de ontwikkeling van een effectief vaccin. De klinische relevantie 
van de verschillende HCV genotypes zal nog uitgebreider moeten worden bestudeerd. 
De in dit proefschrift bescbreven onderzoeken hebben bijgedragen aan de betrouwbare en 
efficiente detectie van Hey RNA en het onderscheiden van de verschillende genotypes. Studies 
naar het natuurlijk verloop van HCV infecties in chimpansees en de genetische variatie van het 
Hey genoom in de loop van de tijd hebben het inzicht in de biologie van dit virus aanzienlijk 
vergroot. 
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Nawoord 
Een nawoord behoort eigenlijk overbodig te zijn. Als een ieder die bij de totstandkoming 
van dit proefschrift betrokken was, pas op deze bladzijde mijn erkentelijkheid moet vernemen, heb 
ik de afgelopen jaren gefaald. De traditie wil echter dat de promovendus, na het leggen van het 
intellectuele ei~ uitbarst in uitvoerige loftuitingen op de betreffende omstanders. vandaar toch een 
poging. 
Prof. Dr. S.W. Schalm, mijn promotor, wil ik bedanken voor de manier waarop wij een 
succesvolle 'working apart together' samenwerking kenden opbouwen en de efficiente wijze 
waarop vooral de afsluitende fase kon worden venvezenlijkt. 
De leden van de promotiecommissie, Prof. Dr. F.T. Bosman, Dr. R.A. Heijtink en Prof. 
Dr. W.1 .M. Spaan, dank ik voor hun inspanning bij het beoordelen van het manuscript. 
Dr. W.G.V. Quint, beste Wim, hartelijk dank voor je co-promotorschap, in goede, 
slechtere en betere tijden! 
Dr. A.F. van Belkum, beste Alex, dank: voor de uiterst kritisch-<:ollegiale manier waarop 
je in de jouw geheel eigen stijl mijn manuscripten hebt proberen te wurgen en voor de vele 
messcherpe ad-rem discussies. 
Dr. H. Schellekens, beste Huub, bedankt voor de leerzame non-A, non-B fase bij het 
Primatencentrum met de vele geboden kansen en de aangename verbale no-nonsense gedurende de 
afgelopen jaren. 
Prof. Dr. K. Murray, dear Ken, it is a great honour and privilege to collaborate with a 
person like you. I will certainly never forget the pleasant visits to Edinburgh, the 'Biogen 
experience' and your continuing support over the past years. 
Dr. G. Maertens en Dr. L. Sruyver. beste Geert en Lieven. dank voor de zeer prettige en 
vruchtbare samenwerking gedurende de afgelopen jaren. 
Drs. G.E.M. Kleter, beste Bernhard, dat wetenschappe1ijk onderzoek teamwork is, mag 
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